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Abstract 
Introduction:  Coronary artery disease (CAD) remains the number one cause 
of mortality worldwide; improving diagnosis and treatment is a priority.  Multi-
parametric cardiovascular magnetic resonance (CMR) offers quantitative 
assessment of the cardiovascular system with a variety of techniques allowing 
assessment of anatomy, function, myocardial composition and perfusion 
during a single scan. 
Aims:  To assess 1.) diagnostic accuracy of visual and quantitative perfusion 
CMR to single-photon emission computed tomography (MPS-SPECT) in 
patients with left main stem CAD. 2.) the hypothesis that patients with 
ischaemic (ICM) and non-ischaemic cardiomyopathy (NICM) have different 
torsion and strain parameters 3.) development and validation of a 
contemporary multivariable risk model of CAD from a large population 
undergoing X-ray angiography. 4.) a rapid 3D mDIXON pulse sequence for 
image quality and quantitation of MI. 5.) T1 rho prepared (T1ρ) dark blood 
sequence and compare to blood nulled PSIR (BN) and standard myocardium 
nulled PSIR (MN) for detection and quantification of scar. 
Methods:  Patients were recruited between 2008 and 2017.  Patients in 
chapters 3,4,6,7 underwent multi-parametric CMR including late gadolinium 
enhancement (LGE) imaging at 1.5 or 3.0T. Patients in chapter 5 underwent 
angiography. 
Results:   
1.) CMR demonstrated significantly higher area under the curve for detection 
of LMS or equivalent disease over MPS-SPECT(P=0.0001).  
2.) Despite no difference in LV dimensions, EF and strain between ICM and 
NICM, NICM patients had significantly lower LV twist(P=0.023) and 
torsion(P=0.017) compared to ICM. 
3.) The developed model discriminated well and was well-calibrated. Diamond 
and Forrester and Duke scores substantially over-predicted CAD risk, whilst 
CAD Consortium risk models slightly under-estimated risk. 
- xviii - 
4.)  Image quality was comparable between 3D and 2D LGE(P=0.162). Time 
for 3D image acquisition was only 5% of the time required for a standard 2D 
acquisition. 
5.) CNRscar-blood was significantly increased for BN and T1ρ compared to MN 
LGE. BN LGE demonstrated significantly higher reader confidence scores. 
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1. General Introduction 
1.1. Background 
Coronary artery disease (CAD) is a leading cause of death and disability 
worldwide (1), and remains the leading cause of death in Europe and the UK 
(2). Despite major advances in the treatment of CAD resulting in significantly 
decreased mortality rates, CAD remains the single most common cause of 
death in the European Union, leading to 19% of deaths in men and 20% of 
deaths in women (2); in the United States, CAD causes 1 in every 7 deaths, 
accounting for 370,213 deaths in 2013 (3). The mortality rate for CAD remains 
higher in the UK and particularly Scotland compared to Europe and it is 
currently estimated that in the UK there are 2.3million people living with 
ischaemic heart disease (IHD) (2, 4). The economic health burden of CAD is 
substantial with an estimated cost of CAD management at €60 billion in the 
European Union (5), and $182 billion in the US (3). Admissions with chest pain 
account for a significant proportion of admissions to the acute medical take 
and whilst it is important to remain vigilant for acute coronary syndromes a 
reasonable proportion of these admissions will represent stable coronary 
disease/angina (6, 7).  
 
1.2. Coronary artery disease 
1.2.1. Stable versus unstable coronary disease 
Coronary artery disease presents in several manners – typically these are 
divided into stable or unstable CAD. The main symptomatic presentations of 
stable CAD are classical angina caused by an epicardial coronary stenosis, 
ischaemic cardiomyopathy and less frequently vaso-spastic angina or angina 
caused by microvascular obstruction/dysfunction (8). Unstable CAD 
encompasses the acute coronary syndromes (ACS) typically caused by 
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rupture of an atherosclerotic plaque with consequent thrombosis and 
consequent myocardial necrosis. 
 
1.2.2. Epidemiology of CAD 
Angina prevalence increases as age increases in both men and women with 
an incidence of about 4% in men and women aged 75-84 years. Myocardial 
infarction is one of the leading causes of mortality worldwide (1). Myocardial 
infarction (MI) is defined as ‘myocardial cell death due to prolonged ischaemia’ 
(9).  In the UK, over 915,000 people are estimated to have previously had an 
MI and coronary artery disease was responsible for 73,500 deaths in 2012, 
representing 16% of all male and 12% of all female deaths (4). National health 
service (NHS) spending on treating coronary artery disease is estimated at 
£6.8 billion pounds each year, representing a significant proportion of the total 
spending budget (4).   
 
1.2.3. Presentation of stable coronary artery disease  
Stable CAD encompasses a variety of different presentations i.) stable 
angina pectoris due to stenotic CAD, ii.) patients with CAD who are 
asymptomatic, iii.) patients with left ventricular (LV) dysfunction from prior 
myocardial infarction, iv.) ischaemic cardiomyopathy (8).  
Stable angina pectoris was first described by William Heberden in 1768 to 
the Royal College of Physicians: 
“They who are afflicted with it, are seized while they are walking, (more 
especially if it be up hill, and soon after eating) with a painful and most 
disagreeable sensation in the breast, which seems as if it would extinguish 
life, if it were to increase or to continue; but the moment they stand still, all 
this uneasiness vanishes.”  
Stable angina is typically exercise related and caused by a mismatch 
between supply and demand of coronary bloodflow to myocardium 
(ischaemia) due to an epicardial coronary stenosis. Typical symptoms of 
angina are retrosternal chest pain, radiating to the neck, jaw and arm brought 
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on by exertion and relieved by rest or nitroglycerine. The degree of 
symptoms however does not necessarily reflect the underlying extent of CAD 
and patients may be asymptomatic despite a large burden of ischaemia. 
Severity of symptoms have been quantified by the Canadian Cardiovascular 
society (CCS). 
 
 
Table 1-1 Canadian Cardiovascular Society grading of angina 
pectoris 
  
Grade Description 
Grade I  
Ordinary physical activity does not cause angina, such as walking 
and climbing stairs. Angina with strenuous or rapid or prolonged 
exertion at work or recreation  
Grade II  
Slight limitation of ordinary activity. Walking or climbing stairs 
rapidly, walking uphill, walking or stair climbing after meals, or in 
cold, or in wind, or under emotional stress, or only during the few 
hours after awakening. Walking more than two blocks on the level 
and climbing more than one flight of ordinary stairs at a normal 
pace and in normal conditions  
Grade III  
Marked limitation of ordinary physical activity. Walking one or two 
blocks on the level and climbing one flight of stairs in normal 
conditions and at normal pace  
Grade IV  
Inability to carry on any physical activity without discomfort, 
anginal syndrome may be present at rest  
 
Ischaemic cardiomyopathy is the end-stage manifestation of stable coronary 
artery disease.  Heart failure attributed to IHD is independently associated with 
an increased mortality over non-ischaemic cardiomyopathy. A variety of 
pathophysiological processes can result in ischaemic cardiomyopathy, 
myocardial hibernation, scarring and mechanical and neuro-humoral factors 
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(10). Hibernating myocardium is the concept of downregulation of myocardium 
following chronic ischaemia and is a retrospective diagnosis following 
functional recovery once revascularisation has occurred (11). 
Revascularisation of hibernating myocardium is the basis of viability 
assessment. The role of revascularisation in ischaemic cardiomyopathy 
remains a subject of debate currently with the results of the STICH study 
showing no benefit contrary to the results of a number of large observational 
studies showing benefit (12, 13).  
 
1.2.4. Presentation of Acute Coronary syndromes  
The typical features of an ACS are severe retrosternal chest pain radiating to 
the arm and jaw, with associated diaphoresis, nausea and dyspnoea.  ACS 
does not always present in this manner with some patients (e.g. diabetics) 
either asymptomatic or  may have vague symptoms; frequently in these 
instances MI is unrecognised at the time of its occurrence (14).   
 
1.2.5. Pathophysiology of CAD 
CAD is a chronic progressive disease that develops in adult life through a 
process of lipoprotein dysregulation and immune cell/inflammatory mediated 
events that occur within the coronary vasculature (15). Atherosclerosis 
begins with a long quiescent phase that initially develops from fatty streaks 
that are typically present from the teenage years onwards. Progressively 
these fatty streaks develop into mature atherosclerotic plaques that comprise 
a fibrous cap overlying a central core of lipid (16). A wide variety of different 
pathologically and structurally distinct subtypes of lesions can occur that give 
rise to varying degrees of vulnerability to manifest in a clinical event (16, 17).  
In stable CAD as the plaque grows the coronary artery will remodel outward 
in order to retain lumen patency and can remain undetected on angiography 
or stress testing. Ultimately however the plaque will encroach on the vessel 
lumen leading to obstruction of blood flow leading to ischaemia. In unstable 
CAD, coronary events occur as consequence of plaque rupture with a 
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resultant thrombotic event. Acute coronary syndromes are typically caused 
triggered by acute fibrous cap rupture, which exposes the thrombogenic, 
tissue factor-rich lipid core to circulating blood (18), although in about 30% of 
cases of infarction, plaque erosion of the endothelium overlying the fibrous 
cap can lead to the formation of a platelet-rich thrombus (19). “Vulnerable” 
plaques tend to have common characteristics that make them distinct from 
plaques that cause stable angina such as a thin fibrous cap, positive 
remodeling, a large necrotic core, inflammation, microcalcification, 
angiogenesis, and plaque hemorrhage (16, 18). 
Following the onset of ischaemia myocardial necrosis can occur within 20 
minutes, with complete cell death occurring after between 2 and 4 hours (9).  
A ‘wavefront phenomenon’ of cell death is seen with the distal sub-endocardial 
myocytes affected first followed by the more proximal epicardial myocytes that 
are adjacent to the coronary arteries (20).  Reduction to the blood supply of 
the myocardium resulting in myocardial infarction can be caused by various 
mechanisms that are summarised in the table 1-2: 
Table 1-2 Classification of Myocardial Infarction 
 (adapted from Thygesen et al. The Fourth Universal Definition of Myocardial 
Infarction. EHJ 2018.  33 (20); 2551-67)(21) 
MI Classification Description 
Type 1 Spontaneous plaque rupture or dissection within an 
epicardial coronary artery. 
Type 2 MI secondary to ‘ischaemic imbalance’ – myocardial 
oxygen supply is temporarily outstripped by demand 
as a result of brady- or tachycardia, hypotension, 
respiratory failure etc.  
Type 3  Myocardial infarction resulting in death  
Types 4a/4b/5 Myocardial infarction resulting from PCI (4a) or 
thrombosis of existing coronary stent (4b) or 
restenosis associated with PCI (4c) or coronary artery 
bypass grafting (5) 
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Myocardial infarction, causes a complex pattern of ventricular remodelling.  
Infarcted myocardium is replaced by fibrotic scar, whilst the remote healthy 
myocardium compensates for the reduced contribution of the infarcted regions 
to maintain cardiac output (22).  This process typically takes around 6 weeks 
according to autopsy studies (23).  Cardiovascular magnetic resonance (CMR) 
imaging identifies that the infarcted LV mass is reduced by around 40% at 4 
months compared with at the time of infarction, with minimal further change at 
12 months, suggesting remodelling is largely complete by 4 months (24). 
Following MI, LV dilatation can occur; this typically occurs with larger infarcts 
involving the left anterior descending (LAD) artery as opposed to right (RCA) 
or circumflex (LCx) coronary artery territories (25).  LV chamber dilatation 
occurs due to thinning and expansion along the circumferential length of the 
scarred myocardium, combined with a concurrent compensatory 
circumferential hypertrophy of remote myocardium (26). 
 
1.3. Cardiac Imaging 
Cardiac imaging has a wide array of potential methods of investigation that are 
available to the cardiologist for the investigation of CAD. These range from 
invasive tests such as angiography to non-invasive imaging tests that give 
anatomical and/or functional information; however currently there is no one 
perfect test and all have potential benefits and limitations. The focus of this 
thesis is stable CAD and the role of these imaging modalities are discussed in 
this context.  
 
1.3.1. Assessment of coronary artery disease  
Invasive coronary X-ray angiography has long been recognised as the 
reference standard for the investigation of coronary artery disease (8, 27). 
Invasive coronary X-ray angiography gives anatomical information and 
identifies coronary stenoses in patients presenting with chest pain, as well as 
allowing invasive pressure measurements. Angiography however does not 
give information on the burden of ischaemia (% of the myocardium that is 
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ischaemic) although invasive pressure wire assessment can be used to give 
lesion specific ischaemia if used (28). X-ray angiography is an invasive 
investigation, and confers both morbidity in terms of radiation burden and 
potential vascular complications and a very low but potential 1/1000 risk of 
mortality. Furthermore there is a low yield of obstructive CAD, around 60% of 
those referred for elective invasive angiography have no significant disease 
(29). Non-invasive imaging modalities such as myocardial perfusion 
scintigraphy by single-photon emission computed tomography (MPS-SPECT), 
stress echocardiography (SE), CMR, CT coronary angiography (CTCA) or 
positron emission tomography (PET) aim to diagnose CAD, as well as quantify 
ventricular function, ischaemic burden, assess viability and confer prognostic 
information and are therefore identified for these roles in current clinical 
practice guidelines (8, 30). 
 
1.3.2. Risk stratification in stable CAD 
In the UK, rapid access chest pain clinics (RACPC) in accordance with the 
National Service Framework for CAD previously utilised clinical history and 
examination followed by an exercise tolerance test (ETT) to risk stratify 
patients presenting with chest pain, followed by MPS-SPECT or invasive 
coronary angiography if warranted. ETT however has a limited diagnostic 
ability estimated at sensitivity of 45-50% (31, 32) and consequently has been 
removed from current guidelines (8, 30). Given the wide variety of non-invasive 
imaging modalities available, National institute of health and clinical 
excellence NICE 2010 CG95 guidelines proposed the use of pre-test 
likelihood” (PTL) of underlying CAD to choose between different investigations 
(table 1-4).  The PTL estimation is based on typicality of symptoms and co-
existent risk factors to give a percentage risk. ‘Typical’ symptoms of angina 
pectoris include retrosternal chest pain, radiating to the neck or arm that 
occurs during exercise and is relieved with rest or GTN (table 1-3)(30, 33). 
Those with a low to intermediate risk should undergo a “rule out test” i.e. 
CTCA; the intermediate risk patients should have a functional test (CMR, 
MPS-SPECT, DSE); with invasive angiography reserved for those with a high 
PTL. Notably for those patients in the very high risk PTL of CAD, NICE 
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guidelines suggested performing no investigation and to treat as angina; 
however this may potentially be denying this group assessment of their 
“ischaemia burden”, a discriminator that is known to confer prognostic 
information (34). The recently published CE-MARC 2 trial identified that the 
2010 NICE guidelines led to higher rates of unnecessary angiography 
compared to functional imaging guided care; a strategy that potentially 
increases patient morbidity and healthcare costs (35). The mechanism is likely 
a result of overestimation of risk of CAD by the PTL model used in the 2010 
CG95 guideline; notably the more recent European Society of Cardiology 
(ESC) guidelines have used an updated PTL model to risk stratify patients (8, 
30).  Subsequently, the NICE CG95 guideline has been updated in 2016 and 
PTL estimation is no longer recommended (36). This is in contrast to US and 
European practice guidelines that still recommend PTL estimation prior to 
investigation. The 2016 update to CG95 now recommends referral for CTCA 
in all patients with typical or atypical chest pain (table 1-3) and in those with 
non-anginal pain but with ECG changes, with functional imaging reserved for 
those who have previously documented coronary disease or revascularisation 
(36). Direct referral to angiography is no longer recommended in current 
guidelines thus a thorough understanding of the contemporary non-invasive 
imaging modalities is paramount. 
Table 1-3 Typicality of chest pain for angina (30) 
Typical angina 
(definite) 
 
Meets all three of the following: 
 Substernal chest discomfort of characteristic quality and 
duration  
 Provoked by exertion or emotional stress 
 Relieved by rest and/or nitrates within minutes 
Atypical angina 
(probable) 
Meets two of the above characteristics 
Non-cardiac chest 
pain 
Meets one or none of the above characteristics 
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Table 1-4 Pre-test likelihood of coronary artery disease based on 
typicality of symptoms, age, gender, and risk factors (30) 
 Non-anginal chest 
pain 
Atypical angina Typical angina 
 Men Women Men Women Men Women 
Age 
(year
s) 
Lo
w 
Hig
h 
Lo
w 
Hig
h 
Lo
w 
Hig
h 
Lo
w 
Hig
h 
Lo
w 
Hig
h 
Lo
w 
Hig
h 
35 3 35 1 19 8 59 2 39 30 88 10 78 
45 9 47 2 22 21 70 5 43 51 92 20 79 
55 23 59 4 25 45 79 10 47 80 95 38 82 
65 49 69 9 29 71 86 20 51 93 97 56 84 
 
Values represent percentage likelihood at mid-decade age of significant 
CAD.  
Men over 70 with atypical or typical symptoms estimate PTL at >90%. 
Women over 70, assume a risk of 61 to 90%, except women with high risk 
with typical symptoms risk of >90% is estimated. 
High = high risk factors that are diabetes, smoking and hyperlipidaemia (total 
cholesterol > 6.47 mmol/l), resting ECG ST-T changes or Q waves. 
Low = low risk when none of the above risk factors are present. 
Non-anginal chest pain should not be investigated for stable angina routinely.  
 
1.3.3. Computed tomography coronary angiography 
Computed tomography (CT) can be used in the assessment of coronary artery 
calcium score (CAC) which uses an estimate of calcium burden within the 
heart to predict the presence or absence of CAD and CTCA which allows 
visualisation of the coronary arteries.  CAC score is a quick and simple test 
acquired in a single breath hold, without the need for any contrast agent.  It is 
used to estimate the degree of calcification within the coronary arteries with 
an excellent correlation to total coronary calcium burden in histological 
samples (37).  A score of 0 is associated with low CV risk, whereas scores 
above 1 are associated with an incremental increase in CV risk (38).  Coronary 
calcium scoring predicts future risk of coronary events (MI, death from 
coronary heart disease or resuscitated cardiac arrest) in asymptomatic 
patients, more accurately than clinical risk scoring alone (39).  Coronary 
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calcium scores in symptomatic patients have been shown to correlate 
positively with the degree of luminal coronary artery obstruction (40).  
However, more recently, a large international, multi-centre trial demonstrated 
that a CAC score of 0 is insufficient to rule-out significant coronary artery 
disease (41).  For this reason, CAC score is now nearly always combined with 
CTCA in the assessment of patients with chest pain at low to intermediate risk 
of chest pain.  
CTCA allows visualisation of the lumen and wall of coronary arteries and 
image acquisition only takes minutes, with few contraindications.  An 
intravenous cannula is required and allows the administration of the iodinated 
contrast agent required to produce images.   Contraindications include allergy 
to iodinated contrast agent or poor renal clearance as contrast is nephrotoxic  
and significant cardiac arrhythmia.  CTCAs key strength lies in its high 
negative predictive value, meaning it correctly classifies a high proportion of 
patients not to have significant CAD.  Its ability to visualise the coronary 
arteries, which typically measure 3-4mm in diameter in adults, stems from its 
high spatial resolution (42) (the ability to discriminate between two adjacent 
high contrast objects). The level of spatial resolution (around 0.625mm with 64 
slice scanners) of modern scanners allows detection of atherosclerotic plaque 
within coronary arteries and thereby a diagnosis of CAD to be made (43).   
Meta-analyses comparing the diagnostic accuracy of 64 slice or more CTCA 
in detecting significant coronary artery stenosis have estimated the sensitivity 
to be between 98% and 99%, and the specificity to be between 64% and 89% 
(44–46).  Specificity is limited mainly due to a phenomenon called ‘blooming 
artefact’ where, in the presence of a high calcium burden (typically a CAC 
score > 400), an exaggerated bright signal is seen which frequently leads to 
overestimate of the degree of luminal stenosis (47). 
Limitations of CT include the potential nephrotoxic effects of the intravenous 
contrast used, exposure of the patient to ionising radiation and its very limited 
ability to assess heart structure and function beyond the coronary arteries. 
Recently however a novel method of CT fractional flow reserve (FFR) to 
measure flow dynamics has been described (48, 49). CT FFR uses 
computational flow dynamics in order to calculate “3 Vessel” FFR from 
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normally acquired CTCA images (49). Recent trials have suggested that as 
these models have progressively evolved, diagnostic accuracy has improved 
for CT FFR compared to invasive FFR (50, 51) and suggest that care guided 
by CT FFR is comparable to that guided by routine invasive FFR (52, 53). A 
recent meta-analysis however is more circumspect identifying that the 
accuracy of CT FFR varies markedly across the spectrum of disease, with 
diagnostic accuracy as low as 46.1%(95% CI:42.9%-49.3%) for vessels with 
an invasive FFR of 0.8-0.9 (54). With current methodology, the radiation 
exposure from CTCA is in the region of 3-4 millisievert or below (55). The 
typical radiation dose associated with CAC scoring is less than 1 millisievert 
(56).    
 
Figure 1-1 Image panel showing CT FFR 
Figure with two case examples with left anterior descending coronary 
artery lesions, showing CTCA images on the left, corresponding CT FFR 
images and corresponding invasive coronary angiograms.  
(Image courtesy of HeartFlow) 
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1.3.4. MPS-SPECT 
MPS-SPECT is noninvasive nuclear imaging test that uses radioactive tracers 
in order to evaluate myocardial perfusion and systolic function in patients with 
suspected CAD. MPS-SPECT requires the administration of a radioactive 
perfusion tracer, which is usually administered intravenously, and a gamma 
camera system, utilizing single-photon emission computed tomography, for 
the detection of the gamma photons. MPS-SPECT is based upon the flow-
dependent and metabolism-dependent selective uptake of the radioactive 
tracer by functional myocardial tissue. MPS-SPECT images are commonly 
taken at rest and following stress. Largely, two-day rest-first MPS-SPECT 
protocols are used. Some centres with expertise in nuclear imaging have 
moved on to the one-day stress-only imaging. Stress testing is performed 
using either exercise (treadmill or bicycle), pharmacologic agents (mainly 
vasodilators, but if contraindicated, dobutamine), or a combination of both 
vasodilator stress and low-level exercise. The vasodilator stressors most 
commonly used are adenosine and dipyridamole. More recently, many centres 
are progressively using regadenoson. Adenosine produces vasodilation of the 
coronary vasculature through activation of the adenosine A2A receptor 
subtypes. Due to its nonselectivity, adenosine also has the ability to activate 
the remaining adenosine receptors (A1, A2B, and A3), which limits its use in 
patients with pronounced bronchospastic airway disease, hypotension, or sick 
sinus syndrome (57). Regadenoson is a selective adenosine A2A receptor 
agonist that was developed to reduce the adverse effects experienced with 
adenosine (58). The benefit of the rest-stress myocardial perfusion scan 
(MPS) protocol is that it also provides information on the presence or absence 
of myocardial infarction and viability. For example, if there is a fixed perfusion 
defect at rest and stress, it implies the presence of scar with no perfusion. 
Conversely, if there is perfusion defect at stress versus no defect at rest, it 
implies myocardial ischaemia in the given territory. Radiation dose from MPS-
SPECT varies around 8-14mSv, depending on the sequence and hardware 
used (59, 60).   
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MPS-SPECT is a well-validated diagnostic tool for the detection of myocardial 
ischaemia. American and European guidelines recommend the use of MPS-
SPECT for investigating patients with stable chest pain where the PTL is 
intermediate to high (8, 61). Additionally, it is a well-validated non-invasive 
technique with documented sensitivity as high as 90% for the detection of 
angiographically defined coronary disease (62), although more recent studies 
have suggested more modest values (63, 64). Large data derived from several 
large population studies demonstrate the prognostic power of MPS-SPECT. 
In a pooled analysis of 20,963 patients from 16 published studies with a follow 
up of slightly more than two years, the event rate of cardiac death and non-
fatal MI was only 0.7% per year (65). 
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Figure 1-2 Image panel showing MPS-SPECT and corresponding 
angiogram 
Image panel showing Single photon emission computed tomography 
myocardial perfusion scintigraphy in a 66-year old male patient who 
presented with typical cardiac chest pain. Image A is a resting short axis 
MPS-SPECT images demonstrating reducing perfusion to the mid 
inferior wall. This is suggestive of sub-endocardial scar with viability. 
Image B is a stress MPS-SPECT images demonstrating reduced 
perfusion in the infarct and peri-infarct zone. Image C is the 
corresponding chronic total occlusion of the proximal right coronary 
artery seen at elective diagnostic invasive coronary angiography. 
 
1.3.5. Stress echocardiography 
Stress echocardiography enables the detection of significant coronary artery 
disease through the use of transthoracic echocardiography to detect the 
characteristic changes in the contraction of the LV myocardium that occur with 
increasing myocardial oxygen demand.  The test is simple, cost effective and 
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does not involve the use of ionising radiation.  A full study takes around 30 
minutes and requires continuous ECG monitoring and an intravenous cannula 
(66).  In addition to ischaemia testing, it provides useful information regarding 
valvular and left ventricular function.  Contraindications include severe aortic 
stenosis and severe uncontrolled hypertension.  The diagnostic accuracy of 
stress echocardiography is dependent on the patient having good acoustic 
windows to allow visualisation of the LV endocardial borders. Where acoustic 
windows are poor, microbubble contrast agent may be used to improve 
endocardial definition and test accuracy (67).  Incremental increases in 
myocardial oxygen demand are brought about through either increasing levels 
of physical exercise (e.g. exercise bike or treadmill) or pharmacologically 
(usually with increasing doses of intravenous dobutamine).  These stimuli in 
turn bring about changes in the contraction of the LV myocardium with 
increasing levels of exercise or increasing concentrations of intravenous 
medication.  Myocardial ischaemia is suggested when a region of LV 
myocardium contracts less well with exercise or pharmacological stress 
compared with rest.  Prior myocardial infarction is indicated when a region of 
LV myocardium fails to contract at both rest and with either exercise or 
pharmacological stress.   
Stress echocardiography has a good safety record, with a recorded incidence 
of life threatening complications of 1 in 6574 with exercise and 1 in 557 with 
dobutamine in a large international registry (68).  For this reason and also due 
its similar diagnostic accuracy, exercise echocardiography is preferred to 
pharmacological stress whenever possible (66).  Overall accuracy of stress 
echocardiography has been demonstrated by meta-analysis to be in the region 
of 81% in terms of sensitivity, and a specificity of 82% (69).   A negative stress 
echocardiogram in a patient with chest pain and suspected coronary artery 
disease is associated with a low risk of cardiac death with one study 
demonstrating a risk of 0.6% per annum over a mean 7 year follow up period 
(70).  
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Figure 1-3 Image panel showing contrast enhanced stress 
echocardiography and corresponding coronary angiogram 
Contrast enhanced stress echocardiography in a male patient who 
presented to chest pain clinic with stable angina symptoms. Panel A-B 
demonstrate resting end-diastolic (Panel A) and end-systolic (Panel B) 
frames of the two chamber view on contrast enhanced stress-
echocardiography. Panel C-D demonstrate end-diastolic (Panel C) and 
end-systolic (Panel D) frames of the two chamber view at peak stress. In 
the peak stress end-systolic frame (Panel D), apical dyskinesia (black 
arrows) is seen with hyper-contractility of all other segments. Panel E 
identifies a severe stenosis of the left anterior descending artery (white 
arrow) at corresponding diagnostic invasive coronary angiography.  
Image courtesy of Dr Ripley – published in Interventional Cardiology 
(third edition) 
1.3.6. PET  
Positron emission tomography (PET) is a highly sensitive imaging modality 
that measures metabolic activity of disease processes as they occur in the 
patient. PET imaging depends on a radioactive tracer targeted toward the 
pathological process being investigated. In cardiac metabolism 11C-labelled 
fatty acids are used and 18F-fluorodexyglucose that can be used in the context 
of assessing myocardial viability and inflammation (71, 72). The majority of 
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studies assessing the diagnostic accuracy of PET perfusion imaging for the 
detection of CAD, have been conducted with static uptake images of 82Rb and 
13NH3 (73). 18F-fluoride–PET/CT has recently been identified as a novel tracer 
that can identify high risk coronary artery plaques in coronary arteries (74, 75). 
PET imaging is somewhat limited by the anatomical information it provides 
and progressively is being combined as hybrid imaging with either MR or CT 
scanners in order to localise tracer activity to specific anatomical sites.  
Currently cardiac PET is predominantly a research tool, but hybrid PET/CT 
imaging is being progressively used in oncology and as scanner hardware 
becomes more widely available clinical adoption in cardiovascular medicine 
may become more widespread. 
 
1.3.7. Coronary angiography 
Coronary angiography is recognised as the invasive reference standard for the 
assessment of CAD. Cardiac catheterisation was first performed in 1929 by 
Werner Forsmann who inserted a catheter into his cubital vein and published 
an x-ray of his chest to prove it was in the right ventricle. Subsequently Mason 
Sones developed the technique of selective coronary angiography. 
Angiography enables visualisation of the coronary arteries, accurate pressure 
measurements and functional assessment of the heart chambers and major 
vessels. Angiography requires percutaneous access via a flexible sheath that 
is inserted in a peripheral vessel (previously predominantly the femoral artery 
though progressively more commonly the radial artery) that allows catheters 
to be passed to the heart. Catheters enable accurate pressure monitoring or 
under fluoroscopic guidance allow injection of radio-opaque contrast agent to 
opacify vessels, as well as providing access for interventional procedures. 
 
The most common diagnostic use of angiography is for the direct visualisation 
of the anatomy of the coronary arteries. However, the 2D representation of the 
coronary anatomy is open to wide interobserver variability (76–78). Even the 
use of quantitative coronary angiography (QCA) is beset by diagnostic 
variability and thus “lumenology”  as a purely anatomical investigation has 
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been somewhat superseded by invasive measurements by wire based 
pressure assessments (28, 79, 80). Both fractional flow reserve (FFR) or 
instantaneous wave-free ratio (iFR) require a pressure sensor mounted on a 
coronary wire to measure pressure before and distal to a coronary stenosis. 
FFR is defined as the ratio of the pressure distal to a stenosis relative to the 
pressure proximal to the stenosis measured during maximal hyperaemia 
induced by a vasodilating agent (typically adenosine). FFR has been shown in 
a number of trials in single and multivessel disease to reduce rates of major 
adverse cardiovascular events (MACE) for FFR guided care compared to 
visual angiography and optimal medical therapy in patients with stable CAD 
(28, 81, 82). In contrast iFR measures the ratio of the pressure of the distal 
coronary (beyond a stenosis) during the “wave free period” of diastole 
(removing the confounders of myocardial contraction) to the aortic pressure. 
Most notably iFR does not require the induction of hyperaemia. Recently 2 
major trials have shown non-inferiority of iFR to FFR for the invasive 
assessment of stenoses of ambiguous haemodynamic significance in patients 
with stable CAD (79, 80). Furthermore, 2 trials have demonstrated superiority 
of FFR guided care of non-infarct related arteries in patients with ACS (83, 84).  
In addition to invasive coronary pressure assessments, two intracoronary 
imaging techniques are available to complement coronary catheterisation in 
the management of CAD; intravascular ultrasound (IVUS) and optical 
coherence tomography (OCT). IVUS and OCT enable visualisation of 
atherosclerotic plaque burden and composition, intracoronary structures and 
assist in stent implantation but have little role in ischaemia testing. 
  
1.4. Cardiovascular Magnetic Resonance 
CMR is a unique multi-parametric imaging modality producing high spatial 
resolution images that can be acquired in any plane for the assessment of 
global and regional cardiac function, myocardial perfusion and viability, tissue 
characterisation and proximal coronary artery anatomy, all within a single 
study and without exposure to ionising radiation (figure 1-4). Historically, long 
scanning times, limited scanner availability and narrow bore sizes restricted 
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the use of CMR, but these issues have been largely resolved, such that CMR 
has become a first line investigation for suspected stable angina in many 
centres in the UK and Europe. Consequently CMR is part of international 
clinical practice guidelines for the assessment of known and unknown stable 
CAD and for the identification of those who may benefit from revascularisation 
(8, 27, 85, 86). 
 
Figure 1-4 CMR Imaging techniques 
Images A and B show short axis and 4 chamber cine images 
respectively for anatomical and functional assessment. Image C shows 
stress perfusion with a septal perfusion defect (arrow). Image D shows 
EGE imaging with a large apical thrombus (arrow). Image E is LGE 
imaging with a transmural inferior infarction (arrows). Image F is 3D 
whole heart MR angiography. (87) 
 
 
1.4.1. CMR in stable CAD 
A CMR protocol for the investigation of stable CAD will typically take between 
30-60 minutes and involves the acquisition of cine images in multiple planes 
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for the assessment of left ventricular function and volumes, stress and rest 
myocardial perfusion imaging and late gadolinium enhancement (LGE) 
imaging for the assessment of myocardial viability and scar quantification 
(figure 1-5).  
 
 
 
Figure 1-5 CMR multi-parametric scanning protocols for the 
investigation of suspected coronary artery disease 
Panel A shows a typical multi-parametric CMR protocol for the 
investigation of stable coronary artery disease with adenosine stress 
perfusion, and B with incremental dose dobutamine stress. (87) 
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CMR is the reference standard non-invasive technique for the measurement 
of left ventricular (LV) and right ventricular (RV) volumes, and ejection fraction 
(EF), with high intra- and inter-observer reproducibility (88, 89). Steady State 
Free Precession (SSFP) cine imaging is typically performed for the 
assessment of LV function to enable visual assessment of global and regional 
myocardial function in a similar manner to echocardiography; however, there 
are no limitations due to poor acoustic windows or large body habitus 
degrading image quality. CMR volumetric analysis is performed by acquiring 
a stack of contiguous breath held cine images from the base of the heart to 
the apex; the endocardial and epicardial borders are subsequently contoured 
giving mass, volumes and function. Thus CMR provides a true 3D analysis of 
LV and RV function unlike 2D echocardiography that relies on geometric 
assumptions for volumetric calculations. Furthermore specific myocardial 
tagging pulse sequences can be performed that enable more detailed 
assessment of intra-myocardial mechanics beyond ejection fraction, including 
torsion, twist, strain and strain rates (90). Additionally, feature tracking is a 
novel post-processing method of quantitatively assessing strain and strain rate 
using standard cine images without having to acquire further imaging 
sequences as is the case with standard CMR tissue tagging (90, 91).  
 
1.4.2. Diagnosis of CAD 
Ischaemia detection by CMR is performed using either vasodilator or inotropic 
stress. Ischaemia detection by CMR is recommended as a first line strategy 
for investigating suspected angina in patients with an intermediate pre-test 
likelihood of CAD in both the current ESC and NICE guidelines (table 1.)(8, 
30), whilst the US guidelines are more conservative and give a grade IIa 
recommendation for stress perfusion CMR in patients with uninterpretable 
ECGs or unable to exercise (27).  
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Table 1-5 ESC and ACCF/AHA Recommendations for CMR in stable 
CAD 
 
ESC guidelines 
Suspected/stable coronary artery disease(8) 
In patients with suspected stable coronary artery disease 
and pretest probability of 15 % - 85 % stress imaging is 
preferred as the initial test option if local expertise and 
availability permit.   
Class I 
An imaging stress test is recommended in patients with 
resting ECG abnormalities, which prevent accurate 
interpretation of ECG changes during stress. 
Class I 
CMR should be considered in symptomatic patients with 
prior revascularisation (PCI or CABG). 
Class IIa 
Risk stratification is recommended based on clinical 
assessment and the results of the stress test initially 
employed for making a diagnosis of stable coronary artery 
disease. 
Class I 
 
CMR is recommended in the presence of recurrent or new 
symptoms once instability has been ruled out. 
Class I 
In symptomatic patients with revascularised stable 
coronary artery disease, CMR is indicated rather than 
stress ECG. 
Class I 
CMR is recommended for risk stratification in patients with 
known stable coronary artery disease and a deterioration 
in symptoms if the site and extent of ischemia would 
influence clinical decision making. 
Class I 
Recommendations for imaging to determine ischemia to plan 
revascularisation(8, 92)  
An imaging stress test should be considered to assess the 
functional severity of intermediate lesions on coronary 
arteriography. 
Class IIa 
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To achieve a prognostic benefit by revascularisation in 
patients with coronary artery disease, ischemia has to be 
documented by non-invasive imaging. 
Class I 
Following MI with multivessel disease, or in whom 
revascularisation of other vessels is considered, CMR for 
ischaemia and viability is indicated before or after 
discharge. 
Class I 
Heart Failure(85) 
CMR should be considered in patients with HF thought to 
have CAD, and who are considered suitable for coronary 
revascularization, to determine whether there is reversible 
myocardial ischaemia and viable myocardium. 
Class IIa 
AHA guidelines 
Diagnosis and management of stable coronary artery disease(27) 
CMR can be used for patients with an intermediate (10-
90%) to high (>90%) pretest probability of obstructive IHD 
who have an uninterpretable ECG and at least moderate 
physical functioning or no disabling comorbidity. 
Class IIa 
CMR is reasonable for patients with an intermediate to high 
pretest probability of IHD who are incapable of at least 
moderate physical functioning or have disabling 
comorbidity.     
Class IIa 
Pharmacological stress CMR is reasonable for risk 
assessment in patients with SIHD who are unable to 
exercise to an adequate workload regardless of 
interpretability of ECG.   
Class IIa 
 
CMR is reasonable in patients with known SIHD who have 
new or worsening symptoms (not unstable) and who are 
incapable of at least moderate physical functioning or have 
disabling comorbidity.   
Class IIa 
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1.4.3. Stress Perfusion CMR 
Stress perfusion CMR requires the induction of hyperaemia by a vasodilating 
agent, and then observation of the first-pass of a gadolinium based contrast 
agent (GBCA) through the myocardium to identify perfusion defects. Typically, 
the vasodilating agent used is adenosine though regadenason and less 
commonly dipyridamole and nicorandil are also used. Adenosine produces 
vasodilatation in most vascular beds, including the coronary circulation, via 
A2A and A2B receptors (57). Adenosine is given as an intravenous infusion 
typically at a rate of 140mcg/kg/min, though this can be increased if there is 
no haemodynamic response; the main side effects of adenosine are transient 
heart block, and bronchospasm can be caused in those with reversible airways 
disease(57). Regadenason is a new selective A2A adenosine receptor agonist 
that is given via an intravenous bolus, has less respiratory side effects than 
adenosine, and has recently been approved by both the FDA and in Europe 
for this indication (93, 94). The coronary micro-vasculature can dilate up to 4 
or 5 times from the resting state to ensure adequate tissue perfusion for 
example during exercise. However, the microvasculature distal to a stenosed 
coronary artery is already near-maximally vasodilated at rest and 
consequently when hyperaemia is provoked a coronary steal effect is caused. 
GBCAs increase the signal intensity in T1 weighted images and the first-pass 
of GBCAs through the myocardium causes healthy myocardium to become 
brighter while regions of hypoperfusion (‘ischaemia’) remain dark (figure 1-6).  
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Figure 1-6 Image panel showing CMR perfusion techniques 
Image A is a high spatial resolution k-t BLAST stress perfusion CMR 
study at 3.0T showing an antero-septal perfusion defect with 
corresponding left anterior descending lesion at angiography in image 
B. Image C shows a transmural lateral perfusion defect at standard 
resolution at 1.5T with corresponding circumflex lesion in image D. 
Image E shows a transmural inferior perfusion defect at standard 
resolution at 1.5T with corresponding right coronary artery lesion in 
image F. (87) 
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The diagnostic accuracy of stress perfusion CMR for the detection of CAD is 
well validated. A meta-analysis of 37 studies demonstrated a combined 
sensitivity of 89% (95%CI: 88%-91%) and specificity of 76% (95%CI: 73%-
78%) for perfusion CMR for the diagnosis of CAD (95). The CE-MARC study 
(n=752), the largest prospective randomised single-centre trial of CMR in this 
context showed superiority of perfusion CMR over MPS-SPECT, with a higher 
sensitivity (87% vs. 67%, p<0.0001) and negative predictive value (91% vs. 
79%, p<0.0001) but similar specificity (83% vs. 83% p=0.916) and positive 
predictive values (77% vs. 71%, p=0.061)(63, 96). Furthermore in a pre-
specified gender sub analysis of CE-MARC, CMR showed similar sensitivity 
for CAD detection in both males and females, whilst MPS-SPECT had 
significantly lower sensitivity in females compared to males (97). 
 
The multi-centre, multi-vendor MR-IMPACT II trial (n=515) also confirmed 
CMR’s superior sensitivity compared to MPS-SPECT (67% vs. 59%, p=0.024) 
but with a lower specificity (61% vs. 72%, p=0.038)(98);  however unlike CE-
MARC only the stress/rest perfusion component  of the CMR protocol was 
analysed. CE-MARC included analysis of LGE for scar detection, cine imaging 
for regional ventricular function and magnetic resonance angiography (MRA) 
for coronary artery anatomy, and a subsequent sub-analysis of CE-MARC 
demonstrated the additive diagnostic accuracy of the summation of these 
components of the multi-parametric protocol (99). 
 
Stress perfusion CMR has also been validated against FFR in a recent meta-
analysis with a pooled sensitivity and specificity of 0.90 (95% confidence 
interval [CI]: 0.86 to 0.93) and 0.87 (95% CI: 0.82 to 0.90) at the patient level 
and 0.89 (95% CI: 0.83 to 0.92) and 0.86 (95% CI: 0.77 to 0.92) at the coronary 
artery and territory levels (100). Furthermore CMR stress perfusion had 
comparable sensitivity and specificity to cardiac CT and PET in a recent meta-
analysis of non-invasive imaging modalities, and was superior to both MPS-
SPECT and DSE when using FFR as the reference standard (73). Most trials 
thus far have excluded patients with arrhythmia amid concerns regarding ECG 
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gating, however the diagnostic accuracy of stress perfusion CMR remains high 
in suspected CAD patients with AF or frequent ectopy (sensitivity 80%, 
specificity 74%) (101).  
 
1.4.3.1. 1.5T versus 3T field strength 
Although 1.5T is remains the standard field strength used in clinical CMR, 
imaging at a higher field strength of 3.0T offers increased signal to noise (SNR) 
and contrast to noise ratios (CNR) thereby giving improved spatial and 
temporal resolution (102). Consequently, the diagnostic accuracy of perfusion 
imaging at 3.0T may be improved, and in a small direct comparison of CMR 
perfusion at 1.5T, 3.0T (n=61) showed greater diagnostic accuracy in both 
single vessel (AUC: 0.89 vs. 0.70; p<0.05) and multi-vessel disease (AUC: 
0.95 vs. 0.82 p<0.05) (103). Furthermore, 3.0T has been compared to 1.5T 
using FFR as reference standard, corroborating it’s superior diagnostic 
accuracy (104, 105). The higher 3.0T field strength does however pose 
challenges with greater field inhomogeneity, susceptibility artefacts and higher 
local energy deposition. Also, many implants deemed “MR compatible” at 1.5T 
cannot be scanned at 3.0T (106). These issues are however being overcome 
with improved technology and the use of multi-transmit radiofrequency CMR 
techniques improving field homogeneity (107). 
 
1.4.3.2. Improving perfusion imaging 
Currently typical CMR perfusion imaging acquires 3 short axis slices of the left 
ventricle with an in-plane spatial resolution of 2-3mm. Developments in CMR 
technology however now allow faster scan speeds; these novel acquisition 
techniques allow accelerated data acquisition based on spatio-temporal 
undersampling (k-t SENSE or k-t BLAST and highly constrained back 
projection HYPR, compressed sensing and others)(108). These faster data 
acquisition techniques have been applied to achieve in-plane spatial resolution 
<2mm or full-coverage of the LV using 3D whole-heart perfusion imaging. High 
spatial-resolution imaging offers benefits by significantly reducing dark rim 
artefacts, as these are directly proportional to voxel size (109). Moreover there 
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is improved ability to detect sub-endocardial ischaemia which is critical in 
multi-vessel disease where there is a lack of reference healthy myocardium 
for comparison (110, 111). High spatial-resolution perfusion CMR has been 
validated at both 1.5 T and 3.0T against QCA with improved diagnostic 
accuracy at both field strengths compared to standard resolution perfusion 
imaging (102, 111, 112). Furthermore, validation against FFR gave sensitivity 
and specificity to detect stenoses at a threshold of FFR <0.75 of 0.82 and 0.94 
(p<0.0001) respectively, and an area under the curve of 0.92 (p<0.0001)(113). 
 
Conventional stress perfusion CMR is typically acquired in 3 short -axis slices, 
and thus unlike MPS-SPECT does not truly calculate global ischaemia burden. 
Accelerated acquisition techniques can also be employed to achieve full LV 
coverage using a 3D whole-heart single shot acquisition. Such 3D acquisitions 
can overcome the assumptions made about ‘missing’ myocardium between 
the slices from conventional 2D multi-slice perfusion imaging. Two studies 
have validated the feasibility and diagnostic accuracy of 3D stress perfusion 
CMR against FFR; at 1.5T 3D perfusion demonstrated a sensitivity, specificity 
and diagnostic accuracy of 90%, 82% and 87% respectively and 91%, 90% 
and 91% respectively at 3.0T (114, 115). Furthermore, in a recent multicentre 
trial of 3D stress perfusion at 3.0T, sensitivity and specificity were 84.7% and 
90.8% relative to the FFR reference (116). The main motivation for 3D 
perfusion is to give a more accurate quantification of total myocardial 
ischaemia burden; evidence from MPS-SPECT suggests a prognostic benefit 
for revascularisation in those with an ischaemia burden >10%, with an 
ischaemia burden of 10% conferring a risk of ~5% for death or MI per year 
(117, 118). Ischaemia burden as measured by 3D stress perfusion CMR has 
been compared to MPS-SPECT and showed good correlation (rs=0.70, 
p<0.001)(119). Intriguingly a recent pilot study compared ischaemia burden by 
high-resolution perfusion (using 3 short axis slices) and 3D perfusion imaging 
(providing whole heart coverage) suggesting that there was also a good 
correlation between the techniques (r=0.72; p=0.001), and that therefore the 
two methods are potentially interchangeable (120). 
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1.4.3.3. Quantitative perfusion 
CMR stress perfusion studies are normally reported in a qualitative manner; 
however this can prove challenging in diffuse or multi-vessel disease where 
there is no healthy reference myocardium to use as a visual comparator. 
These situations can introduce subjectivity into the analysis and consequently 
quantitative measurement techniques have been developed to provide an 
objective assessment of myocardial blood flow. A number of different methods 
of quantitative analysis have been assessed with the Fermi deconvolution 
method showing most accuracy when compared to microspheres in an 
explanted porcine model at 1.5T and mice at 3.0T (121, 122), and when 
compared to MPS-SPECT and with QCA (123). When compared to 
angiography with FFR, an MPR threshold of 1.58 detected a stenosis with an 
FFR <0.75 with a sensitivity of 0.80, specificity of 0.89 (p<0.0001), and area 
under the curve of 0.89 (p<0.0001)(113). Myocardial perfusion reserve derived 
from quantitative CMR perfusion has also shown good correlation to PET 
imaging, the imaging modality that is widely regarded as the reference 
standard non-invasive measure of myocardial blood flow (124, 125). Currently, 
time consuming post-processing has limited quantitative perfusion methods to 
a research tool, but automated methods are being developed that may 
potentially overcome this (126). To date however quantitative perfusion has 
not been shown to improve diagnostic accuracy over visual CMR analysis 
(127, 128). 
 
Recently a dual sequence fully automated quantitative perfusion method was 
proposed (129). This fully automated CMR perfusion mapping method for 
quantification of myocardial perfusion was validated using 13N–NH3 cardiac 
positron emission tomography as the reference method (130). Twenty-one 
patients underwent adenosine stress and rest perfusion imaging with 13N–
NH3 PET and a dual sequence, single contrast bolus CMR on the same day. 
Global and regional myocardial perfusion were quantified both at stress and 
rest using PET and CMR. The study demonstrated good correlation between 
global and segmental myocardial perfusion and myocardial perfusion reserve 
(130). 
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1.4.4. Dobutamine Stress CMR (DSMR) 
GBCAs have an excellent safety profile (131), but in patients with poor renal 
clearance (e.g. on dialysis) there is a risk of nephrogenic systemic fibrosis 
(NSF)(132). In those patients unable to have GBCAs inotropic stress CMR is 
an alternative. Inotropic stress CMR is typically performed with dobutamine in 
a similar manner to DSE with inducible regional wall motion abnormalities 
(RWMA) identified in territories supplied by a stenosed coronary artery at peak 
stress. Unlike DSE however, DSMR’s accuracy is not limited by body habitus 
or in those with poor acoustic windows and in a single centre study DSMR was 
shown to have significantly greater diagnostic performance to DSE in this 
context (133). However echocardiography in this study was performed without 
harmonic imaging and contrast agents, so that the performance of DSE is 
likely to be underreported compared with contemporaneous methods. DSMR 
has a comparable safety profile to DSE with an event rate of 0.1% for 
sustained VT and 0.4% for non-sustained VT, and 1.6% for atrial fibrillation; 
patients thus require close monitoring during scanning and resuscitation 
equipment needs to be available (134). DSMR has been shown to have high 
diagnostic accuracy for the detection of CAD with one meta-analysis of 14 
trials showing a pooled sensitivity of 0.83 (95%CI: 0.79-0.88) and specificity of 
0.86 (95%CI: 0.81-0.91)(135); furthermore a single centre trial of DSMR 
versus perfusion CMR showed similar diagnostic accuracy (136). First-pass 
perfusion can be performed additionally at peak dobutamine stress to provide 
incremental diagnostic accuracy (137), and can be a useful adjunct in 
challenging patient groups such as those with pre-existing wall motion 
abnormalities or dyssynchrony from left bundle branch block (138).  
 
Exercise is commonly used rather than pharmacological agents as the 
stressor in echocardiography, and gives useful prognostic information such as 
workload in metabolic equivalent (METs) in addition to ischaemia testing (139, 
140). CMR is limited in this respect due to the need for supine scanning and 
consistent positioning within the scanner. Recent studies however have 
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assessed the feasibility of exercise stress CMR and showed comparable 
accuracy to echocardiography, though it has yet to reach mainstream clinical 
use (141, 142). Promising developments are ‘steppers’ and cycle ergometers 
that can attach directly to the MRI scanner, and thereby eliminate the need to 
transfer the patient from the exercise equipment into the scanner (143, 144). 
 
1.4.4.1. Prognosis from stress CMR 
Both perfusion CMR and DSMR provide excellent prognostic information, and 
this has recently been shown in two large meta-analyses. One meta-analysis 
of 14 studies including 12,178 patients showed that a negative stress CMR 
was associated with a 1.03% annualised event rate, comparable to the normal 
population (145). A further meta-analysis of 19 studies including 11,636 
patients showed a similar annualised event rate of 0.8% for a negative stress 
CMR over a mean follow up of 32 months (146). In a large prospective study 
of 1,229 patients undergoing adenosine stress with a mean follow-up period 
of 4.2 ± 2.1 years, patients with reversible perfusion deficits had a 3-fold 
increased risk of major adverse cardiovascular events, with significantly more 
cardiac deaths (p<0.0001) and nonfatal myocardial infarctions (p<0.001)(147). 
Similarly the data from DSMR mirrors the results of first-pass perfusion CMR 
with a negative study conferring an equally low annual event rate of 1.3% (145, 
148). Recently the five-year outcome data from CE-MARC were published with 
prognostic data for both CMR and MPS-SPECT in the same patient 
population. The analysis showed that although an abnormal result from both 
tests was a strong indicator of future MACE, CMR was superior at predicting 
time to MACE in this population (149). Furthermore CMR remained the only 
independent predictor of outcome after adjustment for major cardiovascular 
risk factors, stratification for initial patient treatment and coronary angiographic 
findings (149). These findings likely reflect CMR’s overall greater diagnostic 
accuracy, combined with CMR’s higher spatial resolution enabling greater 
identification of subendocardial scar compared to MPS-SPECT (150); a 
feature known to confer prognostic significance beyond ejection fraction, and 
clinical or angiographic features (151). 
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1.4.5. Early and late gadolinium enhancement imaging 
GBCAs have a large molecular weight and cannot penetrate an intact cell 
membrane; consequently GBCAs are constrained to the extracellular space. 
In healthy myocardium the extracellular space is limited and contrast enters 
and clears rapidly. The extracellular space in infarcted myocardium however 
is substantially increased compared to normal myocardium and is less 
vascular. Thus in chronic myocardial infarction scar tissue composed of a 
matrix of collagen fibres has significantly increased extracellular space, 
leading to GBCA accumulation (slow washout), whilst in acute infarction 
GBCAs passively diffuse across disrupted myocardial cell membranes and 
into the intracellular space (greater volume of distribution)(152). Thus both 
acute and chronic myocardial infarctions retain more GBCAs. Imaged with T1 
sensitive acquisition methods, this results in a higher signal in infarcted tissue 
compared to normal reference myocardium.   
 
Early gadolinium enhancement imaging is performed immediately following 
contrast administration; this allows mainly the visualisation of ventricular 
thrombi that appear ‘dark/black’ due to a lack of contrast uptake as they are 
non-vascular (figure 1-7). CMR has been shown to be superior to both trans-
thoracic echocardiography (TTE) and trans-oesophageal echocardiography 
(TOE) for the identification of ventricular thrombi(153–155). LGE imaging is 
performed between 10-20mins after contrast administration, an appropriate 
inversion time (TI) is set to null the normal myocardium and the areas where 
gadolinium is retained enhances (figure 1-7). Typically a stack of short axis 
slices, a 4-chamber view and vertical long axis (VLA) are acquired. 
Alternatively, 3D LGE CMR imaging enables whole heart quantification of scar 
burden to be acquired in a shorter time period (although with a reduction in 
image quality), which may provide an alternative for patients that struggle to 
breath-hold (156, 157).  
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Figure 1-7 Image panel showing early and late gadolinium 
enhancement 
Images A and B show a lateral sub-endocardial infarction on short axis 
and 4 chamber LGE respectively. Images C and D show a full thickness 
inferior infarction on LGE imaging on short axis and VLA respectively. 
Images E and F show EGE and LGE imaging respectively of a full 
thickness apical infarction with an apical thrombus appearing black 
(highlighted by red arrow). Images G shows an extensive acute antero-
apical infarction with a core of microvascular obstruction visible within 
the hyperenhancement on EGE (red arrow). Image H shows an acute 
inferior wall infarction with MVO and extension into the right ventricle 
on LGE (red arrow) imaging. (87) 
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1.4.6. Viability assessment 
CMR viability assessment using LGE enables the accurate detection, and 
extent and trans-murality of previous myocardial infarction to be determined, 
and identifies regions with potential to recover function following 
revascularisation. Hibernating myocardium is dysfunctional myocardium that 
has been down-regulated through a process of chronic/repetitive ischaemia 
and which has the potential for functional recovery when blood flow is restored. 
LGE imaging detects replacement of normal viable myocytes by focal necrosis 
or fibrosis with high spatial resolution, and has excellent correlation to 
histopathology (152). Furthermore the degree of transmural extent of hyper-
enhancement on LGE imaging has a direct association to the potential for 
functional recovery following revascularisation; Kim et al demonstrated that 
segments with less than 25% hyper-enhancement were most likely to attain 
functional recovery whilst segments with over 75% hyper-enhancement were 
unlikely to improve, notably this was irrespective of whether the region was 
initially hypokinetic, dyskinetic or akinetic (158). A meta-analysis of 331 
patients using 50% trans-murality of hyper-enhancement reported a sensitivity 
of 95% (95%CI: 93-97%) and specificity of 51% (40-62%) for predicting 
functional recovery (159). 
 
CMR viability assessment is not however limited to just LGE imaging; whilst 
LGE identifies the transmural extent of scarring, the use of low-dose 
dobutamine (LDD) identifies the contractile reserve. Myocardium is considered 
viable if there is a 2mm or more increase in systolic wall thickening within a 
segment following administration of LDD (5-10mcg/kg/min)(160). While scar 
burden on LGE has been shown to be most sensitive method for assessment 
for functional recovery compared to LDD and diastolic wall thickness (161),  
LDD CMR offers higher specificity and PPV for prediction of functional 
recovery (91% and 93%, respectively)(159). Consequently a stepwise 
approach utilising LGE first followed by LDD if the trans-mural extent of LGE 
in the territory of the diseased coronary is between 1-50% has been proposed 
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(162). Recently both tissue tagging and feature tracking have been used to 
give quantitative viability assessment with LDD and have been suggested as 
possible methods to reduce reliance on operator experience in what is 
currently a qualitative method of assessment (163–165). 
 
LGE imaging has a grade A recommendation to determine myocardial viability 
prior to revascularisation in the ACCF/AHA/SCMR appropriate use guidelines 
(166), though viability assessment by LGE is currently not recommended for 
this indication in ESC or US practice guidelines for management of stable CAD 
or coronary revascularisation (8, 27, 86, 167). The utility of viability 
assessment has been questioned recently following the results of the STICH 
trial and the subsequently published viability sub-study that showed no 
mortality benefit from revascularisation following viability assessment (12, 
168). This is contrary to prior observational data in large meta-analyses 
including over 3000 patients with viability; revascularisation was associated 
with 79.6% reduction in annual mortality (p<0.0001) compared with medical 
treatment(13, 169) and presence of dysfunctional viable myocardium by LGE-
CMR without revascularisation is an independent predictor of mortality in 
patients with ischaemic LV dysfunction (170). Questions have been asked 
however whether the STICH sub-study results would have been different if 
CMR had been used rather than MPS-SPECT, and consequently in Europe 
the third highest indication for CMR remains the assessment of viability (171). 
 
1.4.6.1. Dark Blood 
LGE imaging has become the reference standard for myocardial viability 
assessment giving excellent depiction of myocardial infarction and 
identification of myocardial viability. Many myocardial infarctions due to the 
wavefront of ischaemia are sub-endocardial (20). Identification of contrast 
enhanced sub-endocardial scar that is adjacent to the contrast enhanced 
blood pool can consequently prove challenging. Thus interest has turned to 
methods that suppress the contrast enhanced blood pool yet to retain the 
conspicuity of the gadolinium enhanced scar. Multiple different dark blood 
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methods have been proposed to null the signal from blood pool and more 
clearly delineate sub-endocardial infarction by the addition of extra 
magnetization pulses (172–178). More recently a novel method that does not 
require a separate preparation pulse but by adjusting the TI to null the blood 
pool utilises the phase sensitive inversion recovery (PSIR) reconstruction to 
provide a dark blood method (179). These have not had widespread clinical 
adoption yet but are surely on the horizon. 
 
1.4.6.2. Scar beyond viability assessment 
In addition to identifying viable myocardium, the presence and extent of LGE 
provides valuable prognostic information, and the extent of scar burden by 
LGE is readily quantified and reproducible on CMR (180). Impairment of left 
ventricular ejection fraction is well recognised as an independent risk factor in 
those with coronary artery disease (85, 181); LGE can provide additive 
prognostication in these patients and a recent study of 1560 patients 
established that the presence of scar by LGE irrespective of LVEF identified 
those at risk of increased mortality (182). Furthermore, a meta-analysis 
showed that the presence of LGE increases the risk of death by 4.77% and 
MACE by 3.9% and that each gram of scar measured by LGE increased the 
hazards of death and MACE by 4% and 5%, respectively (183). Additionally 
the identification of previously unrecognised MI by LGE confers a significantly 
increased risk of both mortality and MACE (151, 184).  
 
The extent of scar burden by LGE in patients with IHD has also been identified 
in a number of studies to be an independent predictor of ventricular 
arrhythmias in patients with internal cardiac defibrillators (ICD)(185–187), and 
a recent meta-analysis of 1105 patients with ICDs determined that the extent 
of LGE was predictive of ventricular arrhythmia whilst LVEF was not (188). 
Additionally in a high risk cohort of patients with a mean LVEF of 35% being 
considered for ICD implantation, LGE demonstrated that significant scarring 
(>5% LV) in patients with LVEF>30%, conferred a risk similar to those with 
LVEF≤30% (189). Equally, in patients with LVEF≤30%, minimal or no scar 
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burden established a lower risk cohort similar to those with LVEF>30% (189). 
Other studies have identified the presence of a “grey zone” on LGE imaging, 
a heterogeneous region of viable and non-viable myocardium at the infarct 
periphery, as predictive of VT (190, 191).  
 
LGE and quantification of scar burden has also been used to predict 
responsiveness to cardiac resynchronization therapy (CRT)(192), and 
identification of scarring in the pacing region of the LV lead has been 
associated with non-response to device therapy (193, 194). In a similar 
method to imaging the coronary artery anatomy, coronary venous anatomy 
can be reliably demonstrated using GBCAs, which can potentially aid planning 
of device implantation (195). The combination of coronary venous imaging (not 
typically an MR based assessment), assessment of ventricular function and 
LGE may be a useful adjunct in the management of patients with ischaemic 
cardiomyopathy being considered for CRT, as well as risk stratifying those 
being considered for defibrillator therapy. 
 
1.4.7. Cost effectiveness 
The economic burden of CAD is enormous with £6.8billion spent in 2012 in the 
UK; in the US over 15 million people have CAD costing the US economy 
$108.9 billion/yr (4, 196). Cost effectiveness analyses help to inform optimal 
management pathways in order to maximise health care benefit within the 
constraints of limited resources. In the US a low yield has been reported at 
diagnostic angiography with just over 40% of patients referred having 
obstructive CAD (29). CMR can act as a potential gatekeeper to invasive 
coronary angiography in order to reduce downstream costs as well as reduce 
risk from unnecessary invasive assessments. 
 
Health economic analyses based on the CE-MARC dataset identified that 
despite the higher initial cost of CMR to MPS-SPECT, the superior diagnostic 
accuracy of CMR led to an overall greater cost effectiveness in models of the 
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UK, German and Swiss healthcare systems (197–199). A study of 1,158 
German patients being investigated for suspected CAD were randomised to 
either DSMR prior to angiography or direct to angiography; DSMR prior to 
invasive angiography led to a saving of 12,466€ of hospital costs per life year, 
furthermore this cost saving was maintained through a median period of 7.9 
years follow up (200). 
 
In a cost analysis comparing CMR and X-ray angiography versus angiography 
and FFR to determine the need for revascularisation, CMR and angiography 
was more cost-effective below a CAD prevalence of 62%, 65%, 83%, and 82% 
for the Swiss, German, UK, and the US health care systems, respectively 
(201). These studies confirm that as well as the established high diagnostic 
accuracy, CMR is also a financially advantageous investigative strategy in 
patients with CAD.  
 
1.4.8. Recently published and future studies 
Studies thus far have predominantly focused on the diagnostic accuracy of 
CMR; forthcoming multi-centre clinical effectiveness trials are however 
focused on evaluating clinical pathways to improve patient outcomes. The 
recently published CE-MARC 2 trial was a prospective, multi-centre, 3-arm 
parallel group, randomised controlled trial comparing multi-parametric CMR 
versus UK NICE CG95 guidance (30) versus AHA/ACCF MPS-SPECT 
appropriate-use criteria (202) to investigate patients with suspected CAD (pre-
test likelihood 10%-90%) requiring further investigation (35, 203). The primary 
outcome measure was FFR defined unnecessary angiography (FFR >0.8) with 
the important safety secondary outcome measure of MACE at 1 and 3 years. 
CE-MARC 2 showed overall that CMR guided care resulted in significantly 
reduced rates of unnecessary angiography at 12 months compared to routine 
guideline directed care (35). 
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Contemporary registry data from the US suggests roughly 12-26% of elective 
PCI are deemed inappropriate with considerable variation in practice between 
sites (204, 205). Both FAME and DEFER showed improved outcomes using 
FFR guided revascularisation based on ischaemia detection, compared to 
reliance on visual assessment at angiography (28, 81). These trials would 
suggest that a better way of selecting patients prior to invasive 
revascularisation procedures is required. CMR offers a non-invasive 
ischaemia assessment and the MR-INFORM trial aims to establish if perfusion 
CMR could act as a non-invasive surrogate to FFR to determine the need for 
revascularisation in patients with stable CAD (206). MR-INFORM is a multi-
national, multi-centre, non-inferiority study comparing adenosine stress 
perfusion CMR versus angiography with FFR measurement to guide 
revascularisation decisions in patients with stable angina and moderate to high 
probability of CAD; the primary endpoint was the occurrence of MACE at one 
year. The trial has completed recruitment and the preliminary findings were 
reported at ACC in 2017. The primary outcomes demonstrated that using CMR 
stress perfusion to guide initial management of patients with stable angina and 
an intermediate to high risk for coronary artery disease is non-inferior to a 
strategy with invasive angiography supported by FFR during a follow-up of one 
year. Both strategies CMR and FFR guidance resulted in a low overall clinical 
event rate. The number of revascularization procedures was significantly lower 
when guided by CMR stress perfusion imaging in comparison to invasive 
angiography supported by FFR. 
 
The prognostic benefit of revascularisation in stable coronary artery disease 
is a topic of debate; both the COURAGE trial and BARI-2D failed to show any 
prognostic benefit of revascularisation over optimal medical therapy (OMT) in 
patients with stable CAD (207, 208). Determination of extent of ischaemia in 
both these 2 trials was however limited; in COURAGE only 33% of patients 
had moderate/severe ischaemia and moreover around 40% had <5% 
ischaemia(209). In both trials however those with a higher residual ischaemia 
burden had a worse prognosis (209–211). The ISCHEMIA trial aims to test the 
hypothesis that a routine invasive strategy with early cardiac catheterisation 
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and revascularisation plus OMT is superior to a conservative management 
strategy of OMT for patients with moderate or severe ischaemia (117). The 
trial aims to recruit over 8000 patients worldwide with ischaemia determined 
by non-invasive imaging (CMR, stress echocardiography, MPS-SPECT) with 
a primary endpoint of time to cardiovascular death or non-fatal myocardial 
infarction.  
 
1.4.9. Coronary artery evaluation 
Coronary Magnetic Resonance Angiography (CMRA) allows the non-invasive 
anatomical assessment of coronary arteries; currently clinical indications are 
limited to the detection of aberrant origin of coronary arteries, coronary ectasia 
and/or aneurysms (class I indication) and evaluation of bypass grafts (class II 
indication)(212, 213). CMRA for diagnosis of CAD is not presently part of 
routine clinical practice. The initial multi-centre experience using CMRA in this 
context showed interpretable image quality in 84% of proximal and middle 
coronary artery segments, though with a specificity of 42%; CMRA did 
however exclude triple-vessel disease and left main coronary artery stenosis 
with a negative predictive value (NPV) of 100% (214). Progress in CMRA 
techniques have improved significantly however, and a recent multi-centre 
study showed that CMRA at 1.5T detects significant CAD with a sensitivity of 
88% and specificity of 72% and a negative predictive value of 88% (215). 
Furthermore one study showed in a direct comparison between CMRA and 
CTCA there was no significant difference between coronary imaging at 3.0T 
and 64-slice CTCA for the detection of CAD with a sensitivity of 87% versus 
90% (p=0.16) and specificity of 77% versus 83% (p=0.06) respectively (216).  
 
Currently CMRA techniques are time consuming and there are questions over 
the incremental diagnostic merit they provide in addition to established 
perfusion protocols; the CE-MARC study found no additional diagnostic 
benefit by including CMRA into a full multi-parametric protocol versus the 
perfusion/LV function/LGE combination (overall accuracy 84.6% vs. 84.2% 
(p=0.5316)(99). Moreover there was no significant improvement in diagnostic 
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accuracy when CMRA was added to perfusion imaging at 1.5T and compared 
to FFR as the reference standard (217).  
 
1.4.10. Future directions 
T1 mapping 
T1 mapping and extra cellular volume fraction quantification are novel 
methods for CMR tissue characterisation. These techniques are currently 
research tools that have shown promise for diagnosis and prognostication in 
rare disease processes (e.g. Amyloid and Fabry’s Disease); presently 
however they do not have an established role in the diagnosis or management 
of stable IHD (218, 219). Post myocardial infarction however a role for these 
imaging “biomarkers” is being established in predicting both prognosis and 
adverse LV remodelling (220, 221).  
 
Blood Oxygen Level Dependent (BOLD) CMR uses the paramagnetic 
properties of deoxyhaemoglobin as an endogenous contrast agent; increasing 
deoxyhaemoglobin content leads to a reduction of signal intensity on T2 or T2* 
weighted images (222). The magnitude of the BOLD effect depends on the 
static magnetic field strength, with an exponential increase at 3.0T from 1.5T; 
consequently, most studies have used 3.0T. Thus far BOLD has shown good 
correlation with QCA and conventional CMR perfusion imaging, but studies 
are generally small and single centre, limiting its clinical validation (223, 224).  
 
Diffusion tensor MRI (DTI) is another method that has recently been gaining 
interest in CMR. DTI is a technique that relies on measuring restricted diffusion 
of water to reveal in vivo anatomical structures such as the myocardial 
microstructure by assessing myofiber orientation (225). Although, currently a 
research tool it is giving insight in how histology relates to physiology (226, 
227).  
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Four-dimensional flow cardiovascular magnetic resonance imaging (4D flow 
CMR) enables mapping and quantification of intra ventricular flow and can 
measure its kinetic energy (KE) (228). This method is uniquely placed to 
provide new insight into the manner of intra-ventricular flow in both health and 
disease. 4D flow techniques allow quantification of intra-cardiac flow in a three-
dimensional plane, and as it is automated has the potential to reduce intra-
/inter-observer variability and measure flow indices with high accuracy.  
 
Finally, hyperpolarised CMR is making the transition from animal studies to 
human applications. Hyperpolarisation methods artificially increase the 
number of molecules in one orientation resulting in a significant increase in 
MR signal; combined with 13C enriched metabolic tracers enable real time 
imaging of in vivo substrate metabolism, coronary angiography and 
quantitative perfusion imaging (229). The results of human hyperpolarisation 
studies are eagerly awaited. 
 
 
1.5. Conclusion  
Over the last decade, the evidence base for the diagnostic accuracy of CMR 
for the investigation of stable coronary artery disease has been confirmed 
through the publication of large-scale clinical trials and meta-analyses, and 
CMR is now firmly established in clinical practice guidelines. CMR enables 
assessment of cardiac dimensions, function, ischaemia, scar burden and 
tissue viability in a single study without exposure to ionising radiation. CMR 
also offers prognostic information with a normal stress CMR associated with a 
<1% risk of death or MI at 2 years, whilst the presence of LGE confers added 
prognostication above and beyond simple LV ejection fraction. New technical 
developments continue apace and ongoing large clinical trials will further 
clarify the role of CMR in routine clinical practice and guide the future 
development of international guidelines.  
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The aim of this thesis is to study and refine the utility of both existing and 
emerging CMR imaging techniques in the context of IHD, with a particular 
emphasis on prior myocardial infarction and LGE techniques, risk prediction 
and diagnostic accuracy of ischaemia testing in severe CAD. 
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2. Methods 
Methods common to all the following results chapters are detailed in this 
section.  Further relevant methodology specific to individual results chapters 
is included within the methods section of relevant chapters. 
 
2.1. Study Populations 
 
The details of each specific patient population by chapter are listed in the 
following individual sections.  The exclusion criteria common to all patient 
groups undergoing CMR in Chapters 3,4,5,6,7 included the following: 
 Contraindication to CMR (e.g. intra-orbital metal, intracranial clips, 
claustrophobia, non-CMR conditional permanent pacemaker or 
defibrillator, etc.) 
 Pregnant or breastfeeding patients 
 Weight ≥120kg or obesity where girth exceeds scanner diameter 
 Inability to lie flat for the duration of the CMR scan  
 Inability to give written, informed consent 
 Known adverse reaction to gadolinium based contrast agents 
 glomerular filtration rate < 30mL/min/1.73m2 
 
2.1.1. Common patient population for Chapters 3 and 5  
Both these chapters derived part or all their study populations from the CE-
MARC study. The CE-MARC study protocol has been published previously 
(96). 752 patients were recruited between March 2006 and August 2009 from 
2 hospitals (Leeds General Infirmary and Pinderfields General Hospital).  
Inclusion criteria for CE-MARC were stable chest pain symptoms thought to 
be angina pectoris, at least one cardiovascular risk factor (smoking, family 
history of premature cardio-vascular disease, arterial hypertension, 
hyperlipidaemia, diabetes mellitus), body weight less than 110 kg, suitability 
for coronary revascularisation if required and currently in sinus rhythm. 
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Recruited prior to commencement of my MD, I reviewed Leeds angiographic 
database for the enrichment population. 
 
2.1.1.1. Patient population for Chapter 3 
The patient population in this chapter was derived from the CE-MARC study 
(63). Twenty-seven patients (4% of CE-MARC) with left main stem (LMS) 
coronary disease ≥50% (n=22), and left main equivalent (≥70% stenosis of 
proximal LAD and circumflex arteries) (n=5) by QCA were selected from the 
CE-MARC population, together with 27 control patients without significant 
stenosis on X-ray angiography. The control patients were independently 
matched to the LMS group for age, sex and cardiovascular risk factors. All 
patients had undergone CMR, MPS-SPECT and angiography. Recruited prior 
to commencement of my MD, I reviewed all CRFs for appropriate patients and 
controls. 
 
2.1.1.2. Patient population for Chapter 5 
The patient population in this chapter was derived from patients in the CE-
MARC study that had undergone angiography (63, 96), the CE-MARC 2 trial 
(35, 203) and a further enrichment population from the Leeds General 
Infirmary. 675 patients of the 752 CE-MARC patients were included (inclusion 
criteria outlined above). 264 patients from the multi-centre CE-MARC 2 trial 
that had undergone angiography within 12 months of randomisation (which 
enrolled 1,202 patients) from November 2012 to March 2015 (35, 203). 
Inclusion criteria for CE-MARC 2 were an estimated PTL of CAD of 10-90% 
who were aged ≥30yrs with suspected stable angina requiring further 
investigation, and no prior MI/ACS, and no prior revascularization. 
Anonymised data for 105 patients consecutively undergoing elective coronary 
angiography for the investigation of suspected CAD at Leeds General 
Infirmary with an estimated PTL <10% or >90% further enriched the population 
to make it generalisable. 
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2.1.2. Patient population for Chapter 4 
The study population for Chapter 4 was derived from the VINDICATE (VitamIN 
D treatIng patients with Chronic heArT failurE) trial (230). 223 patients were 
enrolled in the VINDICATE trial and a subgroup of 69 patients underwent a 
baseline CMR scan. Of these 53/69 had myocardial tagging sequences 
performed as part of their multi-parametric CMR protocol and were included in 
the analysis.  
Inclusion criteria were, patients had stable (>3 months) NEW York Heart 
Association (NYHA) functional class II or III symptoms, a left ventricular 
ejection fraction ≤45% on maximally tolerated medical therapy (>3 months) 
and a 25(OH) vitamin D level of <50 nmol/l (<20 ng/ml). All patients were 
invited to enter the CMR substudy at their initial enrolment visit. Exclusion 
criteria included history of taking calcium or other vitamin supplements in the 
preceding 3 months; aetiology of chronic heart failure (HF) due to untreated 
valvular heart disease, anaemia or thyrotoxicosis; existing indications for 
vitamin D supplementation; history of primary hyperparathyroidism, 
sarcoidosis, tuberculosis or lymphoma; cholecalciferol concentration >50 
nmol/l (20 ng/ml); or if there was significant renal dysfunction (estimated 
glomerular filtration rate <30 ml/min/1.73m2)(230). Aetiology of heart failure 
was determined by the enrolling clinician. Ischaemic cardiomyopathy (ICM) 
was defined as left ventricular dysfunction associated with previous significant 
coronary disease (>70% in at least one major epicardial coronary artery) on 
angiography, positive ischaemia testing with MPS-SPECT or stress 
echocardiography and/or history of previous myocardial infarction or 
revascularisation (230); non-ischaemic cardiomyopathy (NICM) was defined 
as left ventricular dysfunction in the absence of the previous conditions.  A 
further healthy 25 age-matched controls with no co-morbidity and taking no 
regular medication underwent an identical CMR scan protocol. Recruited prior 
to commencement of my MD, I supervised/performed CMR scanning.  
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2.1.3. Patient population for Chapter 6 
For Chapter 6, 92 patients with prior myocardial infarction were prospectively 
recruited between June 2016 and June 2017. Of these, 53 patients had 
chronic and 39 patients had acute MI. MI was diagnosed by cardiac 
biomarkers, electrocardiography and coronary angiography. Patients were 
classified as Acute MI if scanned within 7 days of their index admission with 
the acute coronary syndrome. Chronic MI was defined as being scanned at 
least 3 months following the initial presentation of the acute coronary 
syndrome. Inclusion criteria were ≥18 years of age, no contra-indication to 
contrast-enhanced CMR, glomerular filtration rate ≥ 60mL/min/1.73m2.  
Exclusion criteria were patients with atrial fibrillation, non-MR compatible 
implants, renal failure or claustrophobia . I recruited and scanned patients. 
 
2.1.4. Patient population for Chapter 7 
 
The study population for Chapter 7 encompassed 30 patients with prior MI 
who were prospectively recruited between April 2017 and June 2017. MI was 
diagnosed by cardiac biomarkers, electrocardiography and coronary 
angiography. Inclusion criteria were ≥18 years of age, no contra-indication to 
contrast-enhanced CMR, glomerular filtration rate ≥ 60mL/min/1.73m2.  
Exclusion criteria were patients in atrial fibrillation, non-MR compatible 
implants, renal failure or claustrophobia. I recruited and scanned patients. 
 
2.2. Ethics and approvals 
All Chapters were performed in accordance with the Declaration of Helsinki, 
approved by the National Research Ethics Service, with all patients providing 
informed written consent. Ethics for the respective chapters had been attained 
prior to my commencing my MD but in the course of my research time I gained 
experience in applying for ethical approval. For the VINDICATE study (Chapter 
4), the protocol and other relevant documentation had been approved by the 
National Research Ethics Service [12/YH/0206]. CE-MARC and CE-MARC 2 
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(Chapters 3 and 5) were conducted in accordance with the Declaration of 
Helsinki (2000); CE-MARC was approved by the UK National Research Ethics 
Service (05/Q1205/126); CE-MARC 2 was approved by the UK National 
Research Ethics Service (12/YH/0404) (35, 63). For Chapters 6 and 7, the 
study protocol was performed in accordance with approval from the National 
Research Ethics Service (12/YH/0169). CE-MARC and CE-MARC 2 were 
funded by the British Heart Foundation (BHF); grant references RG/05/004 
and SP/12/1/29062. Additional support was received from the Leeds Teaching 
Hospital Charitable Foundation and the National Institute for Health Research 
(NIHR) Leeds Clinical Research Facility. VINDICATE was funded by the 
Medical Research Council, UK. 
 
2.3. MRI Scanner Hardware  
In Chapter 3, patients underwent stress perfusion-CMR on a Philips Intera 
1.5T scanner (Philips Medical Systems, Best, The Netherlands) equipped with 
“Master” gradients (30 mT/m peak gradient, 150 mT/m/ms slew rate) and a 
five-element cardiac phased-array receiver coil. 
For patients scanned in Chapter 4, CMR was performed on a 3.0 Tesla Philips 
Achieva system (Philips Healthcare, Best, The Netherlands) equipped with a 
32 channel coil and MultiTransmit® technology. 
In Chapters 6 and 7, CMR was performed on a 1.5 Tesla Philips Ingenia 
system (Philips Healthcare, Best, The Netherlands) equipped with a 24 
channel digital receiver coil and patient-adaptive RF shimming. 
 
2.4. Common CMR protocols 
 
2.4.1. Survey images 
At the start of any CMR protocol, free breathing low-resolution survey scans 
of the chest were performed to mark anatomical landmarks. For each pulse 
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sequence, images with artefact were repeated until any artefact was removed 
or minimised. The highest quality images were used for analysis. 
 
2.4.2. Localisers  
 
Cardiac localiser scans which define short axis, vertical long axis and 
horizontal long axis acquired with a balanced SSFP, single slice, breath-hold 
pulse sequence. Pulse sequence parameters: echo time (TE) 1.6 ms, 
repetition time (TR) 3.2 ms, slice thickness 8 mm, matrix 192 × 192, field of 
view 320–400 mm according to patient size, SENSE factor 1.7 to 2.0, 30–50 
phases per cardiac cycle. 
 
2.4.3. The CE-MARC CMR protocol  
The protocol commenced with a low-resolution survey scan and localisers.  
Intravenous adenosine was then administered for approximately 4 minutes at 
140 mcg/kg/min, following which first pass stress perfusion imaging was 
undertaken after the injection of 0.05 mmol/kg dimeglumine gadopentetate. 
Stress and Rest perfusion was carried out using a “3 of 5” technique, planned 
from long axis cine images. Three-dimensional whole heart MR coronary 
angiography was performed but not used in the analysis here. Rest perfusion 
imaging was undertaken a minimum of 15 minutes following stress perfusion, 
with a further injection of 0.05 mmol/kg dimeglumine gadopentetate. A final 
injection of 0.1 mmol/kg dimeglumine gadopentetate was given following this 
sequence, bringing the overall gadolinium dose to 0.2 mmol/kg. Resting left 
ventricular function was then assessed, initially for three slices planned 
identically to the perfusion slices, and then for the entire left ventricle using 
contiguous slices. A modified Look-Locker inversion time scout was performed 
prior to LGE imaging in short axis, vertical long axis and horizontal long axis 
orientations. 
 
- 51 - 
 
Figure 2-1 Image panel showing CE-MARC scanning protocol 
 
 
2.4.4. Cine imaging 
2.4.4.1. Chapter 3 
A contiguous cine stack covering the entire left ventricle in 10–12 slices 
(depending on left ventricular long axis length). Three additional slices, with 
identical slice positioning to the perfusion sequence were also be acquired. 
Pulse sequence parameters: balanced SSFP, TE 1.7 ms, TR 3.5 ms, flip angle 
60°, SENSE factor 2, matrix 192 × 192, field of view 320–460 mm, slice 
thickness 10 mm, at least 20 phases per cardiac cycle, 1–2 slices per breath-
hold. 
 
2.4.4.2. Chapter 4 
A contiguous cine stack were acquired covering the entire heart in the LV short 
axis plane (balanced steady state free precession), spatial resolution 
1.2x1.2x10mm³, 30 cardiac phases TR/TE 2.6/1.3ms, flip angle 40o, field of 
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view 300-420mm, typical temporal resolution 39ms) and in orthogonal long-
axis planes. 
 
2.4.4.3. Chapters 6 and 7 
Assessment of myocardial function using standard SSFP cine imaging in a 
contiguous cine stack were acquired covering the entire heart in the LV short 
axis (spatial resolution 1.09x1.09x8mm³, 30 cardiac phases TR/TE 
3.0/1.48ms, flip angle 40o, field of view 360-360mm, SENSE acceleration). 
 
2.5. Common CMR analysis 
CMR analysis in Chapter 3 was carried out by JF, JPG and SP with additional 
post processing by JB. Specifically JF performed the quantitative perfusion 
analysis. CMR analysis in Chapter 4 was conducted by 2 observers (JF overall 
analysis and PS for interobserver variability). CMR analysis in Chapter 6 was 
conducted by 3 observers (JF overall analysis, GF and LAB for interobserver 
variability). CMR analysis in Chapter 7 was conducted by 2 observers (JF 
overall analysis, GF for interobserver variability).  All post-processing CMR 
analysis was carried out using the same software (CVI42, Circle 
Cardiovascular Imaging, Calgary, Canada) with the exception of tissue tagging 
analysis which used separate software (inTag version 1.0, Creatis, Lyon. 
France) and the post processing analysis of perfusion imaging in LMS which 
is described below.  Specific methods of CMR analysis are detailed in the 
respective chapters. 
2.5.1. Assessment of LV function 
The short axis LV cine stack was used to  generate LV end systolic and end 
diastolic volumes according to the summation of discs methodology (231). The 
left ventricular endocardial and epicardial borders were manually traced from 
the short axis LV cine stack at both end systole and end diastole in order to 
generate systolic and diastolic volumes. The LV ejection fraction was derived 
from the equation:  
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Equation 1 LV ejection fraction 
100*)/)(((%) LVEDVLVESVLVEDVLVEF   
 
Where EDV= end diastolic volume(ml), ESV= end systolic volume 
 
Both trabeculations and the papillary muscles were excluded. The LV mass 
values were calculated from the end diastolic myocardial volume according to 
established methods (232).  The Mosteller equation was used to index 
volumetric data to body surface area.   
 
2.5.2. Tagging 
For tagging analysis, endocardial and epicardial contours were drawn on the 
short axis spatial modulation of magnetization images using a semi-automated 
process. Peak circumferential LV strain was measured for the three slices at 
apex, mid-ventricle, and base. Strain was measured in the mid-myocardial 
layer which has previously been reported to be the most reproducible (233). 
LV twist was calculated by subtracting the basal from apical rotation.  Basal 
and apical radius was calculated from cine images in diastole at the same slice 
location as the tagged images. The equation used to determine torsion was 
(234):  
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Equation 2 Calculation of Torsion 
 
 
𝑇𝑜𝑟𝑠𝑖𝑜𝑛 =  
𝑃𝑒𝑎𝑘 𝑇𝑤𝑖𝑠𝑡 × (𝐴𝑝𝑖𝑐𝑎𝑙 𝑅𝑎𝑑𝑖𝑢𝑠 + 𝐵𝑎𝑠𝑎𝑙 𝑅𝑎𝑑𝑖𝑢𝑠)
2 × 𝐴𝑝𝑒𝑥 𝑡𝑜 𝐵𝑎𝑠𝑒 𝑙𝑒𝑛𝑔𝑡ℎ
 
 
2.5.3. Late Gadolinium Enhancement quantification 
In Chapters 4,6 and 7, quantitative assessment of myocardial scar burden was 
performed using a threshold of 50% of the maximum intensity within the scar 
(full width half max method). This method has been proposed as the most 
reproducible quantitative measure of late enhancement of myocardial scar 
(180). On the LGE short-axis images endocardial and epicardial contours were 
manually outlined (excluding trabeculations and papillary muscles); manual 
delineation of two separate user-defined regions of interest (ROIs) were then 
made on the LGE short axis slice where infarcted myocardium was present. 
One ROI was drawn in remote myocardium (where no scar was present); a 
second ROI was drawn around hyperenhanced myocardium where infarcted 
myocardium was present. Automated calculation for the scar tissue mass 
(grams) was then calculated on each LV short axis slice based on these ROIs. 
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Figure 2-2 Image panel showing an example image of an LV slice using 
the  semi-automated full width half maximum LGE quantification method 
on Circle CVI 
 
2.6. X-ray coronary angiography 
 
All patients in the CE-MARC study were scheduled to undergo invasive X-ray 
coronary angiography by a cardiologist blinded to the MPS-SPECT and CMR 
results. Angiography was performed by standard methods from the femoral or 
radial approach. X-ray angiography images were analysed by two 
cardiologists (JY and NM) with experience in invasive coronary angiography 
for CE-MARC. Quantitative coronary angiography analysis was performed off-
line using QCAPlus software (version 8.11.19, Sanders Data Systems, Palo 
Alto, California, USA). Clinically significant coronary disease was defined as 
≥70% stenosis of a first order coronary artery measuring 2 mm or greater in 
diameter, or left main stem stenosis 50% or more as measured by QCA. The 
same QCA parameters were applied to the CE-MARC 2 population 
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undergoing angiography where FFR was not possible and in the enrichment 
population derived from the Leeds General Infirmary (performed by JF).  
 
In the population derived from CE-MARC 2 fractional flow reserve 
(PressureWire; St Jude Medical, Minneapolis, MN) was performed in all 
vessels ≥2.5mm with a stenosis considered ≥40% and ≤90%, following 
intracoronary nitrates. Adenosine at a rate of 140 to 210 μg/kg/min was given 
intravenously to achieve maximal hyperaemia and haemodynamic steady 
state. Totally occluded coronary arteries were assigned a  default FFR value 
of 0.50; for lesions with a visual stenosis of >90%, FFR was also considered 
positive (0.50), and for lesions <40%, FFR was considered normal (0.90). If 
FFR was not able to be performed in patients in the CE-MARC 2 trial, then 
QCA measurements were made during offline analysis by a single 
independent blinded observer at the Glasgow Angiographic core laboratory. 
 
2.7. Statistical Analysis 
All statistical analysis was performed using the PASW software package (V21, 
SPSS, IBM, Chicago, Illinois, USA).  Data are presented as mean±SD, median 
(interquartile range, IQR) or frequency (percentage). Data were tested for 
normality using the Shapiro-Wilks test.  For normally distributed data, two-
tailed unpaired Student’s t tests were used for comparisons between groups, 
and paired Students t tests were used for intragroup comparisons. For non-
normally distributed data, the Related-Samples Wilcoxon Signed Rank Test 
and independent samples Mann-Whitney U test were used. To compare 
between groups an analysis of variance (ANOVA) and Tukey post-hoc tests 
were used. The Chi-squared test was used for comparing categorical 
variables. Pearson’s correlation coefficients were used to assess the 
correlation of dependent and independent variables.  P values <0.05 were 
considered statistically significant.   
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3. A comparison of Cardiovascular Magnetic Resonance and 
Single Photon Emission Computed Tomography Perfusion 
Imaging in Left Main Stem or Equivalent Coronary Artery 
Disease 
3.1. Background 
Left main stem coronary artery disease is found in approximately 5% of 
patients with stable angina and in approximately 7% of patients presenting 
with an acute myocardial infarction (235). Significant LMS disease is typically 
defined as a stenosis of ≥50% and LMS equivalent as ≥70% stenosis of both 
the proximal left anterior descending artery and proximal circumflex artery. 
Significant LMS disease is associated with poor clinical outcomes, with an 
untreated 3-year survival of 50% in those with >50% stenosis dropping to 41% 
in those with stenosis >70% (236, 237). Several studies have demonstrated 
survival benefit for revascularisation of significant LMS stenosis (238, 239). 
Thus, accurate detection and functional assessment of the degree of LMS 
stenosis has both important prognostic and therapeutic implications. 
 
Patients evaluated for suspected CAD frequently undergo functional imaging, 
which may include MPS-SPECT or CMR imaging. A normal myocardial 
perfusion study by either of these techniques is associated with an excellent 
long-term prognosis (146, 149, 240). Published data on the utility of MPS-
SPECT for the diagnosis of LMS disease are limited, with variable diagnostic 
accuracy reported (241–244). Equally, the diagnostic accuracy of stress 
perfusion CMR is poorly established in LMS disease.  
 
The Clinical Evaluation of MAgnetic Resonance imaging in Coronary heart 
disease study (63, 96) was a large prospective study of patients with 
suspected CAD; 752 patients were enrolled and all were scheduled to undergo 
CMR, MPS-SPECT and the reference standard invasive coronary 
angiography. Using the CE-MARC dataset, we hypothesised that CMR would 
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have a greater diagnostic accuracy than MPS-SPECT for the detection of LMS 
or LMS equivalent CAD, and that quantitative CMR perfusion analysis would 
improve diagnostic discrimination compared to visual analysis. 
 
3.2. Methods 
3.2.1. Subjects 
All patients with LMS disease ≥50%, and left main equivalent (≥70% stenosis 
of proximal LAD and LCx arteries) by QCA were selected from the CE-MARC 
population, together with an equal number of control patients without 
significant stenosis on X-ray angiography. The control patients were 
independently matched to the LMS group for age, sex and cardiovascular risk 
factors. The inclusion criteria and full imaging protocol for CE-MARC have 
been previously reported (96). In brief, inclusion criteria were: stable chest pain 
thought to be angina pectoris, at least one cardiovascular risk factor, suitability 
for coronary revascularisation if required and in sinus rhythm. Exclusion 
criteria were: previous coronary artery bypass surgery, evidence of crescendo 
angina or acute coronary syndrome, contraindication to CMR imaging or 
adenosine infusion, and chronic renal failure. The study was performed in 
accordance with the Declaration of Helsinki (October 2000), with all patients 
providing informed written consent. The study protocol and other relevant 
documentation had been approved by the National Research Ethics 
Committee. 
 
3.2.2. CMR protocol 
Patients underwent perfusion-CMR on a Philips 1.5T scanner (Philips Medical 
Systems, Best, The Netherlands) equipped with “Master” gradients (30 mT/m 
peak gradient, 150 mT/m/ms slew rate) and a five-element cardiac phased-
array receiver coil. Stress perfusion imaging was performed using intravenous 
adenosine (140mcg/kg/min) infused for 4 minutes. Perfusion imaging was 
performed every heartbeat during the first-pass in 3 short-axis imaging planes, 
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representing the basal, midventricular, and apical myocardial segments. 
Images were acquired by using a T1-weighted saturation recovery turbo field-
echo imaging sequence, using a shared (non–slice-selective) saturation pulse. 
A bolus of 0.05mmol/kg gadopentetate dimeglumine [Gd-DTPA], (Magnevist, 
Bayer Schering Health Care Limited, UK) followed by a 15ml saline flush was 
administered at 5ml/s into an antecubital vein by a power injector (Medrad 
Spectris Solaris, Medrad, USA). Resting myocardial perfusion was then 
assessed and the data obtained with identical parameters as for the resting 
perfusion acquisition. The CMR protocol also included cine imaging for 
assessment of LV function and LGE imaging (96). 
 
3.2.3. MPS-SPECT protocol 
MPS-SPECT radionuclide imaging was carried out on a dedicated cardiac 
gamma camera (MEDISO Cardio-C, Budapest, Hungary), using a two-day 
scanning protocol, the radioisotope tracer 99mTc tetrofosmin (Myoview), with a 
standard dose of 400 MBq, weight-adjusted to a maximum of 600 MBq, per 
examination. Stress and rest ECG-gated MPS-SPECT images were acquired. 
The stress imaging protocol was performed using intravenous adenosine 
(140mcg/kg/min) for 4 minutes followed by isotope injection to minimise 
variation between MPS-SPECT and CMR (96). 
 
3.2.4. X-ray Angiography 
All patients underwent invasive X-ray coronary angiography by a cardiologist 
(blinded to MPS-SPECT and CMR results).  
 
3.2.5. CMR Analysis 
The methods for the visual analysis of CMR in CEMARC have been described 
previously (96). As per the original analysis, CMR was deemed positive if one 
or more abnormality of perfusion, wall motion abnormality or scar was present 
(63, 96).  
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For quantitative perfusion analysis, perfusion CMR data were exported in 
DICOM format and post-processed off-line using the software cvi42, (version 
5.1.0, Circle Cardiovascular Imaging, Calgary, Alberta, Cananda.)  Contours 
depicting the myocardium and a region within the left ventricular blood pool 
were drawn manually (Figure 3-1). These contours were copied to all time 
frames and manually adjusted for breathing motion by using rigid translation. 
The myocardium was subdivided into six circumferentially equidistant regions 
in the basal and middle sections and four in the apical section according to the 
standard American Heart Association (AHA) model (245).  
 
 
Figure 3-1 Image panel showing angiography and CMR perfusion of 
patient with LMS disease.  
Panel A shows angiography with a critical distal LMS lesion. The 
corresponding mid-slice CMR stress perfusion (B) demonstrates a 
perfusion defect in septum, anterior and lateral wall. Myocardial curves 
(C) of the same mid ventricular slice demonstrates hypoperfusion in 
the segments subtended by the LMS. Orange and red lines represent 
the inferior and infero-lateral segments respectively and show higher 
signal intensity corresponding with no hypoperfusion in these 
segments. Notably a significant LAD stenosis is seen which may 
contribute to the perfusion defect. (128) 
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Quantitative perfusion parameters were calculated using in-house software 
written in Matlab (Mathworks, Natick, MA) (123). Myocardial blood flow (MBF) 
was estimated using Fermi-constrained deconvolution (246). Blood pool and 
myocardial curves were converted to contrast agent concentrations assuming 
a linear relationship between signal intensity and concentration as previously 
described (123). An assumed native blood T1 value of 1435ms and a contrast 
agent relaxivity of 4.3 sec-1·mM-1 was used. The arterial input function was 
taken from the basal slice (which had the shortest preparation delay). 
Concentration curves were baseline subtracted, corrected for temporal shifts 
between the arterial input function and the myocardial curves and limited to 
the first pass of contrast through the left ventricle using previously described 
automated methods (123, 247). Myocardial perfusion reserve (MPR) was 
calculated as the ratio of stress MBF to rest MBF. Segmental MBF and MPR 
were averaged to produce per-patient indices for statistical analysis. This was 
performed with 16 segments to give a global myocardial value, and separately 
for segments in the LMS territory. The LMS territory comprised segments 1, 2, 
5-8, 11-14 and 16 (245). A quantitative summed stress score (SSS) was 
produced by applying the optimal MBF value derived by Youden’s index (as 
detailed in the statistical methods) to the MBF generated in each of the 16 
segments for each patient. 
 
3.2.6. X-ray Angiography Analysis 
X-ray angiography images were analysed by two cardiologists experienced in 
invasive coronary angiography. QCA analysis was performed off-line using 
QCAPlus software (Sanders Data Systems, Palo Alto, California, USA). For 
all LMS patients, visual and quantitative analysis of the invasive angiogram 
were concordant. 
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3.2.7. MPS-SPECT Analysis 
MPS-SPECT data sets were analysed in a blinded manner, simultaneously by 
a cardiologist with >10 years’ experience in nuclear cardiology and an 
experienced medical physicist. Evidence of ischaemia by visual comparison 
of rest/stress perfusion scans, based on the standard 17-segment AHA model, 
was performed. Additionally, evidence of ischaemia by semi-quantitative 
scoring (using the QPS 20 segment) (QPS, Cedars-Sinai Medical Center, 
USA) was also performed. Non-perfusion markers of significant coronary 
artery disease, such as transient left ventricular dilatation (TID) and increased 
right ventricular uptake were also taken in to consideration as felt appropriate 
by the reporting team. 
 
3.2.8. Data analysis and Statistics 
Statistical analysis was performed using commercially available software 
(SPSS, version 22.0, SPSS Inc., Chicago, USA). Two-sided p values ≤0.05 
were considered to be statistically significant. Data were compared using 
Student’s t-test for continuous variables and Fisher’s Exact test for 
proportions, independent samples t tests and Pearson’s correlation 
coefficients as necessary. Normality for MBF values in the normal comparison 
group was evaluated using a Q-Q plot and Shapiro-Wilk test. Receiver 
operating characteristic (ROC) curve analysis for diagnostic tests were 
compared using the method described by DeLong et al (248). For quantitative 
perfusion analysis, the optimal sensitivity and specificity of quantitative 
parameters were derived by calculating Youden’s index (249). The sensitivity 
and specificity and ROC analysis were based on the 54 patients. 
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3.3. Results 
3.3.1. Visual analysis 
Twenty-seven (4%) patients of the 729 patients that received invasive 
angiography from CE-MARC were identified to have LMS or LMS equivalent 
disease by invasive angiography. Twenty-two patients had true LMS disease 
and 5 patients had LMS equivalent disease. Patient characteristics are shown 
in Table 1. 
 
Table 3-1 Baseline Demographics  
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Patient characteristic LMS Controls P 
N 27 27  
Age (years) 65 ± 7 64 ± 6 0.45 
Male 23 (85%) 23 (85%) 1.0 
Body mass index (kg/m2) 27.5 ± 3.89 27.0 ± 2.87 0.60 
Current smoker 5 (19%) 4 (15%) 1.0 
Blood pressure 134/74 ± 20/10 140/76 ± 19/7 0.27 / 0.43 
Hypertension 12 (44%) 17 (62%) 0.27 
Total cholesterol (mmol/L) 5.3 ± 1.4 4.8 ± 1.2 0.25 
Diabetes mellitus 5 (19%) 5 (19%) 1.0 
Family history of CAD* 14 (52%) 13 (48%) 1.0 
Significant CAD*    
 - LMS 22 (81%) 0 (0%) <0.001 
 - LAD 17 (63%) 0 (0%) <0.001 
 - LCx 11 (41%) 0 (0%) <0.001 
 - RCA 11 (41%) 0 (0%) <0.001 
Data as mean ± SD or n (%).*CAD coronary artery disease. 
 
 
 
 
 
Table 3-2 Imaging findings  
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Imaging finding LMS Control P 
CMR    
 - RWMA* positive 17 (63%) 0 (0%) <0.001 
 - FPP positive 22 (81%) 1 (4%) <0.001 
 - LGE positive 15 (56%) 0 (0%) <0.001 
 - Overall positive 22 (81%) 1 (4%) <0.001 
MPS-SPECT    
 - RWMA positive 10 (37%) 6 (22%) 0.37 
 - Fixed defect 6 (22%) 5 (19%) 1.0 
 - Inducible defect 17 (63%) 4 (15%) <0.001 
 - TID 1 (4%) 1 (4%) 1.0 
 - RV uptake 17 (63%) 14 (52%) 0.58 
 - Overall positive 16 (59%) 3 (11%) <0.001 
Data as n (%). *RWMA regional wall motion abnormality, FPP first pass 
perfusion, LGE late gadolinium enhancement, TID left ventricular transient 
ischaemic dilatation, RV right ventricular isotope uptake. 
 
All patients had completed CMR, MPS-SPECT and angiography studies. 
Detection rates for CAD by both CMR and MPS-SPECT are shown in Table 
3.2. Multi-parametric CMR detected evidence of CAD in a non-significantly 
higher proportion of patients with LMS disease than MPS-SPECT (81% vs. 
59%, p=0.14).  All patients with abnormal multi-parametric CMR also had 
abnormal perfusion CMR by visual analysis. One patient was deemed a false 
negative by MPS-SPECT that had 1 segment of inferior ischaemia. For CMR, 
the average SSS for LMS patients was 13.0±9.5, and for controls 0.67±1.0 
(p<0.001). For MPS-SPECT, the average SSS for LMS patients was 5.15±6.5, 
and for controls 1.93±2.3 (p=0.02). ROC analysis demonstrated a significantly 
higher area under the curve (AUC) for detection of LMS disease by visual CMR 
analysis compared to MPS-SPECT (0.95 vs. 0.63; p=0.0001, Figure 3-2). 
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Figure 3-2 ROC curves for visual summed stress scores for CMR and 
MPS-SPECT. Numbers in parentheses indicates AUC with 95% 
confidence intervals. 
 
 
3.3.2. Quantitative CMR perfusion analysis 
 
Table 3.3 shows the results of the quantitative CMR perfusion analysis. Mean 
stress MBF and mean MPR were both significantly lower in LMS patients 
compared to controls (p<0.001); resting MBF was similar between the LMS 
and control groups (p=0.14).  
 
ROC analysis (Figure 3-3) demonstrated the highest AUC (0.88) for global 
MBF as an association with LMS disease. Global MBF of <2.08 ml/g/min was 
associated with a sensitivity of 78% and specificity of 85% for diagnosis of 
significant LMS disease. A quantitative SSS was produced using this value; 
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this score had an AUC not significantly different to CMR visual analysis 
(p=0.18), and more accurate than MPS-SPECT (p=0.003, Figure 3-4). 
 
 
Figure 3-3 ROC curves for CMR quantitative perfusion results. Numbers 
in parentheses indicates AUC with 95% confidence intervals. 
 
 
Table 3.4 shows sensitivity, specificity and predictive values for overall visual 
analysis by multi-parametric CMR and MPS-SPECT, and quantitative 
analysis by CMR global MBF. 
 
 
 
 
 
 
 
Table 3-3 Quantitative CMR perfusion analysis 
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 LMS Control P-value 
Global stress MBF  1.77 ± 0.72 3.28 ± 1.20 <0.001 
Global rest MBF   1.28 ± 0.42 1.48 ± 0.55 0.14 
Global MPR 1.42 ± 0.44 2.31 ± 0.76 <0.001 
LMS territory stress 
MBF  
2.03 ± 0.77 3.38 ± 1.15 <0.001 
LMS territory rest MBF  1.42 ± 0.36 1.54 ± 0.56 0.36 
LMS territory MPR 1.53 ± 0.44 2.34 ± 0.64 <0.001 
MBF values are in ml/g/min. 
 
 
Table 3-4 Sensitivity, specificity and predictive values for detection 
of IHD in LMS patients by visual CMR analysis, MPS-SPECT and 
quantitative CMR.  
 
 
Sensitivity Specificity PPV NPV 
CMR Visual 81 96 48 99 
CMR MBF 78 85 18 98 
MPS-SPECT 63 89 19 98 
Predictive values are corrected based on the prevalence of LMS disease in 
the CE-MARC population. *PPV positive predictive value, NPV negative 
predictive value 
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Figure 3-4 ROC curves for quantitative summed stress score for MBF, 
visual CMR and MPS-SPECT. Numbers in parentheses indicates 
AUC with 95% confidence intervals. 
 
 
3.4. Discussion 
This post hoc exploratory analysis of the CE-MARC study has demonstrated 
the diagnostic accuracy of CMR and MPS-SPECT in the setting of LMS (or 
equivalent) CAD. The main finding is that in patients with stable suspected 
CAD, CMR first-pass perfusion imaging as part of a multi-parametric protocol 
more accurately detected evidence of LMS or equivalent disease than MPS-
SPECT. Additionally, quantitative CMR perfusion showed high diagnostic 
accuracy for the detection of LMS disease with global MBF as the most 
diagnostic, however quantitative perfusion did not outperform visual CMR 
perfusion analysis. 
 
CMR is established as a cost effective investigation with high diagnostic 
accuracy compared to MPS-SPECT for the diagnosis of suspected CAD (63, 
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97, 197, 250). Previous data on the diagnostic accuracy of MPS-SPECT and 
CMR in LMS disease are sparse. Thus far there are no studies specifically 
investigating the diagnostic accuracy of CMR for LMS disease. The MR-
IMPACT study (251), a multicentre comparison of CMR and MPS-SPECT in 
234 patients, included eight patients with LMS disease, while MR-IMPACT II 
analysed 465 patients of which 14 had LMS disease (250); in neither of these 
studies were patients with LMS disease separately analysed. The majority of 
studies validating CMR perfusion techniques have less than five LMS patients, 
effectively precluding meaningful analysis of this subset. In contrast, the CE-
MARC study had a LMS population of sufficient size to allow reasonable 
conclusions to be drawn (63). MPS-SPECT studies of LMS disease have 
largely been un-blinded, retrospective and derived from angiographic 
databases (241–243); in this context referral bias potentially leads to an over-
estimation of the sensitivity of MPS-SPECT for the detection of LMS disease 
(242), as the false negative MPS-SPECT scans go unevaluated.  
 
Non-invasive detection of CAD is clinically useful to both determine the 
presence of clinically significant disease and to estimate the severity and 
extent of disease. The classical finding of an inducible perfusion abnormality 
involving both the LAD and LCx coronary artery territories was not robustly 
seen in LMS patients by either CMR or MPS-SPECT. This perfusion defect 
pattern has been described with varying frequency from 12-59% of MPS-
SPECT patients with documented significant LMS stenosis in retrospective 
analyses (241, 243, 244). This perfusion defect pattern was seen in just 8 LMS 
patients (30%) by CMR and 2 patients (7%) by MPS-SPECT in our study. The 
low diagnostic yield specific for LMS disease may be due, in part, to distal and 
bifurcation LMS lesions, which may have a differential effect on myocardial 
perfusion to the LAD and LCx territories, resulting in underestimation of LMS 
disease. Furthermore, although a visual or QCA reported stenosis of 50% of 
the LMS is deemed significant by convention, not all 50% coronary stenoses 
are haemodynamically significant when assessed by invasive FFR (252). In 
addition, a myocardial perfusion abnormality consistent with LMS disease may 
be less apparent in the presence of coronary collateralisation, or flow-limiting 
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stenosis in the right coronary artery (i.e. 3-vessel disease). However, these 
haemodynamic factors do not account for the differential detection rates of 
CMR and MPS-SPECT (overall 81% vs. 59% for detection of CAD). The 
phenomenon of “balanced ischaemia” in multivessel disease potentially leads 
to an underestimation of disease, in MPS-SPECT this effect is reported with 
variable frequency (253, 254). In this context, CMR has been shown to have 
an advantage over MPS-SPECT to detect perfusion defects (in multivessel 
disease) due to a higher spatial resolution (255, 256). Furthermore, multi-
vessel disease has been shown to not be significantly associated  with false 
negatives in CMR (257).  
Wide interobserver variability for visual severity of stenoses of the LMS have 
been reported (77, 78). In our study QCA was used to determine the severity 
of angiographic stenoses, as per the CE-MARC study protocol (63, 96). In this 
context, there is a potential limitation of the invasive reference standard; 
however FFR and intra-vascular ultrasound are only recommended as 
adjuncts in LMS disease assessment in current guidelines and 
revascularisation decisions are, for the mainstay, based on severity of 
angiographic stenosis (27, 86). 
 
Additional diagnostic aids have been proposed to improve the sensitivity of 
MPS-SPECT for the diagnosis of LMS disease. TID of the left ventricular cavity 
in response to stress has been identified to be a strong predictor of cardiac 
events (258), reflecting global subendocardial ischaemia or stress-induced left 
ventricular dysfunction from left main or three vessel disease (259). Increased 
right ventricular radiotracer uptake has also been independently associated 
with LMS disease, with a 60% increase from 0.33±0.07 at rest to 0.51±0.07 
with stress in LMS patients (p<0.001 compared to controls) (260, 261). When 
non-perfusion markers of widespread ischaemia are used alongside perfusion 
data, the proportion of patients with LMS stenosis identified by MPS-SPECT 
increased from 56% to 83% in one study (241). In our population, however TID 
was seen less frequently, with no significant difference in right ventricular 
uptake between LMS patients and controls suggesting limited discriminatory 
value. These markers were used for MPS-SPECT analysis in this study, but 
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to date have not been used as standard in CMR, and were not prospectively 
evaluated here. 
 
This study also examined the utility of quantitative CMR perfusion as a 
potential approach to account for balanced myocardial hypoperfusion that 
theoretically limits visual analysis in LMS or 3-vessel disease.  Other studies 
have shown that quantitative estimation of myocardial perfusion reserve by 
CMR over visual analysis improved sensitivity from 74% to 88% and specificity 
from 58% to 90% for patients suspected to have coronary artery disease, but 
not confined to LMS (262). The Fermi deconvolution method used in our study 
has been shown to perform as well as any other model for the detection of 
CAD (123). Patel et al identified increased ischaemia burden by quantitative 
perfusion methods using Fermi deconvolution over qualitative assessment as 
severity of coronary disease increased in patients undergoing perfusion CMR 
with multi-vessel disease (263). The value of quantitative CMR analysis for 
LMS lesions has not been previously detailed. In our study, global MBF was 
the best quantitative marker and showed high sensitivity and specificity (78% 
and 85% respectively) for the diagnosis of LMS disease. Quantitative 
perfusion analysis however was not significantly better than visual CMR 
perfusion analysis, suggesting that visual perfusion analysis is sufficient to 
detect heterogeneities in myocardial contrast distribution in LMS disease, a 
finding supported by dedicated analysis of false-negative CMR (257). 
Furthermore, our results suggest there is little additive value to be gained from 
the quantification of rest perfusion when quantitation of stress perfusion is 
performed. 
 
3.4.1. Limitations 
Given the low prevalence of LMS disease, the numbers in this prospective 
study are limited. In our study MPS-SPECT analysis did not use attenuation 
correction; however this was not routine practice when the study was 
performed (264). We did not use FFR as our invasive reference standard, 
however we did use QCA in line with the main CE-MARC paper. The pulse 
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sequence used for perfusion imaging in CE-MARC was not fully optimised for 
quantitative analysis as it used a single preparation pulse for all three slices 
and a relatively high contrast agent dose. This may have led to a lower 
performance of quantitative analysis in this study compared to recent 
approaches. The lack of a completely linear arterial input function 
measurement for MBF analysis, with the assumption that concentration is 
linearly related to signal intensity will result in an overestimate of absolute 
myocardial blood flow. However, post-hoc correction based on baseline signal 
intensity values would introduce noise into the measurements that could 
reduce diagnostic accuracy (265). Furthermore, studies comparing dual-bolus 
and uncorrected single bolus myocardial blood flow estimates have not shown 
significant differences in diagnostic accuracy (266). Our diagnostic accuracy 
values agree well with other studies in the literature, suggesting that these 
limitations have not significantly impacted on our findings. Bystander disease 
in the way of significant LAD or CX or concomitant RCA disease was not 
excluded but may contribute to perfusion defects seen; this would have 
decreased numbers further and LMS disease is rarely seen in isolation.  
 
3.4.2. Conclusion  
This study shows that visual stress perfusion CMR had higher diagnostic 
accuracy than MPS-SPECT to detect significant LMS or LMS equivalent 
disease. Quantitative perfusion CMR by Fermi-constrained deconvolution had 
similar performance to visual CMR perfusion analysis. 
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4. Quantitative deformation analysis differentiates ischaemic 
and non-ischaemic cardiomyopathy: sub-group analysis 
of the VINDICATE trial 
4.1. Background 
Heart failure with reduced ejection fraction (HFrEF) is caused by a diverse 
range of pathologies that contribute to the overall syndrome (267–269). 
Identification of the aetiology of cardiomyopathy provides both insights into the 
pathophysiology, as well as directing specific therapeutic interventions, whilst 
conferring prognostic information (268, 269). Ischaemic and non-ischaemic 
cardiomyopathy can manifest extremely similar phenotypes, though 
management may be divergent and consequently current guidelines suggest 
clarification of the aetiology for this reason (268, 269). Multi-parametric CMR 
can help to distinguish these aetiologies (269). 
Strain, twist and torsion are measures of myocardial performance beyond 
ejection fraction. Strain is an index of deformation from the initial to maximal 
length of a myocardial segment (%) (270). Twist (º) describes the relative 
rotation between the apex and base of the ventricle (peak difference between 
systolic rotation of LV apex and base viewed from the apex/). Torsion (º) 
describes the complex “wringing” motion of the left ventricle that is influenced 
by of both the twisting motion of the heart and size of the ventricular cavity 
(271). The torsional shear angle (º) is calculated by measuring the radius of 
the apical and basal slices multiplied by the twist and divided by the distance 
between them (234). In the normal heart the base of the ventricle rotates 
clockwise during systole whilst the apex rotates counter clockwise (234). Left 
ventricular torsion is a primary component of normal systolic function and has 
been identified as a sensitive marker for transplant rejection, myocardial 
ischaemia and infarction, successful ventricular reconstruction surgery as well 
as a predictor of responsiveness to cardiac resynchronisation therapy (272–
277). These parameters can be quantified by CMR tissue tagging techniques, 
which are highly reproducible and recognised as the reference standard non-
invasive measures of myocardial strain and torsion (233, 273, 278–280).  
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The VINDICATE (VitamIN D treatIng patients with Chronic heArT failurE) trial 
was a randomised placebo-controlled double-blind trial designed to describe 
the safety and efficacy of long-term, high-dose vitamin D3 supplementation on 
submaximal exercise capacity and cardiac function in vitamin D−deficient 
patients with chronic heart failure due to left ventricular systolic dysfunction 
already established on optimal medical therapy (230). A subgroup of the study 
underwent additional investigation using multi-parametric CMR. In this sub-
study we investigated the relationship between strain-derived parameters and 
aetiology of HFrEF and hypothesised that in a prospectively recruited random 
sample of HFrEF patients ICM and NICM would have distinctive myocardial 
torsion patterns.  
 
 
4.1. Methods 
4.1.1. Study participants 
The inclusion criteria for VINDICATE have been previously reported (230). In 
summary, all patients had stable (>3 months) NYHA functional class II or III 
symptoms, a LVEF ≤45% on maximally tolerated medical therapy (>3 months) 
and a 25(OH) vitamin D level of <50 nmol/l (<20 ng/ml). Patients were invited 
to enter the CMR substudy at their initial enrolment visit. Exclusion criteria 
included history of taking calcium or other vitamin supplements in the 
preceding 3 months; aetiology of chronic HF due to untreated valvular heart 
disease, anaemia or thyrotoxicosis; existing indications for vitamin D 
supplementation; history of primary hyperparathyroidism, sarcoidosis, 
tuberculosis or lymphoma; cholecalciferol concentration >50 nmol/l (20 ng/ml); 
or if there was significant renal dysfunction (estimated glomerular filtration rate 
<30 ml/min/1.73m2)(230). Aetiology of heart failure was determined by the 
enrolling clinician. ICM was defined as left ventricular dysfunction associated 
with previous significant coronary disease (>70% in at least one major 
epicardial coronary artery) on angiography, positive ischaemia testing with 
MPS-SPECT or stress echocardiography and/or history of previous 
myocardial infarction or revascularisation (230); NICM was defined as left 
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ventricular dysfunction in the absence of the previous conditions. A control 
group of age-matched volunteers with no significant co-morbidities were 
enrolled and underwent an identical CMR protocol.  
The study was performed in accordance with the Declaration of Helsinki, with 
all patients providing informed written consent. The study protocol and other 
relevant documentation had been approved by the National Research Ethics 
Service [12/YH/0206]; VINDICATE was funded by the Medical Research 
Council, UK. 
 
4.1.2. Cardiac Magnetic Resonance Protocol 
CMR was performed on a 3 Tesla Philips Achieva system (Philips Healthcare, 
Best, The Netherlands) equipped with a 32 channel coil and MultiTransmit® 
technology. Data was acquired at end expiration during breath-holding. Cine 
images were acquired covering the entire heart in the LV short axis plane 
(balanced steady state free precession), spatial resolution 1.2x1.2x10mm³, 30 
cardiac phases TR/TE 2.6/1.3ms, flip angle 40o, field of view 300-420mm, 
typical temporal resolution 39ms) and in orthogonal long-axis planes. Tissue 
tagging by spatial modulation of magnetization (spatial resolution 
1.51x1.57x10mm3, tag separation 7 mm, ≥18 phases, typical TR/TE 
5.8/3.5ms, flip angle 10o, typical temporal resolution 55ms) was acquired in 
three short axis slices at the apex, mid-ventricle, and base. Consistent slice 
positioning was performed according to the widely accepted “3 of 5 technique” 
(281). LGE imaging was undertaken 15 minutes following administration of 
0.15mmol/kg gadolinium DTPA (Gadovist, Bayer Schering) using an inversion 
recovery-prepared T1-weighted gradient echo pulse sequence. Selection of 
the appropriate TI to null normal myocardial signal was ascertained by the 
Look-Locker approach. Between 10 and 12 short axis slices and, 2 chamber 
and 4 chamber images were acquired for each participant. Imaging on 3.0T 
would yield analogous results if imaged at 1.5T. 
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4.1.3. Image Analysis 
CMR data were analysed quantitatively using commercially available software 
(CVI42, Circle Cardiovascular Imaging Inc. Calgary, Canada and inTag v1.0, 
CREATIS lab, Lyon, France). Endocardial borders were traced on the LV cine 
stack at end-diastole and end-systole to calculate end diastolic volume, end 
systolic volume, stroke volume and ejection fraction. Contours were traced to 
exclude papillary muscles and trabeculations. Volumetric data were indexed 
to body surface area calculated by the Mosteller equation. LGE was assessed 
quantitatively using the semi-automated full width half maximum method. 
For tagging analysis, endocardial and epicardial contours were drawn on the 
short axis spatial modulation of magnetization images using a semi-automated 
process (Figure 4-1). Peak circumferential LV strain was measured for the 
three slices at apex, mid-ventricle, and base. Strain was measured in the mid-
myocardial layer which has previously been reported to be the most 
reproducible (233). LV twist was calculated by subtracting the basal from 
apical rotation.  Basal and apical radius was calculated from cine images in 
diastole at the same slice location as the tagged images. The equation used 
to determine torsion was (234):  
 
𝑇𝑜𝑟𝑠𝑖𝑜𝑛 =  
𝑃𝑒𝑎𝑘 𝑇𝑤𝑖𝑠𝑡 × (𝐴𝑝𝑖𝑐𝑎𝑙 𝑅𝑎𝑑𝑖𝑢𝑠 + 𝐵𝑎𝑠𝑎𝑙 𝑅𝑎𝑑𝑖𝑢𝑠)
2 × 𝐴𝑝𝑒𝑥 𝑡𝑜 𝐵𝑎𝑠𝑒 𝑙𝑒𝑛𝑔𝑡ℎ
 
 
Feature tracking rather than spatial modulation of magnetization was used for 
the analysis of global longitudinal strain. For this, endocardial and epicardial 
contours were drawn on 4 chamber cine images using a semi-automated 
process and peak longitudinal strain and systolic strain rate were measured 
for the LV.  
 
4.2. Statistical Analysis 
Statistical analysis was performed using IBM SPSS® Statistics 20.0 (IBM 
Corp., Armonk, NY). Continuous variables were expressed as means ± SD. 
Categorical variables were expressed as N (%). Normality of data was tested 
using a Shapiro-Wilk test. Unpaired Student t-test and Mann-Whitney were 
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used as appropriate to compare continuous variables. Chi-square test was 
used for categorical data. P<0.05 was considered statistically significant. 
 
 
Figure 4-1 Tagged images in inTag© analysis.  
Images A shows apical systolic anticlockwise rotation (red) and B 
clockwise basal rotation (blue) in a healthy control. Images C shows 
reduced apical (yellow/red) and D basal (yellow/green) rotation in a 
patient with ischaemic cardiomyopathy. Images E shows markedly 
reduced apical (yellow/green) and F basal rotation (yellow/green blue) 
in a patient with non-ischaemic cardiomyopathy. (282) 
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4.3. Results 
223 patients were enrolled in VINDICATE, but as CMR was not mandated in 
the clinical trial protocol, only a subgroup of 69 patients underwent a baseline 
CMR scan. Of these 53 had myocardial tagging sequences performed and 
were included in this analysis. 25 age-matched controls with no co-morbidity 
and taking no regular medication underwent an identical CMR scan. Table 4.1 
shows the demographic data for the combined HF group and controls. There 
were no significant differences between age, height, weight and body mass 
index (BMI). Table 4.2 shows the CMR imaging characteristics and strain 
parameters of both the HF and control groups. Compared with controls, 
patients with HF had significantly larger ventricles when indexed to body 
surface area and significantly lower values of LVEF, LV torsion and twist, 
circumferential and longitudinal strain.  
 
Table 4.3 shows the baseline demographics between the ICM and NICM 
patients. There were no significant differences between groups in terms of 
age, blood pressure, heart rhythm or baseline NYHA status. ICM patients had 
undergone significantly more prior revascularisation (PCI, CABG) than NICM 
patients. Table 4.4 shows CMR volumetric data and functional parameters 
between the ICM and NICM patients. There was no significant difference in LV 
dimensions, LV mass and EF between the two groups. ICM patients had 
significantly more infarct pattern LGE than NICM (77% vs. 0% p<0.001). Mean 
percentage of infarction was 19.0±7.6% in the ICM group. Three patients in 
the NICM group had mid wall pattern late enhancement, no other late 
enhancement patterns were seen in this group. Strain parameters showed no 
differences in circumferential strain at any short axis level or in terms of global 
longitudinal strain (GLS) between the two groups. NICM patients had 
significantly lower LV twist (6.0±3.7o vs. 8.8±4.3o, p=0.023) (figure 4-2) and 
torsion (5.9±3.5o vs. 8.8±4.7o, p=0.017) compared to the ICM group. There 
was no significant correlation of twist (r= -0.113 P=0.424) or torsion (r= -0.096 
P=0.4938) with patient functional assessment measures from a standard six 
minute walk test.  
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Table 4-1 Demographic details for HF and healthy control group 
 
 HF group (53) Controls (25) P-value 
Age, years 62.6±16.4 58.0±12.2 0.164 
Sex (female) 17 (32.1) 7 (28) 0.716 
Height, cm 170.1±7.8 172.9±12.6 0.389 
Weight, kg 78.9±15.1 80.2±18.6 0.762 
Body Mass Index, kg/m2 27.2±4.7 26.6±3.3 0.527 
Systolic Blood Pressure, 
mmHg 
117.3±19.8 127.7±14.6 0.026 
Diastolic Blood Pressure, 
mmHg 
70.8±10.9 70.2±12.1 0.828 
Diabetes Mellitus, % 7 (13) 0 0.122 
CABG, % 10 (18.9) 0 0.020 
PCI, % 17 (32.1) 0 0.001 
AF, % 34 (64.2) 0 <0.001 
COPD, % 2 (3.8) 0 0.325 
Data as mean ± SD or n (%). AF, atrial fibrillation. CABG, coronary artery 
bypass grafting. COPD, chronic obstructive pulmonary disease. PCI, 
percutaneous coronary intervention.  
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Table 4-2 CMR data for HF group and controls 
 HF (53) Controls (25) P-value 
LVEDV, ml 210.5±85.4 160.0±44.7 0.007 
LVEDVi, ml/m2 109.2±38.9 82.2±19.9 <0.001 
LVESV, ml 141.6±81.8 68.6±25.3 <0.001 
LVEF, % 35.5±10.9 57.6±7.0 <0.001 
LGE, (%) 26 (49.0) 0 <0.001 
LV twist, o 7.6±4.3 14.6±4.2 <0.001 
LV torsion, o 7.6±4.5 13.4±3.1 <0.001 
Ecc Apex, % 10.4±6.8 22.2±5.3 <0.001 
Ecc Mid, % 10.4±6.6 21.7± 2.3 <0.001 
Ecc Base, % 9.6±6.2 20.5±2.6 <0.001 
LV longitudinal strain, % 11.0 ±7.3  18.4±2.2 <0.001 
LV longitudinal strain rate, 
%/s 
56.5±39.9 93.7±15.9 <0.001 
Data as mean ± SD or n (%). Ecc, Circumferential strain. LVEDV, left 
ventricular end diastolic volume. LVEDVi, left ventricular end diastolic volume 
indexed to body surface area. LVEF, left ventricle ejection fraction. LVESV, 
left ventricular end systolic volume.  
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Table 4-3 Baseline demographic data for ischaemic and non-
ischaemic cardiomyopathy patients 
 ICM (31) NICM (22) P-value 
Age, years 65.2±15.9 59.0±16.9 0.182 
Sex (female) 9, 29% 8, 36% 0.573 
Height, cm 170.1±8.1 170.0±7.4 0.970 
Weight, kg 78.5±14.2 79.7±16.6 0.773 
Body Mass Index, kg/m2 26.9±3.9 27.6±5.6 0.654 
Systolic Blood Pressure, 
mmHg 
119±21 115±18 0.399 
Diastolic Blood Pressure, 
mmHg 
70±11 72±11 0.601 
Heart rate, bpm 69.2±10.8 69.6±9.5 0.903 
Diabetes Mellitus, % 6 (19) 1 (4.5) 0.117 
COPD, % 1 (3.2) 1 (4.54) 0.804 
CABG, % 10 (32) 0 (0) 0.03 
PCI, % 17 (55) 0 (0) <0.001 
AF, % 20 (65) 14 (64) 0.948 
BNP, pg/mL 1084±1196 1118±1172 0.421 
VO2max, mlO2/min/kg 16.8±5.0 19.7±7.7 0.162 
NYHA class II, % 30 (96.8) 22 (100) 0.395 
NYHA class III, % 1 (4) 0 (0) 0.395 
Beta blockers, %  29 (93.5) 19 (86.4) 0.378 
ACEi/ARB, % 28 (90.3) 22 (100) 0.133 
Aldosterone antagonist, % 17 (54.8) 11 (50) 0.728 
Creatinine, μmol/l 87.5±20.9 80.4±20.6 0.227 
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Data as mean ± SD or n (%). AF, atrial fibrillation. ACEi, angiotensin-
converting enzyme inhibitor. ARB, aldosterone receptor blocker. BNP, 
natriuretic peptide. CABG, coronary artery bypass grafts. COPD, chronic 
obstructive pulmonary disease. NYHA, New York Heart Association 
functional class. PCI, percutaneous coronary intervention. 
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Table 4-4 CMR characteristics for ischaemic and non-ischaemic 
cardiomyopathy patients 
 ICM NICM P-value 
LVEDV, ml 199.4±56.7 226±113.9 0.317 
LVEDVi, ml/m2 104.9±30.5 115.3±48.5 0.343 
LVESV, ml 132.8±56.0 153.9±108.8 0.359 
LVEF, % 35.1±10.6 36.0±11.7 0.767 
LVM, g 134.9±42.6 141.8±70.1 0.655 
LVMi, g/m2 70.4±20.9 72.2±28.9 0.795 
LVM/EDV g/ml 0.7±0.3 0.7±0.2 0.378 
LGE infarct pattern, % 24. 77.4% 0. 0% <0.001 
LGE mid wall pattern, % 0. 0% 2. 9.0% 0.162 
LGE, % of myocardial mass 19.0±7.6% 1.4±4.5 <0.001 
LV twist, o 8.8±4.3 6.0±3.7 0.023 
LV torsion, o 8.8±4.7 5.9±3.5 0.017 
Ecc Apex, % 10.1±6.5 10.9±7.4 0.689 
Ecc Mid, % 10.3±6.8 10.7±6.6 0.828 
Ecc Base, % 8.2±6.8 11.4±4.8 0.064 
LV longitudinal strain, % 10.8±7.3 11.3±7.5 0.837 
LV longitudinal strain rate, 
%/s 
54.2±37.1 59.7±44.2 0.629 
Data as mean ± SD or n (%). Ecc, Circumferential strain. LGE, Late 
gadolinium enhancement. LVEDV, left ventricular end diastolic volume. 
LVEDVi, left ventricular end diastolic volume indexed to body surface area. 
LVEF, left ventricle ejection fraction. LVESV, left ventricular end systolic 
volume. LVM, left ventricular mass. LVMi left ventricular mass indexed.  
 
- 85 - 
 
 
Figure 4-2 Plots showing apical (blue) and basal (orange) rotation and 
twist (green) of individual patients with ischaemic and non-
ischaemic cardiomyopathy respectively.  
 
In patients with ICM and no LGE (n=7), again there were no significant 
differences compared to NICM patients in CMR volumetric data (LVEDVi 
95.5±15.4ml/m2 vs. 115.3±48.5ml/m2 p=0.272) or LVEF (40.9±12.2% vs. 
36.0±11.7% p=0.332). Furthermore, there were no significant differences 
between these groups in any strain parameters (EccApex 10.7±7.6% vs. 
10.9±7.4% p=0.947, EccMid 11.8±9.3% vs. 10.7±6.6% p=0.721, EccBase 
8.0±7.3% vs. 11.4±4.8% p=0.168, GLS 12.6±3.5% vs. 11.3±7.5% p=0.627). 
Notably, there was no significant difference in twist or torsion between the 
ICM patients without LGE and the NICM patients (twist 9.6±4.9° vs. 6.0±3.7° 
p=0.051, torsion 7.9±5.6° vs. 5.9±3.5° p=0.248). 
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4.4. Discussion  
We have shown that all myocardial mechanical parameters including strain, 
twist and torsion were reduced in HF patients compared to age-matched 
controls. More importantly, despite having similar left ventricular dimensions, 
EF and strain parameters, patients with NICM have significantly less LV twist 
and torsion than patients with ICM.  
 
Thus far there have been no comparisons of LV mechanics performed 
between different aetiologies of HFrEF. Our study identified a significant 
difference between LV torsion and twist in patients with different aetiologies of 
heart failure. Torsion and strain are currently not routinely measured during 
CMR imaging for cardiomyopathy, although CMR is the reference standard for 
these measurements and it is increasingly recommended to guide 
management (269). Our study shows that measurements of LV strain and 
torsion parameters measured by CMR can give potential mechanistic insights 
into the aetiology and pathophysiology of LV dysfunction. Prognostic benefit 
is seen with therapeutic interventions according to aetiology (283) and thus 
accurate delineation of aetiology becomes paramount (269).  
 
Left ventricular torsion has been proposed as a mechanism to reduce 
myocardial fibre strain in order to improve energy efficiency and decrease 
oxygen demand (284, 285), whilst untwisting contributes to the diastolic 
function of the ventricle during isovolumetric relaxation (234). Torsion can be 
influenced by different loading conditions such as hypertension, athletic 
training and alters with increasing age (234, 286). LV torsion results as a 
consequence of the fibrous architecture of the heart (figure 4-3). Subepicardial 
fibres of the ventricle are arranged helically in a right handed oblique 
orientation of around 60°, whilst subendocardial fibres run in an opposing left 
handed helix of around 80° (234, 271, 287). This opposing arrangement of 
fibres results in shear deformation, with the predominant direction of force 
occurring in a clockwise direction as a result of the greater rotational radius of 
the subepicardial layer (284, 288).  
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Figure 4-3 Schematic image of LV torsion in normal, ischaemic and 
non-ischaemic cardiomyopathy: 
Image A shows the subepicardial fibres in red lines that are 
predominantly responsible for LV torsion. Dotted red lines represent 
subendocardial fibres arrayed in an opposing helix. The blue arrows 
show the predominant direction of twist with the base of the ventricle 
rotating clockwise during systole whilst the apex rotating counter 
clockwise. Image B shows ischaemic cardiomyopathy, with 
infarction/ischaemia in black typically affecting subendocardial fibres 
(yellow) and radial fibres (blue) with preferential sparing of the 
subepicardial fibres. Torsion is reduced (blue arrows) compared to 
normal due to some subepicardial fibres being affected. Image C shows 
non-ischaemic cardiomyopathy with global myocardial fibre dysfunction 
leading to significant reduction in torsion due to the effect on 
subepicardial fibres. (282) 
 
In patients with IHD, the wave-front of myocardial ischaemia first affects 
subendocardial fibres prior to the subepicardial layer, with a similar effect on 
myocardial contraction patterns (20).  In dog models of infarction, endocardial 
fibres show loss of tissue and function, while epicardial fibres demonstrate 
functional recovery, likely as a result of early reperfusion (289, 290). 
Correspondingly in man, Wu et al demonstrated by diffusion tensor MRI (291), 
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subendocardial right handed fibres reduced following infarction whilst the 
percentage of left handed fibres in the subepicardium increased, potentially as 
a result of a compensatory remodelling process (291). These structural 
changes are reflected in imaging studies of LV mechanics that show, 
according to the degree of transmurality of infarction, that subendocardial 
function is similarly reduced in both small and large STEMI, whilst 
subepicardial fibre function is reduced only in large STEMI (full thickness 
infarction) and is severely reduced in those with chronic ischaemic HF (the 
latter finding corresponding with the lack of significant difference seen in twist 
and torsion between the chronically ICM without scar and NICM) (274, 292, 
293).  
 
ICM tends to show regional dysfunction compared to NICM that shows more 
global myocardial fibre dysfunction (267). Torsion and twist have both been 
shown to be reduced in a variety of NICM (294–296). NICM can result in a 
variety of altered contraction patterns including a global reduction in torsion 
(297); paradoxical reversal of LV rotation with the base rotating counter 
clockwise and the apex rotating clockwise (298); and in some cases both 
apical and basal segments rotate in the same direction leading to “rigid body 
rotation” where the wringing motion of the ventricle is lost altogether (296). 
Furthermore a reduction in LV torsion is noted in tandem with the degree of 
spherical LV remodelling (294).  These findings are consistent with our study 
that shows that patients with cardiomyopathy have a reduction of torsion 
compared to healthy controls, but also that patients with NICM have reduced 
torsion relative to ICM. The relative preservation of LV torsion in ICM 
compared to NICM (8.8±4.7o vs. 5.9±3.5o p=0.017) seen in our study is 
explained by the differential effect on subepicardial fibres by necrosis and 
ischaemia in ICM with some regions spared, contrary to the global myocyte 
dysfunction seen in NICM. Furthermore it has been hypothesised that 
remaining subepicardial fibres in ICM undergo hypertrophy and recruitment as 
an active remodelling process following ischaemic insults thus contributing to 
the higher torsion values seen in ICM compared to NICM (290, 291). 
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Strain is a measure of myocardial deformation and has been proposed as 
being more sensitive to changes in LV mechanics than ejection fraction and is 
influenced by compensatory changes such as ventricular dilatation or 
geometrical change (270). Furthermore global longitudinal strain has been 
identified as a marker of prognosis over and above ejection fraction in a variety 
of conditions (299, 300). In our study, neither EF nor strain parameters were 
significantly different between cardiomyopathy of either aetiology. GLS is 
predominantly a result of subendocardial longitudinal fibres, whilst 
circumferential strain is attributed to the radial fibres that are distributed in the 
mid-wall of the ventricle and the subepicardial fibres (271, 287, 300–302). 
These fibres in, or adjacent to, the subepicardium are affected by ischaemia 
prior to the subepicardial fibres and thus intuitively circumferential and 
longitudinal strain are reduced greater than LV torsion in ICM, whilst leading 
to the similar strain values seen in patients with NICM. 
 
4.4.1. Limitations 
Our observational study has a number of limitations. The sample size is 
relatively small and differences in baseline demographics, comorbidities and 
treatment may be a potential source of bias. However both cardiomyopathy 
groups and controls were prospectively enrolled, and were age-matched, 
which is an important consideration as age has been shown to affect strain, 
torsion and twist (303). Through plane motion is a limitation of using 2D 
tagging methods. This may have an effect due to the global deformation 
changes seen in NICM versus local changes in contractile properties in ICM. 
The 2D method used in our paper has consistently been shown to be reliable 
and reproducible in a variety of patient groups(233, 286, 304, 305), and 2D 
and 3D tagging methods for LV torsion have been shown to strongly related 
(306). Currently 3D methods of CMR tagging are time consuming requiring 
multiple breath holds of long duration (307, 308), thus from a pragmatic point 
of view we used a reproducible 2D method that required a single breath hold 
per slice that in general HF patients would be able to tolerate. Estimation of 
diffuse fibrosis by T1 mapping and extracellular myocardial volume fraction 
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extracellular myocardial volume fraction (ECV) calculation were not performed 
in this study, which may have provided further insight.  
 
4.5. Conclusion 
Twist, torsion and strain are reduced in patients with cardiomyopathy 
compared to controls. Torsion and twist are significantly lower in patients with 
NICM compared to ICM, despite similar volumetric dimensions, circumferential 
and longitudinal strain parameters and LVEF. 
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5. Development and validation of a contemporary pre-test 
likelihood model of coronary artery disease referenced to 
invasive angiography, with comparison to pre-existing risk 
models 
 
5.1. Introduction 
Coronary artery disease remains a leading cause of death worldwide and 
invasive X-ray coronary angiography is frequently performed in the 
investigation pathway (8). Increasingly non-invasive imaging acts as a 
gatekeeper to invasive angiography and is recommended by Societal 
guidelines,(8, 27) in which pre-test likelihood scores quantify coronary artery 
disease risk and guide further investigation. US guidelines historically 
recommended the Diamond and Forrester risk model,(27, 33) based on 
Bayesian principles according to age, gender and typicality of chest pain 
symptoms. The 2010 UK National Institute for Health and Care Excellence 
CG95 guidelines and current US practice guidelines, the Duke Score, a 
modified Diamond and Forrester model incorporating additional clinical risk 
factors was advocated (27, 30, 309) (Table 5.1). These risk models however, 
are over three decades old and derived from highly selected patient 
populations; consequently they have been shown to overestimate coronary 
artery disease risk (310–313). Subsequently the CAD Consortium Basic and 
Clinical risk models were developed, based on contemporary patient 
populations and are recommended in the ESC guidelines (8, 311, 312). The 
CAD Consortium study population however, was derived from a number of 
diagnostic accuracy studies with considerable heterogeneity of disease 
prevalence between different sites, and variation between endpoints 
(computed tomography coronary angiography or invasive catheter 
angiography with different methods of analysis); furthermore until recently 
there has been no external validation of the scores (312–314).  
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The 2016 update to the UK NICE CG95 guideline no longer recommend pre-
test likelihood calculation to determine investigation strategy (315). Whilst 
controversial, this may be in part due to perceived limitations of the previously 
recommended Duke Score and lack of applicability to a contemporary UK 
population. The aim of this study was to both develop and validate a 
contemporary multivariable risk model based entirely on invasive angiographic 
data (using data from two recent UK studies of stable coronary artery disease 
(CE-MARC and CE-MARC 2: Clinical evaluation of magnetic resonance 
imaging in coronary heart disease study)), and compare this to pre-existing 
risk models used in clinical guidelines (35, 63, 96, 203). 
 
Table 5-1 Characteristics of risk models used 
 
 Risk Scores 
 DF Duke CAD Basic CAD Clinical 
Year 1979 1993 2012 2012 
Population  4952 168 5677 (3283 
male) 
5677 (3283 
male) 
Risk factors Age, sex, 
angina 
typicality 
Age, sex, 
angina 
typicality, 
previous MI, 
smoking, DM, 
hyperlipidaemi
a, ECG Q 
waves or ST-T 
changes 
Age, sex, 
angina 
typicality 
Age, sex, 
angina 
typicality, DM, 
smoking, 
HTN, 
hyperlipidaemi
a 
Setting US US single 
centre 
Europe and 
US (18 
hospitals) 
Europe and 
US (18 
hospitals) 
Investigatio
n 
Angiograph
y/ Autopsy 
Angiography CTCA 
(5190) 
Angiograph
y (2062) 
CTCA (5190) 
Angiography 
(2062) 
Outcome – 
coronary 
stenosis 
≥50% ≥75% ≥50% ≥50% 
DF – Diamond and Forrester 
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5.2. Methods 
5.2.1. Patients 
The development population was derived from the CE-MARC study,(63, 96) 
which recruited from May 2006 to August 2009 in a single centre (Leeds 
General Infirmary, Leeds, UK); inclusion criteria and study protocol have been 
described previously (96). In brief, inclusion criteria were stable chest pain 
symptoms thought to be angina pectoris, aged 35-79 years, in sinus rhythm, 
and suitable for revascularisation if required. Exclusion criteria included prior 
coronary artery bypass grafting, unstable chest pain symptoms, and 
pregnancy. By protocol, all participants were expected to undergo invasive 
angiography. Of 752 CE-MARC participants, 77 were excluded from this 
analysis due to prior percutaneous coronary intervention or myocardial 
infarction/acute coronary syndrome, in whom pre-test likelihood was already 
100%. Figure 5-1 shows the derivation of participants in the development 
population. 
 
 
Figure 5-1 Image panel showing angiography and CMR perfusion 
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The validation population was drawn from two sources: 1) The multi-centre 
CE-MARC 2 trial which enrolled 1,202 patients from November 2012 to March 
2015,(35, 203) with estimated pre-test likelihood of coronary artery disease of 
10-90% aged ≥30yrs with suspected stable angina requiring further 
investigation, no prior myocardial infarction/acute coronary syndrome or  
revascularisation. From this trial, 264 patients were included in the validation 
population based on them having invasive angiography within 12 months of 
randomisation. 2) The validation population was added to by an “enrichment 
population” by obtaining anonymised data of patients consecutively 
undergoing elective coronary angiography for investigation of suspected 
coronary artery disease at Leeds General Infirmary with estimated pre-test 
likelihood <10% or >90% during the period October 2014 to 2016.  
CE-MARC and CE-MARC 2 were conducted in accordance with the 
Declaration of Helsinki (2000); CE-MARC was approved by the UK National 
Research Ethics Service (05/Q1205/126); CE-MARC 2 was approved by the 
UK National Research Ethics Service (12/YH/0404) (35, 63). Figure 5-2 
shows derivation of the validation population.  
 
 
 
Figure 5-2 Image panel showing angiography and CMR perfusion 
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5.2.2. Classification of Chest Pain and Risk Factors 
Chest pain symptoms were classified as typical, atypical, or non-anginal (8, 
27, 316). Typical chest pain was defined as all following criteria: (1) substernal 
chest pain or discomfort (2) provoked by exertion or emotional stress and (3) 
relieved by rest or nitroglycerine (or both). Atypical chest pain was defined as 
any two of these criteria. If one or none of the criteria was present, symptoms 
were classified as non-anginal (8, 27, 316). Systemic arterial hypertension was 
defined as systolic blood pressure >140mmHg, diastolic blood pressure 
>90mmHg (at >1 occasion) or current diagnosis of hypertension or treatment 
with blood pressure lowering drugs. Hyperlipidaemia was defined as either 
serum cholesterol >6.47mmol/L or patient on medication for hyperlipidaemia. 
Diabetes mellitus was defined as a prior physician based diagnosis (HbA1c 
≥6.5) or use of glucose lowering drugs. Smoking was defined as current, 
former or never. Family history of premature coronary artery disease was 
defined as any first degree relative with history of myocardial infarction, or 
revascularisation <55 years in men and <65 years in women. All patients had 
an ECG performed at their initial clinic visit. 
 
5.2.3. X-ray Angiography 
All patients enrolled in CE-MARC were scheduled by protocol for X-ray 
coronary angiography,(63, 96) and analysed by two experienced cardiologists. 
Clinically significant coronary artery disease was defined as ≥70% stenosis of 
a first order coronary artery measuring ≥2.5mm in diameter, or LMS stenosis 
≥50% as measured by quantitative coronary angiography with use of QCAPlus 
software (version 8.11.19 Sanders Data Systems, Palo Alto, California, USA); 
a post-stenosis diameter was used as the reference vessel diameter in cases 
of ostial disease. 
In those patients that underwent X-ray angiography in CE-MARC 2,(203) 
fractional flow reserve  measurement (St Jude Medical) was recorded in all 
arteries ≥2.5 mm with visually recorded diameter stenosis ≥40% and ≤90%. 
Where fractional flow reserve could not be performed due to clinical/safety 
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reasons, quantitative coronary angiography was performed. Fractional flow 
reserve and quantitative coronary angiography measurements were made by 
a single independent blinded observer at the Glasgow Angiographic Core 
Laboratory. For the enrichment population, quantitative coronary angiography 
analysis was performed as per the CE-MARC study (63, 96). 
 
5.2.4. Model Development 
From the demographic and clinical variables collected in CE-MARC, we 
specifically examined patient age, sex, angina type, diabetes mellitus, current 
smoking, hypercholesterolaemia, diagnosis of hypertension, ECG Q-wave 
abnormalities and ST segment changes. These covariates were chosen as 
they were used in existing Duke risk score and CAD Consortium Clinical 
models (309, 312). Family history of premature heart disease was not thought 
to be as strongly related and was not fully available in the enrichment 
population, so was not considered further for model development. We treated 
age as a linear term in our model, and did not consider any interaction terms. 
Figure 5-3 illustrates selection of predictors for use in developing the risk 
model. 
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Figure 5-3 predictors used in developing the risk model 
 
Binary logistic regression was used to model log-odds of significant 
angiographic stenosis as a function of all candidate predictors. We did not 
employ stepwise selection methods: all covariates were included in the 
development model, regardless of statistical significance or size of effect. 
Since 84 patients (12.4%) of the development population had incomplete data 
for either one or more predictor and/or the outcome (Figure 5-1) we used 
multiple imputation (fully conditional specification or multiple imputation by 
chained equations)(317, 318) to create 20 fully-complete datasets. We then 
Not included 
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fitted our regression model to each dataset, and combined the resulting 
parameter estimates across all analyses using the methods of Rubin,(319) to 
give the overall apparent risk model. Internal validation was performed by the 
regular bootstrap validation method using 200 bootstrap samples to assess 
any need to penalise model performance or adjust estimated coefficients due 
to overfitting (320). We estimated discrimination (area under the receiver 
operating characteristic curve) and calibration in the development population. 
Calibration was assessed in a two-step process: calibration-in-the-large 
(representing difference in overall coronary artery disease prevalence) was 
assessed by fitting a new intercept term holding the existing risk score 
constant; logistic miscalibration was estimated by fitting the risk score to a 
model that included the risk model itself, and the calibration-in-the-large term 
as offset variables (set equal to one), and the risk model again as a covariate. 
Logistic miscalibration would be concluded if the regression parameter was 
significantly different from zero (311, 312). Model ‘optimism’ was calculated, 
which is a measure of how different the discrimination/calibration metric is for 
the model we developed, compared to what it was on average during the 
internal validation process. Small values of ‘optimism’ are preferred, since they 
suggest that model performance reported will be similar to what others may 
see in clinical practice. 
 
 
5.2.5. Validation 
The developed model was validated in the independent external validation 
population. We derived the risk score for all participants, and from that the 
predicted pre-test likelihood of coronary artery disease using our new model. 
We then estimated the discrimination and calibration in the same manner as 
for development. Any missing covariates were imputed using multiple 
imputation. However, positive angiography (or not) was known for all 
participants in the validation population, since angiography defined inclusion 
for CE-MARC 2 patients, and was not missing for any patient in the enrichment 
population. 
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To put our results into current clinical context, we used the validation 
populations to independently validate the performance of four existing 
coronary artery disease risk models: Diamond and Forrester (extended 
version), Duke clinical risk score and CAD Consortium Basic and Clinical risk 
models (33, 309, 311, 312). We estimated their discrimination and calibration 
in the same manner. For completeness, we also repeated this for the 
development population. 
 
5.3. Results 
5.3.1. Development and internal validation 
Of 752 CE-MARC patients, 675 were included in the development population. 
Twenty-five of these (3.7%) had unknown angiogram results and 36 (5.3%) 
had at least one covariate and/or angiogram outcome unknown. Table 5.2 
shows patient demographic characteristics according to presence or absence 
of significant angiographic stenosis. After multiple imputation of missing 
baseline and outcome data, and fitting all covariates, the CE-MARC risk model 
(Table 5.3) was derived. Internal validation of the model by regular bootstrap 
did not reveal any concerns of overfitting: the apparent discrimination 
measured by area under the receiver operating characteristic curve was 0.779 
(95% CI:0.742, 0.814; bootstrap estimated optimism -0.001) and parameters 
of apparent calibration under a 2-parameter approach were alpha=-0.02 
(95%CI:-0.22, 0.18; optimism=0.005) and beta=0.998 (95%CI:0.81, 1.19; 
optimism=0.002). Since estimated model ‘optimism’ resulting from overfitting 
was small, the model was not changed between development and external 
validation. Our ‘optimism’ in performance estimates was close to zero for all, 
i.e. final model performance was very close to that seen in internal validation.  
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Table 5-2 Demographic and clinical characteristics of participants in the development and validation populations 
 CE-MARC (2006-2009) Development population CE-MARC II (2012-2015) + Enrichment (2014-16) Validation population 
 Not CAD (n=415) CAD (n=235) 
No angiogram result 
(n=25) Total (n=675) Not CAD (n=211) CAD (n=158) Total (n=369) 
Patient Age (Derived)        
Mean (SD) 57.9 (9.83) 62.1 (8.34) 57.5 (12.74) 59.4 (9.66) 58.2 (10.08) 61.5 (9.85) 59.6 (10.10) 
Median (IQR) 59.0 (50.0, 66.0) 63.0 (57.0, 69.0) 59.0 (48.0, 66.0) 60.0 (52.0, 67.0) 58.0 (51.0, 65.0) 60.0 (54.0, 69.0) 59.0 (52.0 , 66.0 ) 
Range (35.0, 79.0) (40.0, 79.0) (37.0, 77.0) (35.0, 79.0 ) ( 25.0 , 85.0 ) (39.0 , 86.0 ) ( 25.0 , 86.0 ) 
Male sex 213 (51.3%) 189 (80.4%) 15 (60.0%) 417 (61.8%) 94 (44.5%) 66 (41.8%) 160 (43.4%) 
Chest Pain (Derived)        
Non-anginal chest pain 24 (5.8%) 5 (2.1%) 3 (12.0%) 32 (4.7%) 33 (15.6%) - 33 (8.9%) 
Atypical Angina 344 (82.9%) 139 (59.1%) 14 (56.0%) 497 (73.6%) 98 (46.4%) 56 (35.4%) 154 (41.7%) 
Typical Angina 47 (11.3%) 90 (38.3%) 8 (32.0%) 145 (21.5%) 80 (37.9%) 102 (64.6%) 182 (49.3%) 
Hypertension 211 (50.8%) 128 (54.5%) 15 (60.0%) 354 (52.4%) 74 (35.1%) 91 (57.6%) 165 (44.7%) 
Current Smoker 79 (19.0%) 38 (16.2%) 9 (36.0%) 126 (18.7%) 44 (20.9%) 33 (20.9%) 77 (20.9%) 
Dyslipidaemia 197 (47.5%) 149 (63.4%) 12 (48.0%) 358 (53.0%) 75 (35.5%) 95 (60.1%) 170 (46.1%) 
Diabetic Type II 43 (10.4%) 27 (11.5%) 6 (24.0%) 76 (11.3%) 33 (15.6%) 28 (17.7%) 61 (16.5%) 
ECG Q-Wave 
abnormality 
22 (5.3%) 14 (6.0%) - 36 (5.3%) 2 (0.9%) 13 (8.2%) 15 (4.1%) 
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 CE-MARC (2006-2009) Development population CE-MARC II (2012-2015) + Enrichment (2014-16) Validation population 
 Not CAD (n=415) CAD (n=235) 
No angiogram result 
(n=25) Total (n=675) Not CAD (n=211) CAD (n=158) Total (n=369) 
ECG ST segment 
abnormality 
43 (10.4%) 29 (12.3%) 2 (8.0%) 74 (11.0%) 9 (4.3%) 11 (7.0%) 20 (5.4%) 
CEMARC Clinical PTL        
Median (IQR) 24.5% ( 13.8% , 40.1% ) 47.4% ( 34.0% , 69.0% ) 37.9% ( 15.6% , 51.4% ) 32.8% ( 17.6% , 51.3% ) 32.7% ( 13.2% , 49.2% ) 56.2% ( 39.3% , 69.2% ) 42.2% ( 21.7% , 60.7% ) 
Diamond/Forrester (1979/2011) PTL*       
Median (IQR) 46.3% ( 31.4% , 69.8% ) 77.6% ( 57.4% , 91.1% ) 58.2% ( 23.0% , 82.0% ) 57.4% ( 35.4% , 79.9% ) 63.9% ( 31.4% , 83.3% ) 85.1% ( 73.5% , 92.8% ) 75.2% ( 48.5% , 89.1% ) 
Duke Risk Score (1993) PTL       
Median (IQR) 39.9% ( 21.2% , 68.6% ) 75.8% ( 55.7% , 90.1% ) 64.1% ( 17.5% , 85.1% ) 56.2% ( 27.1% , 80.2% ) 56.0% ( 18.9% , 75.9% ) 79.7% ( 61.1% , 89.5% ) 67.4% ( 35.6% , 83.3% ) 
CAD Consortium (2012) Basic PTL       
Median (IQR) 12.9% ( 7.3% , 24.6% ) 30.9% ( 18.3% , 48.6% ) 21.6% ( 8.0% , 42.5% ) 18.3% ( 9.5% , 34.1% ) 12.6% ( 6.5% , 39.3% ) 22.7% ( 10.9% , 54.0% ) 16.8% ( 7.7% , 47.0% ) 
CAD Consortium (2012) Clinical PTL       
Median (IQR) 11.8% ( 5.8% , 22.3% ) 28.2% ( 16.6% , 48.8% ) 26.9% ( 5.3% , 43.5% ) 17.6% ( 8.2% , 32.7% ) 11.4% ( 5.1% , 31.0% ) 21.8% ( 9.9% , 57.2% ) 14.8% ( 6.6% , 45.5% ) 
 
* The Diamond/Forrester risk score was implemented using the 2011 Genders et al model-based risk function, rather than the 
original 1979 lookup table. In validating this model, patients aged 70 and over had no score calculated. Numbers of participants 
with incomplete or unknown variable values are noted where they occur. For all other variables, data was 100% complete. 
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Figure 5-4 Calibration plots showing relation between predicted PTL and observed rates of CAD  in the validation 
population
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Figure 5-4 cont. Calibration plots showing the relation between 
predicted pre-test-likelihood of CAD and observed rates of CAD by 
decile in the validation population for (A) the CE-MARC risk model, 
(B) the Diamond and Forrester model, (C) the Duke Risk Score 
(1993), (D) CAD Consortium Basic risk score and (E) CAD 
Consortium Clinical risk score. The lower margin of each graph 
presents a histogram of the numbers of patients with each predicted 
risk score. * The Diamond/Forrester risk score was implemented 
using the 2011 Genders et al model-based risk function, rather than 
the original 1979 lookup table. 
 
 
Table 5-3 Developed CE-MARC model 
Model parameter 
Estimated 
effect 
Standard 
Error P-Value 
Intercept (Baseline: Male, non-anginal chest pain, no other risk factors) -4.093 0.812 <.001 
Per year of patient age 0.046 0.011 <.001 
Sex: if female -1.532 0.212 <.001 
Symptoms: if atypical angina 0.609 0.524 0.245 
Symptoms: if typical angina 1.997 0.554 <.001 
Smoking: if current smoker 0.129 0.258 0.616 
Diabetes: if Type II Diabetic -0.247 0.307 0.420 
Cholesterol: if total cholesterol > 6.47mmol/L OR current lipid-lowering 
therapy 
0.481 0.192 0.012 
ECG: If Q-Waves present 0.648 0.397 0.103 
ECG: if S-T segment changes present 0.012 0.293 0.966 
Hypertension: if diagnosed hypertensive 0.140 0.189 0.460 
Footnote: to obtain the risk score, add up the intercept and the values 
related to each characteristic present in the patient (regardless of 
statistical significance). The pre-test likelihood is then given by the 
function Prob(CAD) = 1 / (1 + exp(-Risk Score)). For example: For a 70 
year old female patient with atypical angina, hypertension and no other 
risk factors, the Risk Score is -4.093 + 70 x 0.046 -1.532 + 0.609 + 0.140  
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= -1.656 and the pre-test probability is Prob(CAD) = 1 / (1 + exp(-(-
1.656))) = 16.0%. Alternatively, a 65-year old male patient with non-
anginal chest pain, Type II diabetes and currently smoking with no other 
risk factors has a risk score of -4.093 + 65 x 0.046 – 0.247 + 0.129 = -
1.221 and a pre-test likelihood of 22.8%    
 
5.3.1. External Validation 
Table 5-2 shows clinical and demographic characteristics of patients in the 
validation population. After imputing missing covariate values for the 
validation population, the CE-MARC model was found to discriminate well 
between patients with and without significant angiographic stenosis (c-
statistic=0.777; 95%CI:0.731, 0.824). Figure 5-4 shows calibration of the 
CE-MARC model by plotting observed coronary artery disease proportions 
by calculated coronary artery disease rates for deciles of the population. 
An additional intercept term added to the model was not statistically 
significant (0.045: 95%CI:0.190, 0.280; P=0.71), neither was a coefficient 
representing logistic miscalibration (0.0275: 95%CI-0.214, 0.269; P=0.82). 
 
5.3.2. Validation of other coronary artery disease risk 
models 
Table 5-4 summarises discrimination and calibration of the models in the 
two populations. The performance of these models in development and 
validation populations were similar. 
 
The Diamond and Forrester model and Duke Score were both very poorly 
calibrated. The “calibration-in-the-large” estimates were -1.548 (95%CI:-
1.816, -1.279; P<0.001) and -1.016 (95%CI:-1.265, -0.766; P<0.001) 
respectively in the validation population indicating substantial 
overestimation of pre-test likelihood compared to the average in the two 
populations. After adjusting for the average over-estimation of coronary 
artery disease prevalence, the Duke model remained miscalibrated in the 
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validation population (logistic calibration -0.207: 95%CI:-0.363, -0.050; 
P=0.010) indicating that predicted probabilities of coronary artery disease 
at the extremes were in fact too extreme. After adjustment of the Diamond 
and Forrester model the overall miscalibration effect was not significant (-
0.109: 95%CI:-0.256, 0.039; P=0.148). Figure 5-4B and 5-4C illustrate 
performance of the Diamond and Forrester model and Duke Clinical Risk 
score in the Validation population respectively. 
 
Table 5-4 Model performance statistics (95% CI) 
Model Discrimination (c-statistic) Calibration in the large 
(alpha) 
Logistic miscalibration 
(beta) 
Development 
CE-MARC 0.779 (0.742, 0.814) -[a] -[a] 
Diamond- Forrester 
(1979) 
0.7703 (0.7287, 0.8119) -1.334 (-1.547,-1.121) 
P<0.001 
-0.170 (-0.317, -0.023) 
P=0.024 
Duke Risk Score (1993) 0.763 (0.725, 0.800) -1.108 (-1.305, 0.911); 
P<0.001 
-0.298 (-0.416, -0.180); 
P<0.001 
CAD Consortium (2012) 
Basic 
0.770 (0.733, 0.806) 0.713 (0.532, 0.893);  
P<0.001 
-0.015 (-0.131, 0.101); 
P=0.803 
CAD Consortium (2012) 
Clinical 
0.762 (0.725, 0.7995) 0.822 (0.639, 1.005);  
P<0.001 
-0.051 (-0.159, 0.057); 
P=0.354 
Validation 
CE-MARC 0.777 (0.731, 0.824) 0.045 (-0.190, 0.280); 
P=0.709 
0.028 (-0.214, 0.269); 
P=0.823 
Diamond- Forrester 
(1979) 
0.7547 (0.701, 0.808) -1.548 (-1.816, -1.279) 
P<0.001 
-0.109 (-0.256, 0.039) 
P=0.148 
Duke Risk Score (1993) 0.752 (0.704, 0.801) -1.016 (-1.265, -0.766); 
P<0.001 
-0.207 (-0.363, -0.050); 
P=0.010 
CAD Consortium (2012) 
Basic 
0.755 (0.706, 0.803) 0.738 (0.507, 0.969);  
P<0.001 
-0.007 (-0.182, 0.169); 
P=0.940 
CAD Consortium (2012) 
Clinical 
0.752 (0.703, 0.800) 0.866 (0.629, 1.103);  
P<0.001 
-0.054 (-0.121, 0.105); 
P=0.507 
Discrimination (c-statistic) is equivalent to the Area Under the ROC 
Curve, with 0.5 meaning no ability to discriminate. Calibration in the large 
(alpha) is found by fitting a logistic model in which only an intercept term 
can be fit, and the risk model’s linear predictor is an offset term, set equal 
- 106 - 
 
to 1. Positive and negative values indicate that a model under or over 
estimates risk compared to the average for the population. Logistic 
miscalibration (beta) is estimated by taking the linear predictor for the 
model (adjusted for calibration-in-the-large) and fitting a logistic model 
with no-intercept, said linear predictor as an offset variable (set equal to 
1) and the same linear predictor as a variable in the model. Positive and 
negative values indicate that the range of predicted values is too variable 
or too similar in relation to the spread of risk among the population. [a] A 
model that is validated in the same population as it was derived has 
perfect calibration, so no results are presented for this model. 
 
 
The CAD Consortium Basic risk score underestimated risk of coronary 
artery disease in the validation population (0.738: 95%CI:0.507, 0.969; 
P<0.001). Once this under-estimation was adjusted for, however, the re-
calibrated CAD Consortium Basic model performed well, with predicted 
probabilities more in line with observed rates of coronary artery disease 
(logistic miscalibration was -0.007: 95%CI:-0.182, 0.169; P=0.940). Finally, 
the CAD Consortium Clinical risk model performed similarly to the Basic 
risk model. Calibration in the large showed that this model also 
underestimated risk of coronary artery disease in the validation population 
(0.866: 95%CI:0.629, 1.103; P<0.001). Again, once adjusted, there was no 
evidence of logistic miscalibration in the validation population (-0.054: 
95%CI:-0.121, 0.105; P=0.507). Figures 5-4D and 5-4E illustrate the 
calibration performance of CAD Consortium Basic and Clinical risk models 
in the validation population. Figure 5-5 illustrates calibration of these four 
models when validated in the development population.  
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Figure 5-5 Calibration plots showing the relation between predicted 
pre-test-likelihood of CAD and observed rates of CAD by decile in 
the development population for (A) the Diamond and Forrester 
model (B) the Duke Risk Score (1993), (C) CAD Consortium Basic 
risk score and (D) CAD Consortium Clinical risk score. The lower 
margin of each graph presents a histogram of the numbers of 
patients with each predicted risk score. 
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5.4. Discussion 
The newly-developed CE-MARC risk model, derived from a large 
contemporary UK population undergoing invasive angiography, performed 
very well for estimation of pre-test likelihood in the independent validation 
sample, without needing any adjustment for different risk prevalence or for 
miscalibration. In contrast, the earlier Diamond and Forrester and Duke risk 
models substantially over-predicted risk of coronary artery disease (and 
remained poorly-calibrated once this was corrected). The more recent CAD 
Consortium models (recommended in the ESC guidelines) slightly under-
estimated risk of coronary artery disease, but performed well once this was 
accounted for. 
 
Both Diamond and Forrester and Duke Scores (recommended in US and 
prior UK NICE guidelines) have been recognised to overestimate presence 
of coronary artery disease in contemporary populations (33, 309–313). 
These models were developed over 30 years ago from high risk 
populations in the US (prevalence >60%). Since the inception of the 
Diamond and Forrester and Duke risk scores, prevalence of coronary 
artery disease has declined, with a reduction in rates of smoking, and 
significantly altered pharmacological management of cardiovascular risk 
factors (3, 321). Furthermore, with increased life expectancy many patients 
with stable chest pain present over the age of 70 whilst the Diamond and 
Forrester score only estimates risk for patients up to the age of 69 (33). As 
the performance of a prediction model is related to the population from 
which it is derived, unless these models are applied to a population with a 
high prevalence of coronary artery disease, risk will be overestimated. In 
contrast, the CAD Consortium models have been developed from lower 
risk populations derived from a constellation of diagnostic imaging studies 
(312). The CAD Consortium models have thus far been externally validated 
by Bittencourt, in a low risk US population referred for computed 
tomography coronary angiography, and recently the anatomical arm of the 
PROMISE trial (312–314, 322). The good fit of the CAD Consortium model 
observed in the study by Bittencourt however reflects the low-risk nature of 
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a population referred for non-invasive assessment (only 9% had typical 
chest pain and 47% had non-anginal chest pain symptoms) (312, 313). 
Application of the CAD Consortium models to the PROMISE dataset is 
significantly limited by the lack of 87% of the population having the primary 
endpoint (invasive angiography); furthermore addition of Coronary Artery 
Calcium scoring is of limited clinical benefit, as this information is unlikely 
to be available to physicians at time of initial patient consultation (314, 322). 
 
5.4.1. Strengths of our study  
The CE-MARC development population was derived prospectively from 
across the full spectrum of pre-test likelihood risk groups, as opposed to 
previous studies that have been derived from the amalgamation of 
diagnostic studies of non-invasive imaging modalities (leading to lower risk 
cohorts) or retrospective registries of invasive catheterization (leading to 
high risk cohorts) (63, 310–313, 323). Moreover, the CE-MARC protocol 
mandated all patients underwent invasive angiography regardless of non-
invasive imaging findings or pre-test likelihood of coronary artery disease, 
thereby minimising verification bias (63, 96). Furthermore, we used 
consistent, clinically relevant endpoints from invasive angiography, 
contrary to recent studies estimating pre-test likelihood, principally derived 
from diagnostic accuracy studies of computed tomography coronary 
angiography, where correlation with invasive angiography was not 
mandated (310, 312, 313). Furthermore, in our study a stenosis of ≥70% 
or fractional flow reserve <0.8 was considered significant for coronary 
artery disease and applied to the pre-test likelihood score, as opposed to 
a threshold stenosis severity of ≥50% or indeed a binary yes/no for the 
presence of coronary artery disease that has been used previously (33, 
310–313). 
 
5.4.2. Clinical implications 
Despite a recognition of disease risk overestimation, Diamond and 
Forrester and Duke Scores are recommended in US guidelines, whilst the 
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updated 2016 NICE guidelines have dispensed with pre-test likelihood 
estimation altogether in favour of an anatomically guided approach with 
computed tomography coronary angiography (27, 33, 309, 315). Our 
results support findings by Bittencourt, which suggest that Diamond and 
Forrester and Duke Score overestimate pre-test likelihood of coronary 
artery disease and that  adoption of a contemporary risk score potentially 
re-classifies patients from higher to lower risk groups, thus potentially 
leading to a reduction in the requirement for additional investigations (313). 
The use of a reliable contemporary model that does not over-estimate risk 
could be both reassuring and safer for patients and financially beneficial 
for healthcare systems, as some potentially unnecessary investigations 
could be avoided. The wholesale adoption of computed tomography 
coronary angiography as the initial method of risk stratification, rather than 
pre-test likelihood estimation, potentially leads to increased diagnostic 
testing and exposure to ionizing radiation in what is an increasingly a lower 
risk population (149, 324). Furthermore, the anatomically-guided arm of the 
PROMISE trial, computed tomography coronary angiography led to 
increased rates of invasive catheterisation and revascularisation, with no 
apparent improvement on clinical outcomes (322). Given the derivation 
and validation of the CE-MARC model from contemporary populations 
referenced entirely to invasive angiography, this method of pre-test 
likelihood risk stratification may be appropriate for adoption in future 
guidelines.  
 
Finally, whilst our findings of the effective estimation of pre-test likelihood 
of coronary artery disease by the CE-MARC model are pertinent to patients 
in the hospital setting, future research should evaluate whether this 
estimate is suitable for a primary care setting. Future validation of our 
model in a larger dataset would also be useful to corroborate our findings 
and further scrutinise effect of predictors that we found to be non-
significant. 
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5.4.3. Limitations 
Despite the total sample size of 1044 patients our prospective development 
and validation datasets are small by standards set by the CAD Consortium. 
Consequently, some established clinical predictors were not found to be 
statistically significant (smoking, hypertension, type II diabetes; indeed the 
latter had a small reduction in likelihood of coronary artery disease in our 
population). We included these established major clinical predictors in our 
model, regardless of significance, to take a clinical approach to risk model 
development, rather than a statistical one. In addition, while our 
development dataset was sufficiently-sized (in terms of events per 
variable), and was derived from a study with low risk of work-up bias, it was 
a single-centre study. In addition, although the validation set was largely 
drawn from a 6-centre randomised controlled trial, adding the enrichment 
set to the population meant nearly two thirds of the data came from the 
same hospital as the development set. Excluding the enrichment set from 
the validation of the CE-MARC model did not change the overall calibration 
in the large, but a statistically significant miscalibration effect was observed 
(-0.305; 95%CI -0.611, 0.000; P=0.050) indicating “extreme” predictions to 
be too extreme. However, as the study population in CE-MARC 2 was 
patients with a Duke pre-test likelihood between 10-90%, excluding the 
enrichment set would also mean that the validation population would not 
have the same distribution of pre-test likelihood as the development 
population. 
 
 
5.4.4. Conclusions 
The developed CE-MARC risk model performed very well in the 
independent validation sample, without needing any adjustment for 
different disease prevalence or for miscalibration. In contrast, earlier 
Diamond and Forrester model and Duke Scores substantially over-
predicted coronary artery disease risk, and the Duke score remained 
poorly-calibrated even when this over estimation was corrected for. The 
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CAD Consortium risk models slightly under-estimated average coronary 
artery disease risk, but performed well once this under estimation was 
accounted for. 
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6. Feasibility Study of a Single Breath-hold, 3D mDIXON 
Pulse Sequence for Late Gadolinium Enhancement 
Imaging of Ischaemic Scar 
6.1. Introduction 
Late gadolinium enhancement imaging is the reference standard for 
myocardial scar assessment by CMR (152). LGE imaging is both 
diagnostic for myocardial infarction, and confers prognostic information in 
patients with IHD (99, 151, 158). The transmural extent of myocardial 
infarction delineated by LGE imaging has been shown to accurately identify 
the likelihood of myocardial functional recovery following revascularisation 
therapy and is the cornerstone of viability assessment by CMR (158).  
LGE imaging relies on the altered washout kinetics of gadolinium contrast 
agents caused by expansion of the interstitial space of damaged 
myocardium, with a consequent higher signal intensity compared to 
healthy myocardium demarcating scarred territories. Typically, LGE 
imaging is performed 10-20 minutes following gadolinium contrast 
administration by a two-dimensional (2D) inversion recovery or phase 
sensitive inversion recovery spoiled gradient echo sequence (325). 2D IR 
and PSIR imaging involves a series of repetitive breath holds for the 
acquisition of each short axis plane to cover the left ventricle (325). Three-
dimensional (3D) acquisition methods have been developed in recent 
years that cover the entire left ventricle in a single breath hold (156, 326–
329) or via navigator based free breathing sequences (330–334). Studies 
evaluating 3D techniques have suggested the potential use of 3D LGE 
imaging in a variety of different patient groups (156, 332, 335–337). Thus 
far, single breath hold 3D LGE techniques have typically reported a 
compromise in image quality, mainly due to movement artefacts resulting 
from the very long breath hold durations required (156, 326–329). 
Additionally, typical 3D breath hold durations (>20s) are not possible for 
some patient populations. Navigator gated methods, where the scan is 
triggered to synchronise with the patient’s breathing pattern, require scan 
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times in the order of minutes and yield no observed improvement in image 
quality (330–334).  
 
CMR scans are typically of long duration and require multiple breath holds, 
this is both challenging for patients and impacts clinical workflow. Faster 
scans with less breath holds are sought as they are more tolerable for 
patients, and enable more patients to be scanned per list; the challenge 
though is to retain the excellent image quality that is the strength of CMR. 
 
A shorter breath-hold 3D LGE acquisition can be enabled by additional 
acceleration (undersampling) of data acquisition, such as the use of 
increased parallel imaging factors. However, this naturally yields a loss of 
signal-to-noise ratio (SNR) which can negatively affect image quality. 
Therefore, a data acquisition method is needed which provides more SNR 
so that additional acceleration may be applied whilst maintaining sufficient 
image quality. In this work, we propose use of the modified Dixon 
(mDIXON) method for the specific purpose of enabling a 3D acquisition via 
the additional SNR mDIXON provides (338).  
 
The Dixon method is a historical MRI imaging technique that acquires a 
minimum of two echoes per repetition time in which fat and water signals 
are in-phase and opposed-phase. From the two corresponding images, 
water-only and fat-only images may be calculated (339). The original Dixon 
method is limited by B0 field heterogeneity and long scan times. 
Subsequent three (or more) echo methods were developed that are more 
robust to field inhomogeneity, and are used in many applications, such as 
musculoskeletal imaging and in tissue characterisation (340). However, 
such Dixon techniques are not routinely used in cardiac imaging (173) 
because they do not accommodate reasonable breath hold durations (338, 
341). In this work, we utilised mDIXON in which only two echoes per TR 
are employed,(338) which allows shorter scan times and so may be 
suitable for CMR acquisitions with reasonable breath hold durations. Large 
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field-of-view (FOV) acquisitions with accurate water and fat separation with 
only two echoes is made possible by a full FOV B0 correction, water-fat 
shift correction, and a 7-spectral-peak fat model. Compared to traditional 
Dixon methods, the mDIXON method is uniquely suited to CMR because 
the echo time is not fixed to in-phase and out-of-phase echo times, and 
therefore may be shortened, helping to reduce breath hold durations still 
further.  
 
Moving from 2D to a 3D scan automatically produces an increase in SNR 
because all k-space measurements now contribute to all pixels in all slices. 
However, the use of two echoes per TR in mDIXON allows an additional 
SNR boost compared to a single-echo 3D non-Dixon scan, which can be 
traded for higher sensitivity encoding (SENSE) acceleration factors, which 
in turn help to reduce breath hold duration for the 3D acquisition. The 
further additional signal produced by using 2-echo mDIXON versus a 
single echo 3D non-Dixon scan can be stated as an equivalent number of 
signal averages (NSA) as described by Reeder et al. (342).  
 
Whilst mDIXON is used in this work to enable faster 3D data acquisition, it 
should be noted that from mDIXON data many image contrast types may 
be calculated (water image, fat image, in-phase image, out-of-phase 
image). In this work only the water image is used, and additional clinical 
utility derived from the presence of the other contrast types is not assessed. 
 
The aim of this study was to prospectively evaluate a novel mDIXON 3D-
LGE imaging sequence (in terms of image quality and acquisition duration) 
and compare it to a standard 2D sequence for the detection and 
quantification of myocardial scar in the setting of ischaemic heart disease.  
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6.2. Material and Methods 
6.2.1. Study population  
Patients with prior myocardial infarction were prospectively recruited 
between June 2016 and June 2017. Myocardial infarction was diagnosed 
by cardiac biomarkers, electrocardiography and acute coronary 
angiography at the time of primary PCI. Inclusion criteria were ≥18 years 
of age, no contra-indication to contrast-enhanced CMR, glomerular 
filtration rate ≥60mL/min/1.73m2.  Patients with atrial fibrillation, non-MR 
compatible implants, renal failure or claustrophobia were excluded. 
Patients were classified as Acute MI if scanned within 7 days of their index 
admission with the acute coronary syndrome. Chronic MI was at least 3 
months following the initial presentation of the acute coronary syndrome. 
The study had appropriate ethical approval and was performed in 
accordance with the Declaration of Helsinki, and all patients provided 
informed written consent.  
 
6.2.2. CMR data acquisition 
CMR was performed on a 1.5 Tesla Philips Ingenia system (Philips 
Healthcare, Best, The Netherlands) equipped with a 24 channel digital 
receiver coil and patient-adaptive RF shimming. Imaging acquisition 
included survey images, assessment of myocardial function using standard 
SSFP cine imaging (spatial resolution 1.09x1.09x8mm³, 30 cardiac phases 
TR/TE 3.0/1.48ms, flip angle 40o, field of view 360-360mm, SENSE 
acceleration) and 2D-LGE and 3D-LGE imaging. For LGE imaging, an 
intravenous bolus of 0.15mmol/kg gadobutrol (Gadovist®, Bayer Inc.) was 
administered. The optimal TI to null the myocardium was determined by a 
Look-Locker sequence. 2D and 3D LGE imaging were performed 10 
minutes following contrast administration. 2D and 3D sequences were 
performed separately in random order to avoid bias and systematic error 
caused by contrast washout. Times taken for the 2D and 3D acquisition 
sequences were recorded. Imaging parameters were:  
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(i) 2D breath-hold PSIR sequences with 12 short-axis slices covering the 
full LV, thickness 10mm, no gap, repetition time 6.1ms, echo time 3.0ms, 
flip angle 25º, field of view 300 x 300mm, matrix 127/256, acquired in-plane 
resolution 1.59x2.20mm2 reconstructed to 0.91x0.91mm2, effective 
SENSE factor 2.2. The turbo factor was 20 (7 shots) with an acquisition 
duration of 123.3ms. The receiver bandwidth was 250.2 Hz/px;  
(ii) 3D mDIXON sequences with 24 short-axis slices, slice thickness 5mm, 
repetition time 4.0 ms/echo times 1.21ms and 2.5ms, flip angle 15º, field of 
view 300 x 300 x 120mm, matrix 169/384, acquired in-plane resolution 
1.83x2.00mm2 reconstructed to 1.17x1.17x5mm2, SENSE factors in phase 
and slice directions were 3 and 2 respectively with effective overall factor 
6.86 after oversampling taken into account. The equivalent NSA provided 
by mDIXON compared to an identical single-echo protocol was 1.52 (342). 
The turbo factor was 30 (16 shots) with a shot acquisition duration of 148 
ms, one shot per heartbeat over 18 beats. The receiver bandwidth was 866 
Hz/px. Saturation bands were not used. 
Additional 4 Chamber and 2 Chamber 2D LGE images were acquired but 
not used for analysis/interpretation. 
 
6.2.3. CMR data analysis 
CMR data were analysed quantitatively using commercially available 
software (CVI42, Circle Cardiovascular Imaging Inc. Calgary, Canada). MR 
data analysis of 2D and 3D LGE images was performed blinded in random 
order by a cardiologist (JF with 6 years in cardiac imaging). For 15 patients, 
quantitative analysis was performed again 4 weeks later to assess intra-
observer variability, and to assess interobserver variability by a second (GF 
with 6 years in cardiac imaging) and third cardiologist (LB with 8 years in 
cardiac imaging). For volumetric analysis, endocardial borders were traced 
on the LV cine stack at end-diastole and end-systole to calculate end 
diastolic volume, end systolic volume, stroke volume and ejection fraction. 
Contours were traced to exclude papillary muscles and trabeculations. 
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6.2.4. Qualitative LGE assessment 
Image quality was defined on a scale of 1-4 (4=non-diagnostic, 
3=acceptable diagnostic quality, 2=good quality, 1=excellent quality). For 
scores other than 1, the reason for impaired quality was categorized as a) 
motion or blurring artefacts, b) low contrast or high noise, c) inadequate 
myocardial nulling, or d) wrap around/folding artefacts. Additionally, both 
2D and 3D LGE images were evaluated for the presence of ventricular 
cavity thrombi.   
 
6.2.5. Quantitative LGE assessment  
Quantitative assessment of the myocardial scar burden was performed 
using the semi-automated full-width half-maximum method (threshold of 
50% of the maximum intensity within the scar) which has been proposed 
as the most reproducible method (180, 343).  On both the 2D and 3D LGE 
short-axis images endocardial and epicardial contours were manually 
outlined (excluding papillary muscles); manual delineation of two separate 
user-defined ROIs were then made on an LGE short axis slice where 
infarcted myocardium was present. One ROI was drawn in remote 
myocardium (where no scar was present); a second ROI was drawn 
around hyperenhanced myocardium where infarcted myocardium was 
present. Automated calculations for the remaining LV short axis LGE stack 
based on these two ROIs were then performed. Scar tissue mass was 
calculated (grams). Scar tissue percentage and transmurality were 
calculated automatically for each segment of 16 segments of the 17 
segment model proposed by the American Heart Association (excluding 
the apex) (245). Infarct transmurality was automatically calculated by the 
analysis software and then graded using a 5-point scale from the derived 
quantitative result (0=no scar, 1=1-25% transmural extent, 2=26-50% 
transmural extent, 3=51-75% transmural extent and 4=76-100% 
transmural extent). Time taken for image acquisition of the entire LV for 2D 
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and 3D was recorded (this included time taken for pauses between breath 
holds for each LV slice).  
 
6.2.6. CNR measurements  
In 25 consecutive patients CNR measurement was performed, a single 
slice containing both hyperenhanced and healthy myocardium was 
selected and for this corresponding slice a dedicated noise scan (identical 
pulse sequence without excitation pulses) was performed immediately 
afterwards in order to assess the noise levels (179). ROIs were drawn on 
the normal 3D and 2D LGE images in areas of hyper-enhancement, a 
remote area of normal appearing myocardium, and in blood pool. ROIs 
contained at least 30 pixels, aside from the areas of hyper-enhancement 
where size of the ROI was governed by the size of the scar. A further ROI 
covering the entire LV myocardium was drawn on the corresponding noise 
image, the standard deviation of this measurement was then used to 
calculate CNR measurements. CNR was calculated as the ratio of the 
difference in mean signal intensity between ROIs on the LGE images to 
the standard deviation of signal intensity in the whole LV ROI from the 
separate noise image. The MR system noise level is measured and not 
organ/image level.  
 
6.2.7. Statistical analysis 
Continuous variables are expressed as mean±SD. Categorical variables 
are expressed as N (%) or proportions. Normality of data was tested using 
a Shapiro-Wilk test. Paired two-tailed student t-test and the Wilcoxon 
signed rank test were used as appropriate to compare continuous 
variables. P<0.05 was considered statistically significant. Pearson 
correlation, linear regression and Bland-Altman analysis were used to 
show agreement between the 2D and 3D acquisition sequences for scar 
tissue mass and scar tissue percentage of LV mass. Coefficient of variation 
was used to assess interobserver and intraobserver variability for scar 
tissue mass. Cohen κ statistic was used for interobserver agreement for 
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the image quality score. Cohen κ statistic was also used to measure 
agreement between the 5 point grading of transmurality and the agreement 
for the binary detection of viable/non-viable segments. Statistical analysis 
was performed using IBM SPSS® Statistics 22.0 (IBM Corp., Armonk, NY).  
6.3. Results 
6.3.1. Demographics  
A total of 92 patients (80/92 male, mean age 60.9±11.0 years; BMI 
26.7±4.2kg/m2; LVEDV 175.3±60.8ml; LVEDVi 90.5±31.2ml/m2; LVESV 
97.1±55.2ml; ejection fraction 47.2±12.3%) were prospectively examined. 
Of these, 53 patients had chronic (46/53 male, mean age 59.9±10.9 years; 
BMI 26.7±4.2kg/m2; ejection fraction 47.9±13.9%) and 39 patients had 
acute (male 34/39, mean age 62.3±11.2 years; BMI 26.8±4.25kg/m2; 
ejection fraction 46.3±9.9%;) myocardial infarction. All 92 patients were 
scanned with both 2D PSIR and 3D mDIXON LGE acquisitions (in random 
order) without complications, resulting in a total of 1,472 segments per 
technique.  
 
6.3.2. Image quality  
Image quality was graded as excellent for 65/92 (70.6%) of the PSIR 
images, and 63/92 (68.5%) of the 3D images. No dataset was deemed 
non-diagnostic in either 3D mDIXON or 2D PSIR images (score of 4). 
There was no statistically significant difference in image quality between 
3D and 2D LGE (1.4±0.6 vs. 1.3±0.5, P=0.162) (Figure 6-1). Table 6-1 
shows the reasons why image quality was scored other than excellent for 
LGE sequence. Image quality impairment was predominantly attributed to 
blurring/motion (15/27) in the 3D datasets. Interobserver agreement for 
image quality was good for both observers (between 1 and 2 κ = 0.615 and 
between 1 and 3: 0.706). 
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Figure 6-1 Short axis LGE images from (A) basal, (B) mid-ventricular 
and (C) apical slices from 2D PSIR acquisitions, and (D) basal, (E) 
mid-ventricular and (F) apical slices from 3D mDIXON acquisitions 
of the same patient showing antero-lateral scar following a left 
anterior descending artery territory infarction. (Image from Foley et 
al. JMRI in press) 
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Table 6-1 Reasons for impaired subjective image quality ratings 
(for any rating other than excellent)  
 
 2D PSIR 3D mDIXON 
Motion /blurring 7 15 
Low contrast/noise 7 4 
Nulling 6 5 
Folding artefact 4 3 
Total 24 27 
 
6.3.3. CNR 
The CNR of scar to blood was not significantly different between 3D and 
2D LGE techniques respectively (16.1±10.5 vs. 18.8±12.4, P=0.337). The 
CNR of scar to remote myocardium (36.4±19.8 vs. 56.6±20.8, P=0.001) 
and CNR of remote myocardium to blood (21.3±12.9 vs. 41.0±17.0, 
P<0.001) were significantly lower by 3D mDIXON compared to 2D PSIR.  
 
6.3.4. Quantitative LGE Analysis 
3D mDIXON compared to 2D PSIR identified statistically significantly more 
absolute scar tissue mass (18.9±17.5g vs. 17.8±16.2g, P=0.03) but no 
significant difference in scar tissue when expressed as a percentage of LV 
mass (13.4±9.9% vs. 12.7±9.5%, P=0.07). Bland-Altman analysis of 
absolute 3D scar tissue mass compared to 2D scar mass showed a small 
positive bias of 1.1g (95%CI: -5.8 to 8.0); likewise for percentage scar 
tissue the bias was 0.7% (95%CI: -4.0 to 5.5) (Figure 6-2a and 6-2b).  
3D mDIXON identified significantly greater scar tissue mass compared to 
2D PSIR in acute myocardial infarction (23.3±19.5g vs. 21.5±17.3g, 
P=0.012) and similar scar tissue mass in chronic myocardial infarction 
(15.6±15.3g vs. 15.0±14.9g, P=0.125).  
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There was strong and significant correlation in scar tissue mass (r=0.981 
P<0.001) and scar tissue percentage between 3D and 2D acquisitions 
(r=0.970 P<0.001). 
A total of 5 patients were identified to have intraventricular thrombi in both 
2D and 3D acquisitions, no thrombi were visible in only 2D or 3D images 
(Figure. 6-3). 
 
 
Figure 6-2 Bland-Altman analysis of 3D and 2D LGE acquisitions 
(±1.96 Standard deviations – dashed lines) for assessment of (A) 
absolute scar tissue mass and (B) scar tissue as a percentage of LV 
myocardial mass. 
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Figure 6-3 Laminated thrombus in a chronic myocardial infarction in 
an apical slice of a (A) 2D PSIR acquisition and (B) 3D mDIXON 
acquisition of the same patient (red arrows demarcate the 
thrombus). (Image from Foley et al. JMRI in press)  
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Interobserver coefficient of variability was excellent for both 3D and 2D 
LGE techniques in terms of scar mass (between JF and GF 3D 7.0%; 2D 
4.9%; and between JF and LB 3D: 5.8% 2D: 7.3%) and scar tissue 
percentage (between JF and GF 3D 7.1%; 2D 5.2% and between JF and 
LB 3D: 6.0% and 2D: 7.8%). Intra-observer coefficient of variability was 
also excellent for both 3D and 2D LGE for scar mass (3D 5.3%; 2D 4.8%) 
and scar tissue percentage (3D 5.4%; 2D 5.3%). 
 
 
6.3.5. Segmental and transmurality assessment 
There was excellent agreement (κ=0.870; Pearson’s r=0.956, P<0.0001) 
between the 3D and 2D LGE techniques based upon a segmental scar 
transmurality threshold of 50% (the threshold typically used for clinical 
viability status determination); there was also good agreement between the 
two techniques for the overall 5-point transmurality score κ = 0.736 
(Pearson’s r = 0.922 P<0.0001). Results of the segmental 5 point 
transmurality assessment was 1±1.1 for 2D and 1±1.1 and for the binary 
50% viable threshold was 0.1±0.3 for 2D and 0.1±0.3 for 3D. 
 
6.3.6. Image acquisition time  
Time from contrast injection to image acquisition were as follows: 2D 10.54 
±0.59minutes, 3D 13.06 ±3.12minutes P<0.0001. Time taken to acquire 
LGE images was much shorter for 3D mDIXON compared to 2D PSIR 
(15.6±1.4 vs. 311.6±43.2 seconds, P<0.0001). For PSIR, 1 slice was 
acquired per breath hold; average breath hold duration for each PSIR slice 
acquisition was 10.7±1.2 seconds.  
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6.4. Discussion 
The main findings of this study are i.) 3D mDIXON LGE offers comparable 
image quality for the evaluation of ischaemic scar compared to 2D LGE 
imaging; ii.) quantitative assessment of 3D mDIXON LGE of scar mass and 
transmurality has high agreement with 2D LGE imaging; iii.) 3D mDIXON 
LGE provides a vastly shorter overall scan duration in an acceptable single 
breath-hold time compared to 2D LGE. 
We have used only the water-image calculated from the mDIXON-acquired 
data. The purpose of the study was to use mDIXON to enable 3D LGE in 
a reasonable breath hold duration, not to compare the utility of the various 
contrasts a Dixon-based scan can produce. Others have demonstrated 
clinical utility of Dixon fat-image, for example in detection of lipomatous 
metaplasia in scar (344–346). Similar additional clinical value may be 
available with the 3D mDIXON method used here. Lapinskas et al. describe 
acquisition of a long axis 3D mDIXON LGE in a single breath hold, this 
however is not easily comparable to routine 2D PSIR short axis LGE 
imaging (344). Short axis mDIXON LGE imaging is also described but it is 
limited in that it requires 2 breath holds, thus leading to increased scan 
duration and likely corruption of data from different breath hold positions 
and increasing the potential of breathing artifacts (344).  
It is possible to increase the SNR of a single-echo 3D non-Dixon scan by 
lowering the receiver bandwidth, which might also be considered as an 
enabler for a 3D LGE protocol within a sufficiently short breath hold 
duration. However, lowering the receiver bandwidth will also increase the 
TE, and thus the TR, which increases the acquisition (shot) duration, which 
would increase blurring due to cardiac motion. In order to shorten the shot 
again a higher number of readouts is needed necessitates a longer breath 
hold. mDIXON affords additional SNR without this consequence, which 
was confirmed by Bloch simulation built into the MR system. 
Current 2D LGE imaging techniques are highly discriminatory for the 
diagnosis of myocardial infarction and form the basis of myocardial viability 
imaging by CMR (151, 152). Thus, high image quality is of paramount 
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importance when introducing a new LGE technique, as current 2D methods 
are so effective. The in-plane resolution of the 2D scan was higher than 
the 3D, in our study the 2D scan was clinically optimised and established 
and we wanted to directly compare with it; the 3D scan was separately 
optimised, balancing resolution and acceleration. Typically, 3D LGE 
techniques have been shown to have compromised image quality 
compared to 2D techniques, though differences in qualitative ratings often 
do not reach significance (156, 328, 336, 347, 348). Our findings were that 
categorical image scoring of the 3D mDIXON sequence was in fact very 
comparable to the 2D LGE sequence. This is despite the lower CNR for 
myocardium to scar and myocardium to blood seen in the 3D images 
compared to the 2D images. This is likely due to the similar CNR for scar 
to blood seen between 3D and 2D images; this parameter is arguably more 
important as poor contrast between scar and blood pool can make it difficult 
to identify the endocardial border so consequently compromising accurate 
assessment of scar size and identification of sub-endocardial infarction. 
Furthermore, despite the CNR differences recorded this does not make an 
impact on the automated quantitative LGE assessment. PSIR 
reconstruction used in the 2D protocol mitigates sensitivity of the sequence 
to the precise TI set by the user to null normal myocardium, which varies 
from patient to patient. Since the TI required to null normal myocardium 
changes during contrast washout over the scanning time of the 2D stack 
of slices, the flexibility PSIR allows is helpful. PSIR reconstruction was not 
used in the 3D mDIXON protocol, but since the whole stack of slices is 
acquired in just one breath hold, the effect of contrast washout between 
slice acquisitions is not an issue. There is no theoretical obstacle to 
combining the 3D scan we used with PSIR in further work. However, note 
that since PSIR requires 2 beats, a “3D mDIXON PSIR” scan duration 
might get significantly longer again (the second beat is used to watch the 
magnetisation recover and so determine whether the acquisition in the first 
beat was above or below the null point). 
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Scar burden by LGE imaging has been shown to be proportional to 
likelihood of major adverse cardiovascular events and offers prognostic 
information in patients with ischaemic heart disease (151). Of note, the 3D 
mDIXON technique identified significantly more scar compared to the 2D 
sequence. This is likely a result of the contiguous slices which a single 
breath hold 3D scan affords, compared to the series of breath holds for a 
2D stack of slices which can be affected by inconsistent breath hold 
position even in expiration as used in this work. The 5mm reconstructed 
slice thickness used in the 3D mDIXON technique compared to the 10mm 
used in the routine PSIR sequence may also aid perception of scar; a 
similar result was described by Yin et al who also used a thinner slice 
thickness in the 3D acquisition compared to the 2D (334).  The thinner slice 
thickness may help identify smaller infarcts and delineate the true border 
of the scar being imaged.  
 
The transmural extent of infarction has been shown to directly relate to the 
likelihood of functional recovery following revascularisation. LGE imaging 
consequently has a grade A rating to determine myocardial viability prior 
to revascularisation in the ACCF/AHA/SCMR appropriate use criteria and 
is the third highest indication for CMR in Europe (166, 171) Therefore, 
accurate discrimination of transmural scar extent is important when 
considering a new LGE sequence. Previous studies have showed variable 
results, though more recent studies have shown reasonable agreement 
(156, 327, 336, 349, 350). The 3D mDIXON technique showed strong 
agreement with the 2D sequences. Statistical significance was seen in scar 
mass seen by 3D compared to 2D in the acute but not in the chronic 
infarctions, overall however there was no difference in viability assessment 
or the overall % LV mass. This is potentially a reflection of the smaller 
sample size of acute patients, compared to the overall study group. 
Furthermore, although the difference in scar tissue mass reached 
statistical significance, there is in fact little clinical significance in the 
difference between the two sequences when expressed as a percentage 
of LV mass (0.7% difference).  
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Thus far, a significant limitation in the utility of 3D LGE imaging has been 
that despite a significant reduction in overall scanning time to acquire an 
entire short axis stack, individual breath holds remain overly long leading 
to image degradation or scan failure (156, 336). In the patient groups 
proposed to benefit from shorter scanning times (those with cardio-
respiratory disease and those unable to perform long breath holds) this 
increased breath hold duration negates the perceived advantages. Goetti 
et al., noted a doubling of blurring artifacts due to breath hold durations of 
26.7±4.4seconds compared to a routine 2D inversion recovery sequence 
(156). Bratis et al., observed no increase in blurring artifacts, despite 3D 
acquisitions requiring a breath hold duration of 22-27seconds, however 
60% of patients demonstrated no pathology and comment is made that 
respiratory motion was the main cause of 3D imaging failure (10/57cases) 
(336). Various methods have attempted to overcome the long 3D breath 
hold duration; Bauner et al., used a 3D acquisition sequence that used 3 
consecutive slabs to cover the entire ventricle, however this only resulted 
in a halving of the acquisition time and generated new artefacts due to 
misalignment of the 3D volume stacks as a result of variations in breath 
hold position (350). Alternatively, navigator gated 3D sequences can be 
acquired in a free-breathing manner; however, navigator gated sequences 
can lead to prolonged scan times due to navigator inefficiency, with 
potential scan failure due to drift of respiratory pattern leading to impaired 
image quality as the TI required to null myocardium alters (330–334). 
Bizino presented a free breathing motion corrected 3D sequence but this 
was not compared to 2D LGE for image quality, and still took over 3minutes 
for acquisition (351).  Recently compressed sensing techniques have been 
proposed as a method to reduce scanning times,(352) however recent 
publications of 3D LGE using compressed sensing still require scanning 
times between 3- 7 minutes and have not been compared to currently used 
2D sequences (353, 354). Moreover, the 3D mDIXON method described 
here can be combined with the product “Compressed SENSE” on the MR 
system used for this work for further acceleration and reduction in breath 
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hold duration. Preliminary tests suggest a breath hold duration of just 11 
seconds may still preserve sufficient image quality. More extreme methods 
have also been proposed to overcome the prolonged breath hold durations 
by increasing the patient’s ability to breath hold by supplemental oxygen 
and hyperventilation techniques, however this approach appears 
incongruous if this requires training time and resources (355). Our data 
showed no failed 3D scans in any of the 92 patients, some with significant 
left ventricular dysfunction, resulting in diagnostic quality studies (none 
deemed non-diagnostic) that was obtainable in a single breath hold. Our 
study has shown that a breath hold duration (15.57±1.361seconds) using 
the 3D mDIXON technique is sufficiently short to enable most patients to 
complete, as demonstrated in both acute and chronic MI patient groups. 
 
6.4.1. Limitations 
 
A limitation of our study is the difference in slice thickness between the 2D 
and 3D acquisitions. We chose to use the slice thickness currently used in 
our 2D clinical scanning sequence and ongoing clinical trials at our 
establishment, and used the default 5mm slice thickness on the 3D 
mDIXON sequence as it was apparent from pilot data that this achieved 
acceptable SNR within a sufficiently acceptable breath hold duration. 
Additionally, the 3D LGE scan does not employ a PSIR reconstruction, and 
so the image contrast is more sensitive to correct inversion time selection. 
A further limitation is that there is no pathology based reference standard 
to compare the true size and presence of myocardial infarction from the 
quantitative analysis of either 2D or 3D LGE approaches. A further 
limitation is the difference in time from gadolinium injection to image 
acquisition between the 2 sequences which is inherently impossible to 
overcome, a pragmatic approach of randomizing test order is what 
comparable studies on this topic have done previously (156, 328, 335, 336) 
and although not perfect is an attempt to reduce the effect on image quality 
of contrast washout from the blood pool. 
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6.4.2. Conclusion 
 
In conclusion, single breath-hold 3D mDIXON LGE imaging allows 
quantitative assessment of scar tissue burden and transmurality, with 
comparable image quality, in a significantly shorter acquisition time 
compared to standard 2D LGE imaging. 
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7. Clinical Evaluation of two dark blood methods for late 
gadolinium enhancement imaging and quantification of 
ischaemic scar 
 
7.1. Introduction 
Late gadolinium enhancement imaging is both diagnostic for myocardial 
infarction as well as prognostic in patients with IHD (99, 151, 158). Presence 
of late enhancement has been shown to confer increased risk of MACE and 
cardiovascular mortality above and beyond clinical and angiographic findings 
(151, 356). Furthermore, transmural extent of MI demarcated on LGE imaging 
accurately identifies the likelihood of myocardial functional recovery following 
revascularisation (152, 158). Progress in cardiovascular medicine has resulted 
in a reduction in the number of fatal STEMI, however this has led to increased 
numbers of patients living with ischaemic scar. Thus accurate methods of scar 
quantitation/transmurality assessment are required to guide revascularisation 
decisions and for prognostication (3).  
 
LGE imaging is typically performed 10-20 minutes following administration of 
a gadolinium-based contrast agent, by a two-dimensional IR spoiled gradient 
echo sequence (325). Conventionally this is preceded by a Look-Locker 
sequence enabling the MR operator to set an appropriate TI to null normal 
myocardium, and thus give high contrast between ‘bright’ scarred myocardium 
(where gadolinium contrast agent is retained), and the darker healthy 
myocardium. Phase sensitive inversion recovery sequences have been 
developed to overcome the need to precisely choose the correct TI to null the 
normal myocardium (357). A large proportion of infarctions are sub-
endocardial because ischaemia causes a wavefront-phenomena of necrosis 
that affects the sub-endocardial fibres of the myocardium first (20).  Despite 
good contrast between scar and normal myocardium, contrast between blood 
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pool and myocardial scar can be limited leading to uncertainty for the reporting 
clinician as to the precise location of the scar-blood pool interface, which then 
can impact on the assessment of the transmural extent of the scar.  
 
Several dark blood sequences have been described that attempt to overcome 
the issue of poor contrast between contrast enhanced blood pool and sub-
endocardial infarction by addition of extra magnetisation pulses (172–178, 
358). FIDDLE (Flow-Independent Dark-blood DeLayed Enhancement) 
incorporates an additional magnetisation preparation prior to the inversion 
pulse in a PSIR LGE sequence (178, 358). Numerous radiofrequency (RF) 
preparation types may be employed, such as T1rho (T1ρ), T2 preparation, 
additional inversion pulses etc. T1ρ is the decay rate of magnetisation during 
application of a RF field applied parallel to the net magnetisation of spins, in 
the rotating frame. More complex composite RF preparations for T1ρ 
weighting can be used to compensate for variations in the B1 field, and B0 
inhomogeneity. The preparation pulse incorporates a spin locking time (SL) 
during which T1ρ decay occurs (359). Then standard LGE imaging follows. 
The magnetisation preparation effects a different starting value for the 
magnetisation of tissues before LGE imaging. Then when LGE image 
acquisition immediately follows, adjusted contrast remains between these 
tissues. In each case, the intention is that blood pool remains the most 
incompletely recovered longitudinal magnetisation compared to the other 
tissues of interest, thus yielding the lowest signal – dark blood – in the PSIR 
LGE image. A PSIR reconstruction reduces sensitivity to inversion time 
precision and removes the risk of tissues with different T1 relaxation times 
appearing isointense.  Recently a method using a standard PSIR sequence 
with the inversion time set to null the blood pool rather than the myocardium 
was described in a group of 9 patients (179). This method, albeit in a small 
number of patients, led to improved scar to blood CNR and improved reader 
confidence (179).  
The aim of this study was to prospectively evaluate a novel T1ρ dark blood 
sequence and compare this to the recently described blood nulled PSIR (BN) 
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and the standard ‘clinical’ myocardium nulled PSIR (MN) technique for the 
detection and quantification of scar in the setting of ischaemic heart disease.   
 
7.2. Methods 
7.2.1. Study population 
Patients with prior myocardial infarction were prospectively recruited between 
April 2017 and June 2017. Myocardial infarction was confirmed by cardiac 
biomarkers, electrocardiography and coronary angiography. Inclusion criteria 
were age ≥18 years, no contra-indication to contrast-enhanced CMR, 
glomerular filtration rate ≥60mL/min/1.73m2.  Patients with atrial fibrillation, 
non-MR compatible implants, renal failure or claustrophobia were excluded. 
The study was performed in accordance with the Declaration of Helsinki, 
approved by the National Research Ethics Service, with all patients providing 
informed written consent.  
 
7.3. CMR data acquisition 
CMR was performed on a 1.5 Tesla Philips Ingenia system (Philips 
Healthcare, Best, The Netherlands) equipped with a 24 channel digital 
receiver coil and patient-adaptive RF shimming. Image acquisition included 
survey images, assessment of myocardial function using standard SSFP cine 
imaging (spatial resolution 1.09x1.09x8mm³, 30 cardiac phases TR/TE 
3.0/1.48ms, flip angle 40o, field of view 360-360mm, SENSE acceleration) and 
2D LGE imaging. For LGE imaging, an intravenous bolus of 0.15mmol/kg 
gadobutrol (Gadovist®, Bayer Inc.) was administered. At 10 minutes post-
contrast, the optimal TI to null the myocardium was determined by a Look-
Locker sequence. A routine 2D breathhold phase sensitive inversion recovery 
sequence with 12 slices covering the full LV (thickness 10mm, no gap, 
repetition time 6.1 ms/echo time 3.0 ms, flip angle 25º) was then performed. A 
single short axis slice that included scar, remote healthy myocardium and 
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blood pool was then selected, and a repeat Look-Locker sequence was 
performed for this slice to re-confirm appropriate inversion times for tissues of 
interest. The selected short axis slice was then re-acquired using the PSIR 
LGE sequence with the TI set to null myocardium (MN), the TI set to null the 
blood pool (BN) and a T1ρ FIDDLE sequence. A dedicated noise scan 
(identical pulse sequence without excitation pulses) was performed after each 
slice acquisition, in order to enable accurate measurement of the signal-noise 
level (179). The T1ρ-prepared and the two standard PSIR sequences were all 
performed in random order to avoid systematic bias caused by differences in 
contrast washout. 
 
Imaging parameters were as follows: 
2D breath-hold phase sensitive inversion recovery sequences with 12 slices 
covering the full LV, thickness 10mm, no gap, repetition time 6.1ms, echo time 
3.0ms, flip angle 25º, field of view 300x300mm, matrix 127/256, acquired in-
plane resolution 1.59x2.20mm2 reconstructed to 0.91x0.91mm2, effective 
SENSE factor 2.2. The turbo factor was 20 (7 shots) with an acquisition 
duration of 123.3ms. The receiver bandwidth was 250.2 Hz/px. The same 
sequence was used for both the single slices of the MN and the BN with the 
TI set to null myocardium and blood pool respectively. 
The T1ρ preparation employed a ΔB0 and B1 insensitive spin lock (360) 
consisting of 90x,SLy,180y,SL−y,90-x pulses as seen in Figure 7-1, with the two 
spin lock (SL) pulses using an locking frequency of 500Hz. The spin lock time 
was 40ms. The SL pulses with opposed phase compensate for B1 variation, 
and the central 180 pulse compensates for B0 inhomogeneity. A modified 
Look-Locker inversion-recovery (MOLLI) T1-mapping scan (3–5 scheme) was 
performed to determine T1 values of the viable myocardium, LV blood, and 
scar tissue. 
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Figure 7-1 shows the T1 rho preparation for the FIDDLE (T1ρ) pulse 
sequence 
 
 
7.3.1. CMR data analysis 
CMR data were analysed quantitatively using commercially available software 
(CVI42, Circle Cardiovascular Imaging Inc. Calgary, Canada). MR data 
analysis of the three types of LGE images was performed blinded in random 
order by a cardiologist (Observer 1 with 6 years in cardiac imaging).  For all 
patients, quantitative analysis was performed again 4 weeks later to assess 
intra-observer variability and for all patients by a second cardiologist (Observer 
2 with 6 years in cardiac imaging) to assess inter-observer variability. For 
volumetric analysis, endocardial borders were traced on the LV cine stack at 
end-diastole and end-systole to calculate end diastolic volume, end systolic 
volume, stroke volume and ejection fraction. Contours were traced to exclude 
papillary muscles and trabeculations. 
 
7.3.2. Image analysis 
7.3.2.1. Qualitative LGE assessment  
Maximum scar transmurality was visually assessed using a 5 point scale (0=no 
LGE, 1=1-25%, 2=26-50%, 3=51-75%, 4=76-100%). Confidence in scar 
detection and degree of transmurality was assessed using a 4 point scale 
(1=non-diagnostic, 2=low, 3=moderate, 4=high confidence).  
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7.3.2.2. Quantitative LGE assessment 
Quantitative assessment of the myocardial scar burden was performed using 
the semi-automated full-width half-maximum method (threshold of 50% of the 
maximum intensity within the scar) which has been proposed as the most 
reproducible method (180, 343).  On the 2D BN, MN and T1ρ LGE short-axis 
images endocardial and epicardial contours were manually outlined (excluding 
trabeculations and papillary muscles); manual delineation of two separate 
user-defined ROIs were then made on the LGE short axis slice where infarcted 
myocardium was present. One ROI was drawn in remote myocardium (where 
no scar was present); a second ROI was drawn within hyperenhanced 
myocardium where infarcted myocardium was present. Scar tissue mass 
(grams) was then calculated on the BN, MN and T1ρ LGE LV short axis slice 
based on these ROIs.  
 
7.3.2.3. CNR measurement 
ROIs were drawn on each single slice MN, BN, and T1ρ LGE images in areas 
of hyper-enhancement, a remote area of normal myocardium, and in the blood 
pool. ROIs contained at least 30 pixels, aside from the areas of hyper-
enhancement where size of the ROI was governed by the size of the scar. A 
further ROI covering the entire LV myocardium was drawn on the 
corresponding noise image, the standard deviation of this measurement was 
then used to calculate CNR measurements. CNR was calculated as the ratio 
of the difference in mean signal intensity between ROIs on the LGE images to 
the standard deviation of signal intensity in the whole LV ROI from the 
separate noise image. CNR was calculated for difference between scar and 
blood pool (CNRscar-blood), scar and myocardium (CNRscar-myo) and between 
blood and remote myocardium (CNRblood-myo). 
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7.3.3. Statistical analysis 
Continuous variables are expressed as means ± SD. Categorical variables are 
expressed as N (%) or proportions. Normality of data was tested using a 
Shapiro-Wilk test. Repeated measures ANOVA with post hoc Bonferroni 
correction was used to compare means of the three groups. P<0.05 was 
considered statistically significant. Coefficient of variation was used to assess 
interobserver and intraobserver variability for scar size. Cohen κ statistic was 
used for interobserver and intraobserver agreement for transmurality 
assessment and the image confidence score. Statistical analysis was 
performed using IBM SPSS® Statistics 22.0 (IBM Corp., Armonk, NY).  
 
7.4. Results 
7.4.1. Study population 
A total of 30 patients (26/30 male, mean age 63.8±10.7 years; mean BMI 
26.3±3.6kg/m2; mean LV ejection fraction 47±11%; LVEDV 167±53ml; 
LVEDVi 87±25ml/m2; LVSV 75±17ml/m2; LVESV 92±48ml) were prospectively 
examined. 
 
7.4.2. MR imaging 
Imaging using routine PSIR, blood nulled PSIR and T1ρ were successfully 
completed in all patients with no imaging failures. There was no significant 
difference in time of image acquisition between the three pulse sequences MN 
17.58±0.53minutes BN 18.07±0.47minutes T1ρ 18.11±0.46minutes P=1 
between timing of all sequences.  
 
7.4.3. Qualitative image analysis 
7.4.3.1. Transmurality assessment  
The transmural extent was deemed significantly larger in the BN (66 ± 34%) 
and T1ρ (66 ± 36%) compared to MN 48 ± 37%, (P<0.001 compared to both 
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BN and T1ρ). Interobserver agreement for transmurality assessment was 
excellent for all methods (κ = 0.81 (MN), 0.95 (BN), 0.85 (T1ρ)). Intraobserver 
agreement for transmurality assessment was also good or excellent for all 
methods (κ = 0.70 (MN), 0.85 (BN), T1ρ 0.85 (T1ρ)).  
 
7.4.3.2. Confidence scores for assessment of transmurality 
No images were deemed non-diagnostic. Confidence scores were significantly 
higher for BN (3.87 ± 0.346) compared to MN (3.10 ± 0.76 P <0.001) and T1ρ 
(3.20 ± 0.71 P<0.001), there was no difference in confidence scores for T1ρ 
compared to MN (P=0.977). Interobserver agreement was excellent for the 
three methods (κ=0.843 (MN), 0.865 (BN), 0.870 (T1ρ)). Intraobserver 
agreement was also excellent for all three methods (κ = 0.948 (MN), 0.839 
(BN), 0.865 (T1ρ)). In one patient both BN and T1ρ identified sub-endocardial 
scar that was mistaken for outflow tract by both readers on the MN LGE image 
(figure 7-2; further representative images are seen in figures 7-3 and 7-4). 
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Figure 7-2 A, B, C (Patient 1) shows a small sub-endocardial anterior 
infarct imaged with each of the pulse sequences. 
A is T1ρ, B is MN and C is BN. B shows limited contrast between the 
blood pool and scar and it could be mistaken for outflow tract, whereas 
in C the scar is clearly apparent. A demonstrates increased contrast 
between scar and blood pool but limited contrast between myocardium 
and blood pool. 
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Figure 7-3 shows 2 patients with acute infarctions with each of the 
pulse sequences. 
A, B, C (Patient 2) shows an acute inferior infarction with RV 
involvement and microvascular obstruction (MVO). B is MN compared 
to A, and C (T1ρ and BN respectively) it is difficult to discern the extent 
of the RV infarction. D, E and F (Patient 3) show an acute lateral 
infarction with extensive MVO imaged with T1ρ, MN and BN 
respectively. It is difficult to discern the papillary muscle MVO except in 
the T1ρ (D). 
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Figure 7-4 shows 2 patients with chronic infarction imaged with each 
of the pulse sequences: 
 A and D are T1ρ, B, E is MN and C, F BN. 
 
7.4.4. Quantitative image analysis 
7.4.4.1. Scar size  
There was no significant difference in scar size between the three LGE 
methods: MN (2.28 ± 1.58g) BN (2.16 ± 1.57g) and T1ρ (2.29 ± 2.5g) (MN:BN 
P=0.066, BN:T1ρ P=0.385, MN: T1ρ P=1). Interobserver coefficient of 
variation was good for all three methods (MN 9.32%, BN 7.63%, T1ρ 9.40%.) 
Intraobserver coefficient of variation for scar size was also good for all three 
methods (MN 7.36%, BN 7.39%, T1ρ 9.18%).   
 
7.4.4.2. CNR analysis 
The CNRscar-blood was significantly increased for both the BN (27.1 ± 10.4) and 
the T1ρ (30.2 ± 15.1) compared to the MN (15.3 ± 8.4 P<0.001 for both 
sequences) (Figure 7-5). There was no significant difference in CNRscar-myo 
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between BN (55.9 ± 17.3) and MN (51.1 ± 17.8 P=0.512); these both had 
significantly higher CNRscar-myo compared to the T1ρ (42.6 ± 16.9 P=0.007 and 
P=0.014 respectively). The CNRblood-myo was significantly higher for MN 
compared to BN (28.0 ± 12 P<0.001); CNRblood-myo was also significantly higher 
for both MN and BN compared to T1ρ (13.6 ± 7.2 P<0.001 for both 
sequences).  
 
 
 
 
Figure 7-5 shows CNR for the respective sequences. Downward lines 
of the asterisked (*) bars demarcate significant difference between 
the CNRs of the respective pulse sequences. 
 
7.5. Discussion 
The main findings of this study are: i) both PSIR with TI set for blood nulling 
and the T1ρ LGE sequence demonstrated significantly higher scar to blood 
CNR compared to routine MN; ii) PSIR with TI set for blood nulling 
demonstrated significantly higher reader confidence scores compared to both 
routine MN and the novel T1ρ LGE sequence iii.) quantitative LGE scar size 
measurement showed no statistical difference between the three LGE 
methods. 
Current conventional LGE imaging using IR and PSIR spoiled gradient echo 
sequences give high resolution images that are firmly established as the 
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reference standard for viability imaging by CMR. Accurate determination of 
transmurality is vital to guide revascularisation; currently however a significant 
limitation is that of the limited contrast between hyperenhanced scar and 
residual contrast in the LV blood pool. Several previous studies have used a 
variety of different preparation pulses, including T2 preparation, double and 
triple inversion recovery,  or T1ρ with spin locking to produce dark or black 
blood LGE images (172–178). Most recently focus has been concentrated on 
using a T2 preparation pulse to null the blood pool; Basha et al noted a 
significantly increased signal ratio between scar to blood using a T2 
preparation pulse sequence versus a standard inversion recovery LGE 
sequence (361). Furthermore, recently a non-breath held motion corrected 
method using an inversion recovery T2 preparation combined with SSFP 
imaging demonstrated an increase in CNR of 13% for scar to blood compared 
to standard IR LGE sequence (177). This sequence has subsequently been 
assessed in 172 patients and identified significantly more LGE compared to 
standard LGE imaging (362). Most of these sequences currently remain 
research investigations and are vendor/platform specific and are yet to see 
mainstream clinical adoption. The recent study by Holtackers et al 
demonstrated an increased scar to blood contrast when nulling blood in a 
standard PSIR pulse sequence, without the need for additional preparation 
pulses (179).   
 
Both the T1ρ and blood nulling PSIR LGE images in our study significantly 
increased the CNR between scar and blood pool compared to routine 
myocardium nulling PSIR images. Notably this only led to an increased reader 
confidence in the BN, but not however for the T1ρ sequence despite this 
increased CNR. The lower confidence scores for the T1ρ compared to the BN 
are likely representative of the lower CNRblood-myo for the T1ρ compared to the 
BN leading to difficulty in ascertaining the true anatomy of the left ventricle 
(distinction between remote myocardium and blood pool); this finding suggests 
that high CNRscar-blood is not the only facet necessary for high reader 
confidence. The anatomy of the ventricle can potentially be derived from the 
previously acquired SSFP images and transposed onto the T1ρ images in 
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order to clarify scar location; this however would add time to reader 
interpretation. The BN images retain the excellent image quality that 
characterise routine 2D MN PSIR images, whilst increasing the confidence of 
the reader for the identification of scar border.  Quantitatively derived scar size 
was not significantly different between the three LGE methods despite the two 
dark blood methods objectively identifying greater transmural extent of scar to 
the two readers. Other LGE studies have demonstrated an increase in scar 
size using dark blood sequences, however these have been by visual 
assessment only or using less conventional methods of LGE quantitation (179, 
362). There is no histological correlation for these findings, this corroborates 
those seen previously where histological correlation was performed (358).  
 
This is the first study to compare PSIR with blood nulling and myocardium 
nulling to a dark blood sequence using additional preparation pulses. A 
primary benefit of the BN method is that the acquisition used in pulse 
sequence is already established in routine clinical use and requires no 
additional magnetisation pulses to perform. Importantly, this makes it simple 
for standard clinical adoption as it requires very little radiographer/clinician 
training to employ. This is in contrast to the recently described T2 sequence 
that led to a comparative doubling of acquisition time for a stack of 9 short axis 
slices (typically 12 short axis slices are acquired suggesting this length of time 
would increase further) (177). As CMR becomes ever more established in 
clinical guidelines efficient workflow in CMR departments is vital especially 
given that viability assessment is currently the third highest indication for CMR 
assessment in Europe (171). 
 
7.5.1. Limitations 
In this study, we only used single slices and did not cover the entire ventricle 
with the three different acquisitions. This approach however minimised the 
time elapsed between acquisition of the different sequences and consequent 
reduced the observed change in CNR to be due to the washout kinetics of the 
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gadolinium contrast agent. There was no histological reference standard to 
compare the actual presence or size of scar detected by the three sequences.  
 
7.5.2. Conclusion 
Both BN images and T1ρ increase CNR for scar to blood compared to MN 
images with the TI set to null the myocardium. Routine adoption of the blood 
nulled PSIR would seem appropriate as reader confidence is heightened 
compared to MN images and T1ρ sequences; as this LGE sequence is already 
in clinical use it requires little training to enable widespread clinical 
implementation.  
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8. Discussion 
 
The mortality from cardiovascular disease remains the number one cause of 
death worldwide and continues to form a significant burden on modern 
healthcare systems.  
Multi-parametric CMR is well-established to diagnose and guide the 
management of patients presenting with IHD. Progressively CMR methods are 
developed that allow insights to be gained into the pathophysiology of 
cardiovascular disease and diagnostic accuracy to be improved.  
 
CMR imaging is ideally suited to investigative cardiovascular research due to 
the lack of ionising radiation for the acquisition of images and the high quality 
of image generation enables highly reproducible quantitative comparison of 
studies across patient groups. The central aim of this thesis was to study and 
refine the utility of both existing and emerging CMR imaging techniques in the 
context of IHD, with a particular emphasis on prior myocardial infarction and 
LGE techniques, risk prediction and diagnostic accuracy of ischaemia testing 
in severe CAD. 
 
Chapter 3 compares the accuracy of non-invasive imaging methods of CMR 
with MPS-SPECT to identify significant left main coronary artery disease. 
 
Chapter 4 uses quantitative analysis of myocardial function to give insights 
into myocardial mechanics and differentiate ischaemic and non-ischaemic 
cardiomyopathy that can appear phenotypically very similar.  
 
Chapter 5 aimed to refine and update the Diamond and Forrester risk 
stratification score, commonly advocated in clinical practice guidelines, in 
order to risk stratify and identify those patients presenting with chest pain who 
should be sent for further investigation.  
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Chapters 7 and 8 are CMR method development chapters aiming to refine and 
advance upon existing LGE imaging techniques that are the cornerstone of 
viability and scar assessment in CMR.   
 
8.1. Discussion, study limitations and future direction 
relating to Chapter 3 
 
Chapter 3 “A Comparison of Cardiovascular Magnetic Resonance and Single 
Photon Emission Computed Tomography (SPECT) Perfusion Imaging in Left 
Main Stem or Equivalent Coronary Artery Disease” aimed to compare the 
diagnostic accuracy of the non-invasive imaging modalities of CMR and MPS-
SPECT to identify significant left main coronary artery disease as measured 
by quantitative coronary angiography. Additionally, quantitative CMR 
perfusion analysis was compared to routine visual CMR analysis in the 
investigation of left main coronary artery disease. Significant left main stem 
coronary disease is associated with high mortality rates and is a relatively 
common finding in patients presenting with symptoms of stable coronary 
disease. Modern methods of coronary revascularisaton have demonstrated 
significant survival benefits for patients with left main stem coronary disease. 
Data on the diagnostic accuracy of non-invasive imaging modalities for the 
assessment of coronary disease are often limited to observational 
retrospective studies in respect to MPS-SPECT, or not at all in respect to the 
utility of CMR. Both these imaging modalities are well established in the 
investigation of stable CAD and the findings seen on both CMR and SPECT 
have been related to prognosis and long term outcomes.  
In this study, we demonstrated that in patients with stable suspected CAD, 
CMR first-pass perfusion imaging as part of a multi-parametric protocol more 
accurately detected evidence of CAD in LMS patients (AUC: 0.95; 0.85-0.99) 
than MPS-SPECT (AUC: 0.63; 0.49-0.76) (p=0.0001). Furthermore, although 
quantitative CMR perfusion showed high diagnostic accuracy for the detection 
of LMS disease with a global MBF <2.08ml/g/min had sensitivity of 78% and 
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specificity of 85% for diagnosis of LMS disease, as the most diagnostic 
quantitative marker (AUC: 0.87; 0.75-0.94); quantitative perfusion however did 
not outperform visual CMR perfusion analysis (p=0.18) however was 
significantly more accurate than investigation with MPS-SPECT (p=0.003). 
 
There were some limitations to this study, the numbers of patients with LMS 
disease in this prospective study are limited. In this study MPS-SPECT 
analysis did not use attenuation correction; this was however not routine 
practice when the CE-MARC study was undertaken (264). In this study, 
anatomical assessment with QCA was used as the endpoint for coronary 
angiography rather than FFR which has been used as a more contemporary 
method of physiological assessment. The CMR perfusion imaging pulse 
sequence used in CE-MARC was not fully optimised for quantitative analysis. 
The pulse sequence used a single preparation pulse for all three slices and a 
relatively high contrast agent dose that potentially may have led to a lower 
performance of quantitative analysis in this study compared to more recently 
developed methods. Studies comparing dual-bolus and uncorrected single 
bolus myocardial blood flow estimates however have not shown significant 
differences in diagnostic accuracy (266), and our diagnostic accuracy values 
corroborate other comparable studies in the literature, suggesting these 
limitations have not significantly affected our results. 
 
Future directions in this area of research should build upon this exploratory 
analysis of the CE-MARC dataset. Further studies in this area should include 
a larger sized patient population. Furthermore, using a more contemporary 
pulse sequence that have been optimised for quantitative perfusion analysis 
would also add merit to further studies. Additionally, using a physiological 
reference standard such as FFR or alternatively IVUS that are often used in 
contemporary invasive assessment of left main coronary disease would add 
merit to further studies of non-invasive imaging in LMS disease. 
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8.2. Discussion, study limitations and future direction 
relating to Chapter 4 
 
Chapter 4 “Quantitative deformation analysis differentiates ischaemic and 
non-ischaemic cardiomyopathy” aimed to investigate the relationship between 
strain-derived parameters of myocardium and the aetiology of patients with 
heart failure with reduced ejection fractions and hypothesised that in a 
prospectively recruited random sample of HFrEF patients with ICM and NICM 
would have distinctive myocardial torsion patterns. LV torsion results as a 
consequence of the fibrous architecture of the heart and is altered by different 
loading conditions such as hypertension, athletic training and alters with 
increasing age. Thus far there have been no comparisons of LV mechanics 
performed between different aetiologies of HFrEF. 
 
This study demonstrated that all quantitatively derived CMR myocardial 
mechanical parameters including strain, twist and torsion were reduced in HF 
patients compared to healthy age-matched controls. Furthermore, despite 
patients being phenotypically comparable with analogous left ventricular 
dimensions, EF and strain parameters, patients with NICM generate 
significantly less LV twist and torsion than patients with ICM. Twist, torsion and 
strain are reduced in patients with cardiomyopathy compared to controls. 
Torsion and twist are significantly lower in patients with NICM compared to 
ICM, despite similar volumetric dimensions, circumferential and longitudinal 
strain parameters and LVEF. 
 
Our observational study has a number of limitations. Overall this is a relatively 
small sample size with some differences in baseline demographics, 
comorbidities and treatment that may potential have led to a degree of bias. 
However this study was prospectively enrolled and age matched in both 
cardiomyopathy groups and controls particularly as age has been shown to 
affect the myocardial mechanics (strain, torsion and twist) measured here 
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(303). A recognised limitation of 2D tagging methods is through plane motion, 
the 2D method used in our paper has consistently been demonstrated to be 
reliable and reproducible in a variety of patient groups (233, 286, 304, 305) , 
and 2D and 3D tagging methods for LV torsion have been shown to strongly 
related (306). Current 3D methods of CMR tagging are time consuming 
requiring multiple breath holds of long duration (307, 308, 363), thus from a 
pragmatic point of view we used a reproducible 2D method that required a 
single breath hold per slice that HF patients would be able to tolerate. This 2D 
tagging method may potentially have had an effect on our results due to the 
global deformation changes seen in NICM versus local changes in contractile 
properties in ICM.  
Future directions in this area of research should endeavour to build upon the 
findings of this study. Potential areas of work would be to reproduce these 
findings in a larger cohort of patients. Furthermore, different groups of heart 
failure subtypes and varying severity of disease phenotype could be 
investigated to further increase understanding of different pathophysiology. 
Additionally, the myocardial mechanical indices measured here by CMR could 
potentially be used to investigate patient response to medications or clinical 
interventions and be related to patient prognosis.  
 
8.3. Discussion, study limitations and future direction 
relating to Chapter 5 
 
Chapter 5 “Development and validation of a contemporary pre-test likelihood 
model of coronary artery disease referenced to invasive angiography, with 
comparison to pre-existing risk models” sought  to both develop and validate 
a contemporary multivariable risk model based entirely on invasive coronary 
angiographic data (using data from two recently published contemporary UK 
studies of stable coronary artery disease (CE-MARC and CE-MARC 2: 
Clinical evaluation of magnetic resonance imaging in coronary heart disease 
study)), and to compare this to pre-existing risk models that are currently used 
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in clinical practice guidelines (35, 63, 96, 203). Non-invasive imaging is 
increasingly used as a first line investigation in stable CAD and advocated by 
societal practice guidelines prior to invasive assessment by X-ray coronary 
angiography; the use of PTL scores help to quantify risk of CAD and to guide 
choice of investigation. Historical risk scores based on X-ray angiography have 
been shown to overestimate the risk of coronary artery disease most likely as 
a consequence of being derived from highly selective higher risk populations 
that do not represent the lower risk populations undergoing assessment seen 
in current practice; whilst more modern risk scores are typically derived from 
heterogeneous populations derived from non-invasive imaging studies often 
using CTCA as the marker of presence of CAD with no invasive reference 
standard.  
 
In this study, we corroborated the findings of previous studies that have 
indicated that the pre-existing Diamond and Forrester and Duke scores 
overestimate the risk of CAD in a contemporary population. Additionally, the 
more recent models by the CAD Consortium (recommended in the ESC 
guidelines) slightly under-estimated risk of CAD, but performed well once this 
was accounted for. The CE-MARC risk model that we developed in this study, 
that was derived from a large contemporary UK population undergoing 
invasive angiography, performed very well for estimation of PTL in the 
independent validation sample that again used invasive x-ray coronary 
angiography as the reference standard for the diagnosis of stenotic coronary 
artery disease, without needing any adjustment for different risk prevalence or 
for miscalibration. 
 
There a few limitations to this study. The total sample size of 1044 patients of 
the prospective development and validation datasets are comparatively small 
to the standard set by the CAD Consortium study. In this study some 
established clinical predictors were not found to be statistically significant 
(smoking, hypertension, type II diabetes) which may well be due to the sample 
size. Furthermore, while our development dataset was sufficiently-sized (in 
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terms of events per variable), and was derived from a study with low risk of 
work-up bias, this was however a single-centre study. Similarly, although the 
validation set was developed from a 6-centre randomised controlled trial, 
adding the enrichment population led to almost two thirds of the data being 
derived from the same hospital as the development set. A significant 
miscalibration effect was observed (-0.305; 95%CI -0.611, 0.000; P=0.050) if 
the enrichment set was removed from the validation of the CE-MARC model; 
this was due to the study population of CE-MARC 2 having a Duke PTL 
between 10-90%, (removing the enrichment set would mean the validation 
population would not have the same distribution of PTL as the development 
population). Excluding the enrichment set from the validation of the CE-MARC 
model did not however change the overall calibration in the large. 
 
Future directions in this area would be to increase the overall sample size with 
a more even spread across the different risk groups derived from multiple 
centres and additionally with a larger representation of those in the older age 
groups and in the lower risk groups that are progressively more prevalent in 
rapid access chest pain clinics in contemporary practice.  
 
8.4. Discussion, study limitations and future direction 
relating to Chapter 6 
 
Chapter 6 “Feasibility Study of a Single Breath-hold, 3D mDIXON Pulse 
Sequence for Late Gadolinium Enhancement Imaging of Ischaemic Scar” 
utilised a novel mDIXON 3D-LGE imaging sequence in the setting of both 
acute and chronic MI. Multiple 3D LGE sequences have been proposed as an 
alternative to the standard 2D sequences that are used in clinical practice that 
cover the entire left ventricle in a single breath hold (156, 326–329) or via 
navigator based free breathing sequences (330–334); clinical adoption 
however has not occurred as these often compromise image quality and 
require long breath hold durations. The primary objectives of this study were 
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to prospectively evaluate the mDIXON 3D-LGE sequence for the detection and 
quantification of myocardial scarring and compare it to a standard 2D PSIR 
acquisition sequence used in routine practice.  
 
In this study 3D mDIXON LGE was shown to offer a comparable level of image 
quality for the evaluation of ischaemic scar in the setting of both acute and 
chronic MI compared to standard 2D PSIR LGE imaging. Additionally using 
quantitative LGE assessment, 3D mDIXON LGE has high agreement with 2D 
LGE imaging for both scar mass and transmurality. Furthermore, the 3D 
mDIXON LGE sequence evaluated in this study had a significantly shorter 
overall scan duration with an acceptable single breath-hold time compared to 
2D LGE for coverage of the entire LV. 
 
Limitations of our study include the difference in slice thickness between the 
2D and 3D acquisitions. Additionally, the 3D mDIXON LGE scan that we used 
in this study does not employ a PSIR reconstruction, and consequently the 
image contrast is more sensitive to correct inversion time selection. A further 
limitation is that there is no pathology based reference standard to compare 
the true size and presence of myocardial infarction from the quantitative 
analysis of either 2D or 3D LGE approaches. 
 
Studies of LGE imaging techniques are often limited by the lack of a 
histological reference standard. Further studies based on this work could 
utilise pathology as the reference standard for quantification of myocardial 
scarring. This study was performed in the setting of IHD and this method could 
be evaluated in patients presenting with alternative forms of cardiomyopathy 
with scarring from patchy fibrosis to mid wall fibrosis. Additionally, the utility of 
3D mDIXON LGE imaging should be clinically evaluated to assess if its 
adoption improves clinical workflow. 
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8.5. Discussion, study limitations and future direction 
relating to Chapter 7 
Chapter 7 “Clinical Evaluation of two dark blood methods of late gadolinium 
quantification of ischaemic scar” aimed to prospectively evaluate a novel T1ρ 
dark blood sequence and compare this to blood nulled PSIR and standard 
myocardium nulled PSIR for the detection and quantification of myocardial 
scarring in the setting of IHD.   
 
The principle findings of this chapter were that both PSIR with the TI set for 
blood nulling and the T1ρ LGE sequence demonstrated significantly higher 
scar to blood CNR compared to routine MN PSIR.  The study also showed that 
PSIR with TI set for blood nulling demonstrated significantly higher reader 
confidence scores compared to both routine MN and the novel T1ρ LGE 
sequence. For quantitative LGE scar size measurement there was no 
statistical difference demonstrated between the three LGE methods. 
 
Limitations In this study, are the use of only single slices rather than covering 
the entire ventricle with the three different acquisitions. This was a pragmatic 
approach that minimised the time elapsed between acquisition of the different 
pulse sequences and consequently reduced the observed change in CNR to 
be due to the washout kinetics of the gadolinium contrast agent. There was no 
histological reference standard to compare the actual presence or size of scar 
detected by the three sequences.  
 
As with the previous chapter, future studies evaluating dark blood LGE 
imaging could utilise histology as the reference standard for quantification of 
myocardial scarring. A larger patient group could be used in order to identify if 
scarring was missed on the bright blood sequences that were identified on the 
dark blood sequences. This study was performed in the setting of IHD and this 
method could be evaluated in patients presenting with alternative forms of 
cardiomyopathy with scarring from patchy fibrosis to mid wall fibrosis. 
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Additionally, comparison of the blood nulled PSIR could be made to other dark 
blood sequences that are being adopted on differing platforms. 
 
8.6. Overall future directions  
CMR is now recognised as the reference standard for cardiac volumetric 
analysis and function (88, 89) and highly diagnostic for myocardial ischaemia 
and scarring; consequently CMR is firmly established in clinical practice 
guidelines for the investigation and management of IHD. Progress and future 
directions for CMR will come from progression of technological advances and 
their application to improve diagnostic accuracy as well as speed up clinical 
workflow; perhaps more importantly will be the application of CMR to 
demonstrate altered clinical outcomes.  
 
Despite rapid progress in CMR technology, clinical CMR scanning due to its 
multi-parametric nature remains relatively time consuming compared to other 
non-invasive imaging modalities used in the investigation of IHD (47).  
Technological advances in accelerated CMR methods aim to improve 
temporal and spatial resolution as well as reduce overall scan durations. 
Accelerated methods utilising parallel imaging and kt undersampling are well 
established in clinical MR imaging (364). Recently interest has turned to 
compressed sensing (365); like k-t methods compressed sensing also exploits 
sparsity in a transform domain but instead of reducing the overlap in the 
transform domain, compressed sensing uses incoherent sampling and non-
linear reconstruction. Compressed sensing techniques have been 
demonstrated to acquire a full cardiac cycle LV cine stack in a single breath 
hold with high reproducibility (352, 366).  
 
In addition to the improvement in scanner hardware and pulse sequences, 
improvements to analysis software should enable improved clinical workflow 
and speed of reporting. Machine learning and the use of artificial intelligence 
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are both being adopted to accelerate software analysis (367, 368). The most 
recent update of Circle CVI uses machine learning in order to provide 
automatic contouring for left ventricular volumetric analysis and ejection 
fraction. Despite the progress in technological advances in CMR that continue 
apace, this is not however the only area of research that requires focus for 
progress in the field of CMR. Technological advances remain a technical 
endeavour without clinical application.  
 
8.6.1. Studies showing outcomes in ischaemic heart disease 
Progressively studies involving non-invasive imaging are using hard endpoints 
of mortality (322, 369). Thus far despite basic science studies showing 
improvement of function following viability assessment and suggestion from 
meta-analyses showing improved outcomes for patients using viability testing 
to improved patient outcomes, this has yet to be borne out in clinical studies 
(152, 370). The STICH viability substudy investigated this subject and showed 
no benefit to patient outcomes using viability assessment; however this was a 
sub-study of a negative trial and was fraught with confounders (12). Despite 
this viability assessment remains the 3rd highest indication for CMR in Europe 
(171); a randomised controlled trial of revascularisation versus optimal 
medical therapy in patients with viability as measured by LGE is surely 
clinically warranted.  
 
Progressively non-invasive imaging studies are used as a gatekeeper to 
invasive coronary angiography. Despite the publication of the PROMISE trial 
as yet it is not clear whether functional imaging or anatomical imaging should 
be the imaging method of choice prior to angiography (322). A multi-centre 
study comparing functional imaging (CMR or DSE) compared to anatomical 
imaging (CTCA) to guide the management of patients with suspected CAD 
using a physiological reference standard such as FFR is another avenue that 
should be explored.  
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Newer methods of quantitative perfusion have been developed that are readily 
accessible to the clinician and that have been shown to have good correlation 
with PET (129, 130). This modality is beginning to be placed beyond a 
research tool and into clinical practice. Clinical trials using quantitative 
perfusion should be performed to assess whether it has any benefit compared 
to qualitative assessment for management of patients with suspected CAD 
and has utility other than as a research tool. Additionally quantitative perfusion 
is ideally placed to assess the concept of prognostic benefit being derived from 
revascularisation in patients with >10% ischaemia burden; a figure derived 
from historical observational studies (371).  
 
 
8.7. Conclusions 
CMR with its multiparametric nature and high reproducibility is ideally suited 
to the diagnosis of ischaemic heart disease and it’s sequelae, as well as 
providing insights into disease mechanisms.  
In this thesis CMR has been demonstrated to have higher diagnostic accuracy 
over MPS-SPECT for the investigation of significant left main coronary artery 
disease. Using MR derived strain indices, it has been demonstrated that 
patients with non-ischaemic cardiomyopathy generate significantly less LV 
twist and torsion than patients with ischaemic cardiomyopathy. A 
contemporary risk score to assess the pre-test likelihood of coronary artery 
disease has been developed and validated in patients presenting with chest 
pain. A novel 3D mDIXON LGE method has been shown to generate 
comparable image quality for the evaluation of ischaemic scar compared to 
routine 2D LGE imaging in an overall greatly shorter scan time. Additionally 
this thesis has validated a novel method for dark blood late gadolinium imaging 
that does not utilise extra preparation pulses.
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CE-MARC STUDY 
 
Clinical Evaluation of MAgnetic Resonance imaging in 
Coronary heart disease 
 
Patient information Leaflet 
Version 2.1 December 2005 
Dear  patient, 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, 
relatives and your GP if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take 
part. 
 
 
WHY HAVE I BEEN CHOSEN? 
This study is looking at people like you, who have been referred to a cardiology clinic 
with chest pain. We will be asking 750 people to take part in this study. 
 
 
WHAT IS THE PURPOSE OF THE STUDY? 
We currently have several tests available to help us find out if chest pain is caused by 
heart disease. These include treadmill exercise testing, coronary angiography and 
SPECT perfusion imaging. More recently we have begun to use another test, Magnetic 
Resonance Imaging (MRI) to obtain pictures of the heart. MRI produces pictures with 
much greater detail than with other types of heart scans. Importantly, MRI is also a 
safer test than most other heart scans, because it does not expose patients to any 
harmful radiation and pictures of the heart can be taken “from the outside”. Because 
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of all of these qualities, MRI might become one of the most important tests in patients 
who suffer with chest pain and coronary heart disease. As for any new test, before 
being able to use MRI on a daily basis, we need to find out how accurate it really is 
compared with the currently available tests. This is why we are carrying out this 
research study.  
 
 
DO I HAVE TO TAKE PART? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you receive. 
 
 
WHAT WILL HAPPEN TO ME IF I TAKE PART? 
All patients in this study will have three or four heart tests. One of the tests is the MRI 
scan, which is done solely for research purposes. The other three tests are those that 
are currently used to detect coronary heart disease, namely an exercise treadmill test, 
a SPECT myocardial perfusion study (to obtain information on the blood flow to the 
heart muscle) and an x-ray angiogram (to detect any blockages in the heart arteries). 
Of these other three tests, your hospital consultant may want you to have some or even 
all anyway. However, because for this study all patients must have all four tests (to 
allow us to compare them with each other), if any of the other three tests are not 
requested by your hospital consultant, we will carry them out for this research study.  
 
All tests will be performed at the Leeds General Infirmary and we will try to carry out 
as many as possible on the same day to minimise the time you have to spend travelling 
to the hospital. Information leaflets that give you more details about all of the tests 
will be provided.  
 
1. The MRI scan will take approximately 60 minutes to complete. You lie in a short 
'tunnel', which holds a large magnet. Short bursts of magnetic fields and radio waves 
from the MRI scanner allow images to be created. You will hear periodical loud 
“banging” noises while we are acquiring the images of your heart. We will remain in 
communication with you throughout the scan. Twice during the scan, we will inject an 
MRI contrast medication into a vein in your arm. The needle used for this will feel 
like a sharp scratch. Usually people are not aware of the contrast dye injection. At one 
point we will also inject a medication (Adenosine) into a vein in your arm, which is a 
drug to increase the blood flow to your heart. This can cause a brief feeling of warmth, 
breathlessness or chest discomfort. However all of these feelings, if they occur, 
usually settle within one or two minutes.  
 
2. The exercise treadmill test requires you to walk on a treadmill while your heart trace 
(ECG) and blood pressure are measured. This test will of course only be carried out if 
you are physically able to walk on the treadmill. Almost all patients referred to 
hospital with chest pain have a treadmill test anyway. 
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3. The SPECT perfusion study is carried out on two separate days and takes 
approximately 2 hours on each day. On one day pictures of the heart will be taken at 
rest and on the second day after injection of the same medication (Adenosine) that we 
use for the MRI scan to increase the blood flow to your heart. On both days you will 
also have an injection of a radioactive dye into the blood, which is taken up by the 
heart muscle. Usually people are not aware of the contrast dye injection. One hour 
after the injection, pictures of the heart are taken with a special camera that slowly 
moves around you while you lie on a bed with one arm raised above your head. Taking 
these pictures takes approximately 20 minutes.  
 
4. With the x-ray angiogram, we take x-ray pictures of the heart arteries. This test 
requires you to come into hospital for one day. You will be taken to an x-ray room 
and lie down on your back. After cleaning the groin area, local anaesthetic is given 
into the groin or the forearm and a needle put into the artery in the groin or arm. 
Because of the local anaesthetic putting the needle in should not be painful. A fine, 
hollow tube called a ‘catheter’ is then introduced into the artery and is gently advanced 
through the blood vessels to the heart. The catheter is roughly the diameter of the lead 
in a lead pencil. You will not feel the catheter being moved around inside your chest. 
A dye is then injected into the heart blood vessels and X-rays taken from several 
angles. Some injections cause a hot, flushing sensation which lasts a few seconds. 
When the test is over, the catheter is removed and simple pressure is applied to the leg 
or arm for about 10 minutes. Most patients referred to hospital with chest pain will 
have an x-ray angiogram at some point. 
 
In addition to the heart scans you will have one blood sample taken and stored to 
measure a number of biochemical markers of cardiovascular risk. The sample would 
be taken by a qualified nurse or doctor and if at all possible will be taken at a time 
when you are having blood taken for another reason. 
 
After you have had the heart tests, we will monitor your progress for three years. This 
will involve a short telephone call once a year to find out how your health has been. 
 
Sometimes we collaborate with commercial companies to pursue our research. This may 
be necessary for example if we find a new blood marker and need to develop a kit to 
measure it. Although this may involve the use of samples or research results from 
patients, these would be anonymised and there would be no direct financial gain to 
patients taking part in the study.  
 
 
WHAT ARE THE RISKS AND DISCOMFORTS? 
Magnetic Resonance Imaging (MRI) is safe and no x-rays or radiation are used for 
this scan. There are no known risks from this technique. Some patients may experience 
claustrophobia. The staff will provide every possible means to reduce this sensation. 
The contrast medication which we use is very safe but, as with any injection, reactions 
may occur. These include a warm sensation at the injection site, nausea or vomiting and 
transient skin rash. These effects usually only last for a few minutes. People with a history 
of allergy are more likely to suffer a more severe reaction, but this is rare (less than 1 in 
3000). The department is equipped to cope with allergic reactions if they happen. 
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Adenosine, the medication we use to increase the blood flow to the heart, can cause 
flushing, breathlessness and chest discomfort. However, all of these feelings usually 
subside within one or two minutes or even more quickly if the medication is stopped.  
The Exercise treadmill test can cause angina or heart rhythm changes in some people. 
Should you develop such side effects, the test would be stopped immediately. 
 
SPECT imaging is very safe but exposes patients to a small amount of radiation. As for 
MRI, Adenosine, the medication we use to increase the blood flow to the heart, can cause 
flushing, breathlessness and chest discomfort. However, all of these feelings usually 
subside within one or two minutes or even more quickly if the medication is stopped. 
 
The most common complication of the X-ray angiogram is for a bruise to form in the 
groin. This is not serious, but may be inconvenient for a few days. Serious complications 
are very rare, but there is a small risk of the test causing a heart attack, stroke or kidney 
damage (about 1 in 1000). The test also exposes patients to a small amount of radiation. 
 
All radiation doses carry a small risk. The radiation dose that you would receive from all 
the tests in this study together would be equivalent to between two and ten years of 
exposure to natural background radiation.  
 
 
BENEFITS TO YOU 
If you take part in this study, your chest pain will be studied very thoroughly and a lot of 
information about the health of your heart will be obtained. Most, but not all of this 
information would be gathered if you did not take part in the study and some of the 
information could help to plan what is the best treatment for you. 
 
 
EXPENSES 
We will provide reasonable travel expenses should this be necessary for you to attend the 
follow-up scan. We are also happy to arrange transport to the hospital and return you 
home if needs be. 
 
 
WILL MY TAKING PART BE KEPT CONFIDENTIAL? 
All information, which is collected about you during the course of the research will 
be kept strictly confidential. This information will be securely stored at the Clinical 
Trials Research Unit (CTRU) at the University of Leeds and at the Cardiac MRI Unit 
at Leeds General Infirmary on paper and electronically, under the provisions of the 
1998 Data Protection Act. You will not be identified in any publication that may result 
from this research.  
 
We will inform your General Practitioner (GP) of your participation in this study as 
well as in the event of an unexpected abnormality on the scan. We will also contact 
the Office of National Statistics at a later stage for information that they already hold 
on patients treated in the UK. 
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With your permission, your data may also provide a resource for future studies. If any 
information from this study is used to develop new research, data protection 
regulations will be observed and strict confidentiality maintained. Ethical approval 
will be obtained for any future studies involving your data. You will not be identified 
in the results of any future studies.  
 
If you withdraw consent from further study follow-up, your data will remain on file 
and will be included in the final study analysis.  
 
 
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? 
When the study is complete the results will be published in a medical journal, but no 
individual patients will be identified. If you would like a copy of the published results, 
please ask your doctor. 
 
 
INDEMNITY/COMPENSATION 
If you are harmed as a direct result of taking part in this study, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then you 
may have grounds to a legal action. Regardless of this, if you have any cause to complain 
about any aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms are available to 
you. 
 
If you have a private medical insurance please ensure that participation in the study does 
not affect your cover. 
 
 
WHO IS ORGANISING AND FUNDING THE STUDY? 
This is a research project of the Cardiac MRI department at Leeds General Infirmary, 
which is funded by the British Heart Foundation. 
 
 
WHO HAS REVIEWED THE STUDY? 
The study has been reviewed and approved by an independent local NHS Research 
Ethics Committee 
 
 
 
For further information please contact:         
Dr. Neil Maredia, Research Fellow, or 
Petra Bijsterveld, Research Nurse 
British Heart Foundation Cardiac MRI Department, 
B Floor, Clarendon Wing,  
Leeds General Infirmary. 
Tel: 0113 39 2 5481  Mobile: 07922 512 887. 
http://www.cmr.leeds.ac.uk/ 
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------------------------------------------------------------------------------------------------------
------------------- 
 
When you attend for your Cardiology out-patient appointment, a Doctor or Nurse 
connected with the research programme will talk to you about the study and give 
you further information. 
 
If, after reading this information leaflet you definitely do not want to consider this 
study, please tear off this slip and give it to the receptionist with your name written 
below. 
 
Name: 
…………………………………………………………………………………………
………..  
 
Thank you for your time. 
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                                   CE-MARC Study 
Clinical Evaluation of MAgnetic Resonance imaging in  
Coronary heart disease 
 
Patient Study Number: ………………..   Date of Birth: ………………… 
 
Hospital Number: …………………….   Initials: ……………………….. 
                                                                                                                                         Please initial 
boxes         
1. I have read the Patient Information Sheet dated December 2005          
              (Version 2.1) for the above study and I have had the  
 opportunity to ask questions and discuss the research study  
 and I am satisfied with the answers to my questions. 
            
2. I have received enough information about this study. 
 
3.  I understand that my participation is voluntary and that I am  
             free to withdraw from the study at any time without  
             giving a reason and without affecting my future care.  
 
4. I understand that my medical records may be looked  
at by authorised individuals from the Clinical Trials  
Research Unit in order to check that the study is 
being carried out correctly.  
 
. I understand that information held by the NHS and  
records maintained by the Office of National Statistics  
(ONS) may be used to follow up my health status,  
should I lose contact with my hospital doctor.  
I give permission for this information to be obtained  
from the ONS and/or NHS if necessary. 
 
6. I agree that my medical data maybe used to help develop  
future research studies and I understand that my identity will  
remain anonymous. 
 
7.       I understand that my samples may be used in future research  
             projects which may involve collaborations with 
commercial companies and I understand that I will not 
benefit financially if the research leads to the 
development of  a new test or treatment. 
 
8.          I agree to take part in this research study.  
 
 
Signature.............................................................. 
 
 
Name (block capitals)........................................................... Date................ 
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Signature of witness............................................. 
 
 
Name (block capitals)............................................................Date………… 
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10.2. Ethical approval, Patient information and consent 
forms for Chapter 4 
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10.3. Ethical approval, Patient information and consent 
forms for Chapters 6 and 7 
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